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ABSTRACT  
 
Microglial Reactivity and Functional Deficits Following Traumatic Brain Injury in 
the Neonate Rat 
 
Lauren Hanlon 
Advisor: Ramesh Raghupathi, Ph.D. 
 
 Traumatic brain injury (TBI) is a leading cause of disability in young children as 
survivors face life-long physical and cognitive impairments.  Inflammation, specifically 
microglia/macrophage activation, has been identified as a target for acute therapeutic 
intervention for the traumatically-injured adult brain, but it is unclear whether this 
strategy will be effective in the immature injured brain.  Closed head injury in the 11-
day-old rat induced robust microglia/macrophage reactivity in multiple brain regions and 
was associated with neurodegeneration and axonal injury.  Additionally, brain-injured 
animals demonstrated cognitive deficits and motor function impairments at 4 weeks post-
injury, mirroring the sustained functional deficits observed in humans.  Immediately after 
injury, intracerebral depletion of microglia/macrophages with clodronate or inhibition of 
active microglia/macrophages systemically with minocycline decreased the number of 
total and activated microglia/macrophages in the injured brain. This effect was 
accompanied by an increase in neurodegeneration at 3 days post-injury, suggestive of a 
lack of clearance of degenerating cells.  Both of these acute manipulations, however, 
were associated with an increase in microglia/macrophage reactivity and 
neurodegeneration at 4 weeks post-injury that coincided with hyperactivity (clodronate) 
xi 
 
or hypoactivity (minocycline) within the injury site. In addition, systemic minocycline 
administration reversed alterations in cortical activity, deficits in working memory, and 
impairment of forelimb function that were not associated with neurodegeneration or 
microglia/macrophage activation.  These results are not only suggestive of off-target 
effects of minocycline, but also emphasize the importance of acute post-injury 
microglia/macrophage reactivity and the need for a more target-specific anti-
inflammatory therapeutic strategy in the developing brain.    
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CHAPTER 1: GENERAL INTRODUCTION  
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1.1 CLINICAL REVIEW OF PEDIATRIC TBI: EPIDEMIOLOGY, 
CHARACTERIZATION, PATHOLOGY, FUNCTIONAL 
OUTCOMES, AND MANAGEMENT.  
 
1.1.1 Epidemiology 
 
 In the United States, an estimated 1.7 million people sustain a traumatic brain 
injury (TBI) each year and while 80% of these people are acutely treated and released 
from the hospital, approximately 52,000 people die after incurring a TBI (Faul et al., 
2010).  Older adults over the age of 75 have the highest rates of hospitalization 
(339/100,000) and death (57/100,000) due to TBI, but children ages 0-14 account for 
35% of TBI-related emergency room visits making them the age group with the highest 
incidence of TBI.  Within this age group, the youngest children (ages 0-4)  have the 
highest incidence of emergency room visits due to TBI with a rate of over 1200 visits per 
every 100,000 people (Faul et al., 2010).  The incidence of TBI in this age group consists 
of both accidental and inflicted abusive trauma (Ewing-Cobbs et al., 1998, Keenan and 
Bratton, 2006) as 29% and 43% of TBI-related deaths in children 0-4 are due to motor 
vehicle accidents and abuse, respectively (CDC Website).  Abusive head trauma (AHT) 
in infants is not just restricted to what has been conventionally defined as “shaken baby 
syndrome” and now encompasses impact-driven traumas and while it has been 
historically very difficult to diagnose AHT, the incidence of diagnosis has increased in 
the last decade (Jenny et al., 1999, Kelly et al., 2015, Narang et al., 2016).    
 In a population-based study of severe or fatal pediatric TBI, children under the 
age of 1 had a higher rate of inflicted TBI (29.7/100,000) compared to accidental TBI 
(20.1/100,000).  Male children of non-European descent were more likely to be the 
victims of inflicted trauma and that while children with young, first-time mothers (less 
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than 21 years of age) were more likely to be abused, the abuser was often a male adult 
(Keenan et al., 2003) (Parks et al., 2012).  The rate of severe and fatal inflicted TBIs, 
however, drastically decreased after the age of 1 (3.8/100,000) (Keenan et al., 2003).  The 
most common cause of TBI in children over the age of 1 is falls as the children are 
learning to walk and have trouble avoiding obstacles (Keenan and Bratton, 2006).  As the 
children age, motor vehicle accidents and sports accidents become more common causes 
of injury (Faul et al., 2010).  
 
1.1.2 Classification of pediatric TBI  
 
Injury Severity 
Over 40 years ago, the need for a universal brain injury severity scale was 
recognized and thus the Glasgow Coma Scale (GCS) was born (Teasdale and Jennett, 
1974).  This scale assesses eye opening, verbal responses, and motor responses in order 
to give the patient a score ranging from 3 to 15 that denotes injury severity (Table 1.1).  
 
Table 1.1. Standard Glasgow Coma Scale (GCS) 
Eye Opening Verbal Response Motor Response 
  6: Obeys commands 
 5: Oriented  (to self and 
environment) 
5: Localizes to stimulus 
4: Spontaneous 4: Confused 4: Withdraws to pain 
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3: To Speech 3: Inappropriate words 3: Abnormal flexion 
2: To Pain 2: Incomprehensible sounds 
(moaning/groaning) 
2: Extension 
1: No Response 1: No Response 1: No Response 
Table recreated from: (Teasdale and Jennett, 1974, Matis and Birbilis, 2008)  
 
In an attempt to classify brain injury severity, assigned GCS scores correspond to either a 
mild injury (13-15), a moderate injury (9-12), or a severe injury (3-8) (Sternbach, 2000).  
It is believed that taking loss of consciousness (LOC) into consideration when 
characterizing the severity of injury is beneficial in terms of treatment and predicting 
outcomes.  The Head Injury Severity Scale (HISS) uses GCS scores and LOC to separate 
severities into 5 different intervals that better characterize the differences in mild and 
moderate injuries: minimal (score of 15 with no LOC), mild (score of 14-15 with LOC of 
less than 5 minutes or impaired alertness/memory), moderate (score of 9-13 with LOC 
greater than 5 minutes or a focal neurological deficit), severe (score of 5-8), or critical 
(score of 3-4) (Stein and Spettell, 1995).   
Due to the nonverbal nature of infants, it can be difficult to accurately diagnose 
the severity of a head injury (both inflicted and accidental) as these children often present 
with symptoms that are similar to a range of different ailments- lethargy, crying, 
vomiting, irritability (Jenny et al., 1999, Keenan and Bratton, 2006).  An infant GCS has 
been adapted with a better characterization of responses in very young children (Reilly et 
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al., 1988) (Table 1.2).  The verbal response column was modified to cater to the verbal 
abilities of infants.    
 
Table 1.2 Infant Glasgow Coma Scale 
Eye Opening Verbal Response Motor Response 
  6: Obeys commands 
 5: Cooing and babbling 5: Withdraws from touch 
4: Spontaneous 4: Irritable cries 4: Withdraws from pain 
3: To speech 3: Crying in reaction to pain 3: Flexion to pain 
2: To pain 2: Moaning to pain 2: Extension to pain 
1: No response 1: No response 1: No response 
 Table recreated from: Reilly et al., 1988; Matis and Birbilis, 2008  
 
Concerns were still raised, however, about an infant’s ability to follow commands in 
assessment of the motor response and the ease at which verbal responses could be 
misinterpreted (i.e. the criteria for an irritable cry or the distinction between moaning and 
babbling) (Martens, 1993, Matis and Birbilis, 2008).  In 2000, the Children’s Hospital of 
Philadelphia released a novel coma scale for use in children under the age of 2 called the 
Infant Face Scale (Durham et al., 2000, Table 1.3).   
 
Table 1.3 The Infant Face Scale (IFS) 
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Eye Opening Verbal/Facial Response Motor Response 
  6: Spontaneous normal 
movements 
 5: Crying spontaneously 
(with grimacing and tears), 
with handling, or to minor 
pain; alternating sleep with 
periods of quiet 
wakefulness 
5: Spontaneous normal 
movements reduced in 
frequency, hypoactivity 
4: Spontaneous 4: Crying spontaneously 
(with grimacing and tears), 
with handling, or to minor 
pain; no periods of quiet 
wakefulness maintained 
4: Nonspecific movement to 
deep pain only 
3: To verbal stimulation or 
touch 
3: Crying only in reaction to 
deep pain 
3: Abnormal rhythmic 
spontaneous movements, 
seizure activity 
2: To pain 2: Grimaces only to pain 
with no sounds or tears 
2: Spontaneous extension or 
to painful stimuli 
1: No response 1: No facial response to 
pain 
1: Flaccid 
Table recreated from: Durham et al., 2000.  
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This scale addresses concerns over the subjective nature of the infant GCS and the child’s 
verbal and motor abilities by basing the measures on objective behaviors that are 
appropriate for the age group. When this scale was tested, the interrater reliability was 
substantially increased in assessment of infants that sustained a TBI or suffered a 
hypoxic-ischemic insult when compared to the interrater reliability of the GCS (Durham 
et al., 2000).  The adaptation of the GCS and the utilization of the IFS emphasize the 
need for consideration of age-dependency in characterizing injury severity in young 
children and further demonstrate a common theme in pediatric brain injury research- 
what works for the adult brain may not work for the immature brain.  
 
Biomechanics of Injury 
 Traumatic brain injuries are often placed in one of two biomechanical categories: 
focal injuries and diffuse injuries. Focal injuries are associated with impact-driven trauma 
and involve skull fractures, evidence of contusion, and hematomas whereas diffuse 
injuries are associated with trauma caused by rapid acceleration/deceleration forces and 
tend to result in tearing injuries that often affect the white matter (Andriessen et al., 
2010).  Injuries to the developing brain, however, may result in pathologies associated 
with both of these broad injury categories as both impact and rotational forces are 
common mechanisms of injury in both accidental and inflicted trauma.  The 
characteristics of shaken baby syndrome, for example, have been expanded to include 
impact-based pathology and may now be referred to as “shaken impact syndrome.”  
Using doll models of 1-month old infants, Duhaime et al. (1987) demonstrated that 
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impact was necessary to break the injury threshold associated with subdural hematoma 
and diffuse axonal injury.  Additionally, the properties of the infant skull differ from the 
adult and may further facilitate the melding of these two types of injury (Duhaime et al., 
1987).  Margulies and Thibault (2000) demonstrated that the decreased thickness and 
overall pliancy of the infant skull resulted in a decreased ability of the skull to absorb 
energy during the application of an external force.  They also demonstrated that, due to 
these parameters, an external force would cause much greater deformations therefore 
affecting more than just the area of direct application and causing a more diffuse pattern 
of injury (Margulies and Thibault, 2000).  These findings emphasize the complexity of 
pediatric TBI and indicate that the pathology may reflect aspects of both focal and diffuse 
injuries.  
 
1.1.3 Tissue pathology of pediatric TBI 
   
Skull Fractures 
 Skull fractures are a common pathologic occurrence following TBI in the infant, 
are indicative of impact-based trauma, and are often identified through X-ray imaging or 
computed tomography (CT) (Ewing-Cobbs et al., 1998, Ewing-Cobbs et al., 2000, 
Keenan et al., 2004, Alhelali et al., 2015, Culotta et al., 2017).  The presence of skull 
fractures has been reported in both inflicted and accidental TBI.  In an early prospective 
study, children that sustained a TBI due to either accidental or non-accidental causes did 
not differ in the frequency or types (multiple, linear, depressed, diastatic) of skull fracture 
(Ewing-Cobbs et al., 1998).  Further studies, however, indicated that skull fractures were 
more common in children that sustained a TBI from accidental causes (motor vehicle 
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accident, fall, drop, etc.) (Ewing-Cobbs et al., 2000, Keenan et al., 2004).  While the 
number of fractures was higher in the non-inflicted group, the distribution of the types of 
fractures (linear, depressed, diastatic) was similar between the non-inflicted and inflicted 
groups (Ewing-Cobbs et al., 2000).  In a separate study, 59% of children that sustained an 
accidental TBI had skull fractures whereas only 17.5% of the children that sustained an 
inflicted injury group had a skull fracture (Keenan et al., 2004).  In a histopathologic 
study of severe inflicted injury in infants and young children, however, 85% of subjects 
showed evidence of impact to the head at the time of autopsy with 42% of these children 
sustaining skull fractures and 58% showing evidence of sub-scalp bruising (Geddes et al., 
2001b).  With the expansion of the criteria for abusive head trauma to include impact-
based injuries, skull fracture alone may not be enough to separate accidental and inflicted 
injuries.  
 
Extra-axial Collections    
 Extra-axial collections encompass any fluid collection outside of the brain 
parenchyma and include epidural, subdural, and subarachnoid hematomas and 
hemorrhages.  These bleeds occur in both inflicted and non-inflicted cases, but may differ 
in frequency and severity between the different external causes (Ewing-Cobbs et al., 
1998, Ewing-Cobbs et al., 2000, Tung et al., 2006).  In a prospective review, subdural 
hematomas occurred more frequently in children who sustained TBIs due to non-
accidental (80%) rather than accidental causes (45%), but epidural hematomas were 4 
times more likely in children with accidental TBI.  Collections in the subarachnoid space, 
however, did not show any differences between accidental and non-accidental injury 
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mechanisms (Ewing-Cobbs et al., 1998).  Further analysis of subdural hematomas 
revealed that inflicted TBI in infants resulted in mixed-density subdural hematomas that 
may be suggestive of repetitive brain trauma where accidental trauma resulted in 
hyperdense subdural hematomas (Tung et al., 2006).  
 
Retinal hemorrhage 
Retinal hemorrhage (RH) has been used as a marker of an inflicted TBI diagnosis 
as the rapid acceleration and deceleration forces often associated with “shaken 
baby/shaken impact syndrome” can cause ocular damage (Duhaime et al., 1998).  In a 
small prospective study of 20 infants with inflicted TBI and 20 infants that sustained a 
TBI due to accidental causes, 70% of the inflicted TBI victims presented with RH.  Of 
these 70%, all but one of the children presented with hemorrhages in both retinae while 
there was no evidence of RH in the accidental injury group (Ewing-Cobbs et al., 1998).  
In a larger study, a large proportion of children that sustained inflicted TBI had RH 
(76%), but there was a proportion of non-inflicted cases that presented with RH (8%) 
indicating that RH is not just a characteristic of inflicted TBI (Keenan et al., 2004).    
 
Atrophy and Ventriculomegaly 
 Evidence of cerebral atrophy in the acute period post injury may be indicative of 
previous unreported injuries.  A proportion of children that sustained an inflicted TBI 
demonstrated evidence of cerebral atrophy and ex vacuo ventriculomegaly (enlarged 
ventricular space) on their entry scans while those that were treated for an accidental 
injury did not (Ewing-Cobbs et al., 2000).  There is evidence, however, that a moderate to 
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severe accidental injury can result in chronic atrophy and ventricular alterations (Wilde et 
al., 2005, Ghosh et al., 2009).  In a study that used MRI to investigate volumetric changes 
in children (ages 3-13 at the time of injury) a year after an accidental moderate to severe 
traumatic brain injury, whole brain volume and grey matter volume were decreased in 
injured subjects compared to age-matched uninjured controls and injury resulted in an 
increased ventricular volume, CSF volume, and an increased ventricle-to-brain ratio 
(Wilde et al., 2005).  In a separate study that investigated the correlation between 
ventricular abnormalities and GCS score, children with lower original GCS scores were 
more likely at 4 months post-injury to develop an abnormal ventricle-to-brain ratio 
(Ghosh et al., 2009).  These studies indicate that with time, a single moderate to severe 
injury will result in atrophy and ventricular enlargement irrespective of whether the 
injury was accidental or inflicted.  
        
White Matter Injury 
The sampling for neuropathologic studies in post-mortem tissue comes primarily 
from severe inflicted injuries, but these studies have made interesting discoveries about 
the nature of axonal injury following these types of injuries (Vowles et al., 1987, 
Shannon et al., 1998, Gleckman et al., 1999, Geddes et al., 2001a, Geddes et al., 2001b). 
Using the silver stain method, Vowles et al. (1987) observed axonal swellings in the 
subcortical white matter and corpus callosum in infants that had sustained TBIs and 
determined that DAI (diffuse axonal injury) was more common in infants that sustained 
skull fractures and contusional tears (Vowles et al., 1987).  Over a decade later, beta-
amyloid precursor protein (β-APP) immunohistochemistry was used to visualize axonal 
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injury and the idea that shaking alone was sufficient to cause axonal damage or whether 
axonal injury was a consequence of hypoxic damage following injury was tested.  
Shannon et al. (1998) reported that, in a group of infants whose primary injury 
mechanism was shaking (all subjects lacked skull fractures), there was evidence of β-
APP labeling in the cerebral white matter- specifically the corpus callosum and internal 
capsule. They also reported, however, that 86% of control brains from infants that died 
from hypoxic-ischemic injury demonstrated similar evidence of axonal injury indicating 
that respiratory distress (apnea following injury) and brain swelling may be contributing 
factors to DAI.  Shaking produced evidence of axonal injury in the cervical spinal cord 
that distinguished the victims of inflicted injury from those that incurred a hypoxic-
ischemic insult (Shannon et al., 1998).  A similar study found evidence of β-APP labeling 
indicative of DAI in both infants that were shaken and infants that were struck, but did 
not find evidence of labeling in the control brains, one of which sustained a hypoxic-
ischemic injury (Gleckman et al., 1999).  Geddes et al. (2001a, 2001b) identified a 
pattern of DAI in the midbrain and brainstem of infants that sustained inflicted injuries 
that they believed was related to the increase in intracranial pressure and hypoxic damage 
due to the geographic relation to affected vasculature. Additionally, infants that 
demonstrated severe traumatic damage also exhibited evidence of TAI (traumatic axonal 
injury) within the hemispheric white matter, corpus callosum, and internal capsule.  
These studies suggest that both non-impact and impact-based trauma can result in axonal 
injury that may also be related to acute hypoxia and increased intracranial pressure.  
Imaging studies have given us insight into the white matter damage sustained in 
children that survive their injuries. MRI analysis revealed acute evidence of shearing in 
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the corpus callosum of infants that sustained accidental TBIs and evidence of impaired 
myelination, indicative of previous injury, in infants that sustained inflicted injury 
(Ewing-Cobbs et al., 2000).  Imaging studies allow for investigation into the long-term 
integrity of the white matter tract after pediatric brain injury (Suskauer and Huisman, 
2009).  A relationship between atrophy of the white matter and GCS score was identified 
as children with lower GCS scores at the time of injury were more likely to have higher 
percentages of white matter loss at least a year after injury (Ghosh et al., 2009).  In a 
study that investigated the integrity of white matter tracts at least one year after injury in 
early childhood (approximately 3 years old) using diffusion tensor imaging (DTI), 
reduced fractional anisotropy (FA) was observed in several white matter regions 
including the corpus callosum, internal capsule, and longitudinal fasciculus.  These 
reductions were also associated with lower GCS scores at the time of injury indicating 
that moderate to severe injuries are more likely to result in long-term alterations in white 
matter integrity (Yuan et al., 2007).  In a more recent study, brain-injured young children 
(ages 6-10) showed a greater decrease in FA compared to brain-injured adolescents (ages 
11-15) indicating age-dependency in white matter damage, but both age groups 
demonstrated similar degrees of change in FA between the 3-month and 24-month scans 
(Ewing-Cobbs et al., 2016).  These, and the results from post-mortem studies, indicate 
that axonal injury may result in axotomy and long-term white matter atrophy.               
 
1.1.4 Functional Outcomes  
 
 Young children and infants that sustain traumatic brain injuries demonstrate a 
wide range of neurobehavioral deficits in the months to years following the injury that 
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include deficits in different areas of cognition, the development of psychiatric disorders, 
deficits in social interaction, locomotor difficulties, and the appearance of seizure activity 
and development of seizure disorders.  
 
Cognition 
 Sustaining an injury in infancy or early childhood has strong implications for the 
development of cognitive skills.  Very young children (up to 42 months of age) are 
typically evaluated using the Bayley Scale of Infant Development (BSID) that takes into 
account age-appropriate behavior and levels of arousal/responsiveness through a series of 
play activities. As the child ages, the tests within the BSID begin to encompass language 
and emotional development as well (Nellis & Gridley, 1994).  Using the BSID, Ewing-
Cobbs et al. (1999) demonstrated that infants and young children that sustained moderate 
to severe TBIs had significantly decreased Bayley Behavior Rating Scores for mental 
development at both baseline and at the 3-month follow-up when compared to control 
subjects (Ewing-Cobbs et al., 1999).  In a separate study, approximately 4 years after 
sustaining a moderate to severe TBI, children demonstrated cognitive development scores 
that were below average with over 50% of the subjects falling in the “extremely 
abnormal” range (Barlow et al., 2005).  Furthermore, children aged 4 months to 7 years 
that sustained severe inflicted TBIs showed no improvement in a variety of different IQ 
measures (composite, verbal, perceptual-performance) between 6 months and 24 months 
post-injury indicating a lack of improvement and developmental arrest (Ewing-Cobbs et 
al., 1997).  Anderson et al. (2005) even indicated that children that sustained their injury 
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when they were younger than 3 years of age showed evidence of continued cognitive 
impairment at the 12 and 30 month follow-up assessments (Anderson et al., 2005).  
 In addition to this general lack of cognitive development, children that sustain 
TBIs also exhibit deficits in specific areas of cognition such as verbal working memory, 
visuo-spatial memory, and attention that may contribute to difficulties in a school setting. 
Researchers administered two working memory assessments to children that sustained 
TBIs (aged 0-15 years at the time of injury) and age-matched controls: the category 
listening span dual-task (CLS-DT) as a measure of verbal working memory that dealt 
with correct responses regarding the content and order of word strings and the 
visuospatial span dual-task (VSS-DT) as a measure of visuospatial working memory that 
dealt with correct responses regarding the content and order of strings of 4x4 block sets.  
Children that sustained injuries demonstrated significant decreases in correct responses in 
the VSS-DT and a mild, but insignificant decrease in correct responses in the CLS-DT 
(Treble et al., 2013).  Similarly children that incurred TBIs in early childhood showed 
deficits in verbal working memory when they were simultaneously asked to decide if 
sentences were true or false and remember the last word of these sentences in order 
(sentence span task) (Ewing-Cobbs et al., 2008).  In addition to deficits in memory, 
children that sustain TBIs demonstrate difficulties in different areas of attention.  
Children that sustained severe injuries had greater deficits in sustained attention, reaction 
time, and shifting attention compared to children that sustained mild injuries and healthy 
controls (Catroppa and Anderson, 2005).  Brain-injured children are also at high risk for 
developing attention-deficit hyperactivity disorder (referred to as secondary ADHD or s-
ADHD).  Children with TBI and children with diagnosed ADHD had similar deficits in 
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response inhibition in a task that required the children to respond to a stop signal 
(Ornstein et al., 2013). Additionally, 12% of children that sustained a TBI were 
diagnosed with s-ADHD and exhibited increased deficits in working memory and 
attention compared to uninjured children diagnosed with ADHD (Ornstein et al., 2014). 
 Many cognitive outcomes do not manifest in childhood TBI survivors until they 
reach school-age and heavily involve deficient language processes (Ewing-Cobbs and 
Barnes, 2002).  Children that sustained early TBIs, for example, demonstrated deficits in 
both expressive and receptive language (Ewing-Cobbs et al., 1989) and in word fluency 
(Levin et al., 2001).  Brain-injured children also demonstrated deficits in several different 
areas of reading ability such as word reading accuracy, fluency, and reading 
comprehension (Johnson et al., 2015).  Cognitive deficits may also contribute to deficits 
in mathematical skills based on the observation that brain-injured children exhibit deficits 
in standardized math skills such as simple calculations and applied word problems 
(Raghubar et al., 2013).  Due to an increase in cognitive deficits affecting basic school 
subjects such as reading and math, brain-injured children utilized more specialized 
support services and have lower academic competency scores compared to their 
normally-developing peers (Prasad et al., 2016).             
 
Social and Behavioral Outcomes 
 Children that sustain brain injuries in early childhood demonstrate decreased 
social competencies and are at risk of developing psychiatric disorders.  Parents of 
children that sustained severe accidental TBIs between the ages of 3 and 7 years reported 
scores on two separate social skills assessments that were significantly decreased 
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compared to controls and children that sustained moderate injuries (Ganesalingam et al., 
2011).  Additionally, children with severe TBIs demonstrated increased gesturing during 
the initiation of social communication indicating a lack of proper verbalization compared 
to age matched children that sustained mild injuries (Ewing-Cobbs et al., 2012).  When 
children were separated by mechanism of injury (accidental vs. inflicted injury), social 
abilities did not differ between the two groups, but social responsiveness and caregiver 
sociability ratings were significantly decreased in children with severe TBI irrespective 
of mechanism (Ewing-Cobbs et al., 2013).  
 Max et al. (2001) characterized personality changes in brain-injured children that 
encompassed five different alterations: labile, aggressive, disinhibited, apathetic, and 
paranoid. Brain-injured children demonstrated evidence of personality changes over a 
series of follow-up psychiatric assessments and children with severe injuries were more 
likely to exhibit personality changes compared to those with mild injuries (59% vs. 5%).  
These personality changes were most commonly characterized as an increase in 
irritability or an increase in aggression associated with disinhibited verbalizations (Max 
et al., 2001).  The development of psychiatric mood disorders has only recently been a 
point of focus in pediatric TBI research.  It has been reported that 11% of children in a 
sample of pediatric TBI survivors develop novel depressive disorders in the years 
following injury, but that the development of depression may be more common in 
children that are slightly older at the time of injury (average of 12 years old) (Max et al., 
2012).  Interestingly, the incidence of novel anxiety disorder following injury was similar 
(10%), but was associated with a younger age at injury (average of 8 years old) and 
documented changes in personality (Max et al., 2015).  These studies indicate that brain-
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injured children that survive their injuries go on to deal with severe psychiatric and 
psychosocial alterations that could negatively impact their overall development.            
 
Locomotor Outcomes 
 While cognitive outcomes are widely considered and studied, brain-injured 
children may also demonstrate motor difficulties as areas of the brain dealing with motor 
planning and control may be affected directly by the injury and secondarily by alterations 
in neural development caused by the injury.  In assessments using the motor component 
of the Bayley Infant Development Scale (children 4-42 months) and the McCarthy Motor 
Scale (children 42-72 months), children with severe injuries had significantly decreased 
motor scores at both initial testing and 6 month follow-up compared to the mild/moderate 
injury group (Ewing-Cobbs et al., 1989). In a separate study, severely injured children 
only improved in motor score in the first 6 months following injury and did not show any 
further improvement at the 12- or 24-month follow-up assessments (Ewing-Cobbs et al., 
1997). In a more in-depth measure of timed motor dexterity where children were asked to 
place pegs in a pegboard (the grooved pegboard test), severely injured children exhibited 
decreased accuracy in this task compared to age-matched controls (Ewing-Cobbs et al., 
2008).  
 
Post Traumatic Seizures 
 Abnormalities in neural network activity can manifest as seizure activity 
following a traumatic brain injury. Injuries in children can disrupt the development of 
optimal connectivity in the brain as the immature brain may still be forming the correct 
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synaptic connections. Children under the age of 5 that sustain severe injuries demonstrate 
an increased incidence of seizures in the early stages following injury (Annegers et al., 
1998). In a study where 11% of severely injured children demonstrated seizure activity, 
68% of these children had seizures in the first 12 hours post-injury (as evidenced by 
physician report or EEG (electroencephalogram) activity) (Liesemer et al., 2011). In 
addition to severity of injury (severely-injured children demonstrate a higher rate of 
seizure activity compared to more mild injuries), the age at injury has been identified as a 
significant risk factor for the development of seizure activity as 62% of children under 
the age of 1 developed seizures compared to only 30% of children over the age of 1 
(Arndt et al., 2013). In 20% of children where the injury was so severe that they needed 
decompressive craniectomies, a diagnosis of epilepsy was made and anti-epileptic 
medications were prescribed in the chronic post-injury period (Kan et al., 2006).  
 
1.1.5 Management of Pediatric TBI 
 
Acute Management 
 There are guidelines in place to aid emergency department physicians in initiating 
the best course of treatment for children presenting with a traumatic brain injury 
(Hardcastle et al., 2014).  Very acute management following TBI in children is primarily 
focused on establishing a clear airway and monitoring intracranial pressure (ICP).  It is 
common for children to be intubated and rely on a respirator to combat any episodes of 
post-injury apnea.  Physicians may administer sedatives or other pharmacologic 
interventions to try to slow cerebral metabolism and decrease intracranial pressure to 
combat further secondary injury mechanisms.  If children are unresponsive to 
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pharmacologic intervention and ICP continues to increase, physicians may turn to more 
drastic measures such as craniectomies or cerebrospinal fluid drainage.  There has also 
been evidence that acute hypothermia may aid in lowering ICP (Adelson et al., 2005). 
   
Long-Term Management 
 Long-term management following pediatric TBI is focused on two aspects: 
treating comorbid developments such as psychiatric illnesses or epilepsy and providing 
rehabilitative support such as physical rehabilitation, cognitive therapy, or specialized 
educational support.  Anti-convulsant and anti-psychotic medications are common after 
pediatric TBI to manage epilepsy and common psychiatric changes such as increased 
aggression or depression (Ylvisaker et al., 2005).  Physical rehabilitation in children may 
focus on repetitive exercises to strengthen synaptic connectivity of the desired circuit and 
improve long-term function. Cognitive rehabilitation has shifted focus in the recent past 
from cognitive exercises in clinical settings to community-based therapy focused on the 
individual’s needs, every day routine, and education of the child’s parents and teachers.  
Home-based therapy directly involving the child’s caregivers has shown positive effects 
on neurodevelopmental outcomes in very young children (Prasad et al., 2008).  There has 
also been a push for teachers to receive training in TBI-specific educational methods so 
as to facilitate educational success in the pediatric TBI population (Ylvisaker et al., 2001, 
Glang et al., 2004).   
 
A main focus in both clinical and pre-clinical pediatric TBI research is to acutely 
combat the initiation of secondary injury processes that increase the likelihood that the 
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children will develop comorbid pathologies and long-term functional impairments thus 
hoping to decrease the burden associated with long-term management following injury.  
Identified therapeutic targets, however, must undergo rigorous preclinical testing in 
relevant animal models of pediatric TBI.  
 
1.2 ANIMAL MODELS OF PEDIATRIC TBI     
 
 Several pre-clinical animal models for pediatric TBI have been developed that use 
different species such as mice, rats, rabbits, and pigs. These models span several different 
age groups to encompass different developmental time points and utilize a number of 
various injury mechanisms including fluid-percussion injury, rotational-acceleration 
injury, weight-drop injury, and controlled cortical impact. Additionally, various injury 
severities are used to simulate different injury pathologies associated with pediatric TBI 
such as atrophy, inflammation, ventriculomegaly, white matter injury, and behavioral 
impairment.  
 
1.2.1 Fluid-Percussion Brain Injury 
 
 Fluid-percussion brain injury (FPI) is induced by delivering a rapid pulse of saline 
through a craniotomy onto the intact dura to create a deformation of the brain.  This pulse 
can be delivered at different atmospheric pressures to create varying levels of injury 
severity and the craniotomy can be conducted in different areas of the skull (i.e. midline 
vs. lateral) to affect different brain regions.  This technique, however, is technically 
taxing as the device requires a large amount of space and cannot be readily moved.  
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While this technique is commonly used in adult animals (Sullivan et al., 1976, Dixon et 
al., 1987, McIntosh et al., 1989, Carbonell et al., 1998, Spain et al., 2010), a few groups 
utilize this injury technique in the developing animal.  Prins et al. (1996) compared lateral 
(left parietal cortex) fluid-percussion injuries of increasing severities (mild: 1.35-1.45 
atm, moderate: 2.65-2.75 atm, severe: 3.65-3.75 atm) in 3 different age groups: adult rats, 
PND 28 rats, and PND17 rats.  The immature rats demonstrated increased hypotension 
and increased mortality at every injury severity compared to the adult rats. Additionally, 
moderately injured (2.65-2.75 atm) adult rats and PND28 rats demonstrated deficits in 
spatial learning that corresponded to decreased glucose metabolism in the hippocampus 
whereas moderately injured PND17 rats did not demonstrate any cognitive deficit or 
alteration in metabolism (Prins and Hovda, 1998, 2001).  They also demonstrated that 
this injury could inhibit enrichment-induced neuroplasticity by reducing dendritic 
arborization (Fineman et al., 2000, Ip et al., 2002).  Fluid-percussion has also been used 
to induce TBI in a model using neonatal and juvenile piglets.  Armstead and Kurth (1994) 
compared a moderate (1.9-2.3 atm) lateral FPI in newborn (PND1-5) and juvenile (3-4 
weeks) pigs and found that the newborn pigs had pronounced acute increases in 
hemoglobin oxygen saturation response that then severely decreased and this swing was 
not as severe in the juvenile pigs.  Additionally, newborn pigs demonstrated a more 
prolonged reduction of cerebral blood flow following the injury (Armstead and Kurth, 
1994).  
 
1.2.2 Rotational-Acceleration Brain Injury 
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 The rotational-acceleration injury model is a non-impact model of diffuse brain 
injury that seeks to replicate the rotational forces involved in motor vehicle accidents and 
sports collisions. Because this injury device is uniquely constructed, it has not been 
reproduced. The model was developed for use in adult minipigs and injury resulted in 
transient coma, astrogliosis, and diffuse axonal injury (Ross et al., 1994, Smith et al., 
1997).  The model has since been adapted for use in both newborn (3-5 days old) and 
juvenile piglets (4 weeks old).  Following axial (horizontal) rotation of moderate 
intensity, 4-week old piglets demonstrate increased apnea and suppressed EEG activity in 
the minutes to hours following the injury compared to sham-injured and piglets that 
received a mild severity (Ibrahim et al., 2010).  Additionally, moderately-injured animals 
demonstrated increased subarachnoid hemorrhage and more pronounced axonal injury 
compared to the mild injury group. In newborn pigs, rotational injury in the axial 
(horizontal) plane resulted in apnea and transient coma immediately following the injury. 
Evidence of subdural bleeding and diffuse axonal injury was observed histologically at 6 
hours post-injury (Raghupathi and Margulies, 2002). Further study determined that the 
direction of rotation mattered as animals that underwent rotational accelerations in the 
sagittal and axial (horizontal) planes showed exacerbated pathology (subarachnoid 
hemorrhage, brainstem injury, and diffuse axonal injury) at 6 hours post-injury compared 
to animals that underwent rotational acceleration in the coronal direction (Eucker et al., 
2011).  Additionally, piglets injured in the sagittal plane demonstrated exacerbated acute 
injury responses as evidenced by increased incidence of apnea and duration of 
unconsciousness and a reduction in cerebral blood flow compared to the coronal and 
horizontal groups. Behaviorally, piglets that were subjected to a moderate injury 
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demonstrated decreased exploratory behavior and deficits in visual problem solving out 
to 4 days post-injury (Friess et al., 2007).  
 Recently, this model has been expanded to incorporate repetitive cyclic rotations 
such as those sustained by children that incur repetitive abusive shaking episodes. 
Newborn piglets that underwent cyclic rotations did not demonstrate any axonal injury 6 
hours post-injury, but showed an increased presence of axonal injury at 24 hours and 6 
days post-injury (Coats et al., 2017).  Also, cyclic injuries produced more pronounced 
decreases in cerebral blood flow and increased the incidence of extra-axial hemorrhage 
compared to non-cyclic injuries.   
 
1.2.3 Weight-Drop Brain Injury  
 
 The weight-drop model of TBI is popular because it can be used to induce both 
diffuse and focal injuries at different severities and can incorporate various aspects of 
injury biomechanics.  For example, this injury is most-often conducted on a pliable 
surface (i.e. anything from foam padding to a suspended kim wipe) to allow the head 
some degree of free movement with the impact (Marmarou et al., 1994, Meehan et al., 
2012).  To induce injury, a weight is dropped down a tube and connects with the footplate 
that is directly against the intact dura for a more focal injury (Feeney et al., 1981) or the 
intact skull for a more diffuse injury (Marmarou et al., 1994). Additionally, this technique 
is technically favorable due to the ease at which the device is constructed and the 
portability of the apparatus.  In a weight-drop model that utilizes open injury directly to 
the dura (10g weight), the cerebrovascular responses of juvenile (PND25-32) and adult 
(2-3 months) rats were compared (Grundl et al., 1994).  While there were no differences 
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in infarct area in either age group, the immature animals had increased brain water 
content compared to the mature group out to 48 hours post-injury, but the mature rats 
demonstrated decreased local cerebral blood flow in more regions than the immature rats 
at 2 hours post-injury.     
The use of closed head weight-drop injury has been well-characterized in a model 
using PND17 rats (Adelson et al., 1996).  Different weights were utilized to induce a 
gradation of injury severity (75g, 100g, or 125g) and acute injury responses were 
characterized.  The 100g weight produced a severe injury that exacerbated acute post-
injury responses (increased apnea time, longer time to reflexive responses, decreased 
weight gain) and resulted in increased edema and enlarged ventricles.  When the severe 
injury (100g) was compared to an ultra-severe injury (150g), both injuries produced 
alterations in motor function post-injury, but only the ultra-severe injury produced a 
spatial learning impairment in the second post-injury week (Adelson et al., 1997) that 
was sustained out to 3 months post-injury (Adelson et al., 2000).  These behavioral 
alterations were accompanied by histopathologic evidence of edema and 
ventriculomegaly, as well as axonal injury and astrocytic reactivity but no overt evidence 
of neuronal cell death (Adelson et al., 2001).  
  Injury-induced cell death was investigated in this injury model in different age 
groups using an array of biochemical techniques and revealed severe age-dependent 
effects in the presence and severity of neuronal damage after injury (Bittigau et al., 
1999).  In two different protocols (one in which the same force was applied and one in 
which the force was altered to take brain weight into account) in PND3, PND7, PND 10, 
PND14 and PND30 rats, apoptotic cell death was detected via TUNEL and silver stains 
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at 24 hours post-injury in the PND3, PND7, PND10, and PND14 rats, but not those 
injured on PND30.  The severity of apoptotic damage was greatest in the rats injured on 
PND3 and PND7 and only these two age groups still showed cellular evidence of 
apoptosis at 5 days post-injury. The presence of apoptotic cell death in the PND7 animals 
was confirmed by increased c-jun and decreased bcl-2 mRNA expression in the injured 
cortex as well as increased detection of histone-associated DNA fragments and caspase 3-
like activity in the injured cingulum, cortex, thalamus, and hippocampus at 24 hours post-
injury.  When put together with the previously cited studies, irrespective of potential 
differences in injury severity, there seems to be age-dependent effects in the acute 
response to injury and the cellular neuropathology resulting from weight-drop injury.  
 
1.2.4 Controlled Cortical Impact Injury 
 
 Controlled cortical impact (CCI) is a modification of the weight-drop injury and 
was first characterized in the adult ferret using a pneumatically-driven piston that allowed 
for control of the velocity and depth of deformation associated with the impact (Lighthall, 
1988).  The model was soon adapted for use in the rat (Dixon et al., 1991) and is now 
also available as an electrically-powered device.  This model is extremely popular due to 
its ability to control for injury biomechanics (i.e. velocity and depth of deformation), its 
ability to simulate both focal and diffuse injuries depending on craniotomy, injury 
biomechanics, and impactor tip (i.e. metal vs. silicone tips, flat vs. protruding tips), and 
because the device itself is not overly large or cumbersome.  Pediatric CCI models utilize 
a wide range of animals, age groups, and injury severities to simulate the pathologies 
associated with human pediatric TBI. 
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 In the juvenile mouse (PND21), lateral impact to the intact dura resulted in the 
formation of a cavity under the impact site at 1 day post-injury indicative of a focal injury 
(Tong et al., 2002).  This lesion continued to worsen as the size of the cavity increased 
between 2 weeks and 3 months post-injury indicating prolonged neurodegenerative 
processes (Pullela et al., 2006).  The injured mice demonstrated neurodegeneration in the 
cortex surrounding the impact site and the hippocampus at 1 and 3 days post-injury and 
in the thalamus at 3 days post-injury. This neurodegeneration corresponded with loss of 
Neu-N labeled cells and the presence of activated microglia in these regions at 7 days 
post-injury.  Similarly, brain-injured mice demonstrated evidence of degeneration in the 
subcortical white matter (Tong et al., 2002). These mice also demonstrated prolonged 
hyperactivity, decreased general anxiety-like behavior, deficits in spatial learning, and 
deficits in social behavior weeks to months after the injury (Pullela et al., 2006, Semple et 
al., 2012).   
 Adelson et al. (2013) compared mild, moderate, and severe focal CCI injuries to 
the intact dura of PND7 (1.5mm, 1.75mm, 2.0mm) and PND17 (1.5mm, 2.0mm, 2.5mm) 
rats. Four weeks after injury, rats that were injured on PND7 demonstrated severe cortical 
atrophy at the mild deformation and exhibited large lesions at the moderate and severe 
depths that affected the cortex, underlying white matter, and the hippocampus. The 
moderate and severe injuries also resulted in spatial learning and memory deficits in the 
second week post-injury.  Rats that were injured on PND17 had cortical lesions that 
increased in size with the increasing severity, but did not involve the hippocampus 
although there appeared to be hippocampal atrophy.  Brain-injured animals showed 
spatial learning deficits at all injury severities, but animals in the moderate and severe 
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groups demonstrated visual impairment.  These results indicated that these two age 
groups responded to injury differently as evidenced by the differences in lesion formation 
and spatial learning deficits.   
 The Raghupathi lab has also conducted age-at-injury experiments as well as 
comparisons between injury severities and injury types (focal vs. diffuse, lateral vs. 
midline).  The injury model that we utilize in our immature rats (PND11 or PND17) 
involves an impact to the intact skull rather than the intact dura and this allows for 
consideration of the role that the skull plays in pediatric TBI.  In PND17 rats, midline 
injury with a metal impactor tip did not result in cavitation or overt tissue atrophy, but 
demonstrated a diffuse pattern of degeneration present in the cortex, white matter, 
hippocampus, and thalamus, as well as traumatic axonal injury in the corpus callosum, 
cingulum, and lateral white matter in the form of amyloid precursor protein 
accumulation, neurofilament compaction, and neurofilament dephosphorylation (Huh et 
al., 2008, DiLeonardi et al., 2009, 2012).  Injury to the white matter also manifested as 
compound action potential impairment as injured animals showed decreased signal 
amplitudes in both the myelinated and unmyelinated components of the signal across 14 
days post-injury with the myelinated axons showing a greater impairment than the 
unmyelinated axons (Dileonardi et al., 2012).  Additionally, these animals exhibited 
spatial learning impairment out to the third week post-injury (Huh et al., 2008).   
In a study comparing lateral focal injury PND11 and PND17 rats, both age groups 
demonstrated evidence of cortical lesion and calpain activation in the cortex and white 
matter at 6 hours, 24 hours, and 3 days (Huh et al., 2006).  Injury at PND17 resulted in 
the formation of a cavity by 4 weeks post-injury whereas injury at PND11 resulted in 
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cortical atrophy and enlargement of the lateral ventricle (Huh and Raghupathi, 2007).  
Both age groups exhibit evidence of traumatic axonal injury in the form of amyloid 
precursor protein accumulation (Huh et al., 2006, Huh et al., 2011).  While both age 
groups demonstrated deficits in spatial learning at 28 days post-injury, the extent of the 
deficit was significantly larger in the animals injured on PND11 and only PND11 animals 
showed spatial memory deficits in the probe trial (Huh and Raghupathi, 2007), indicating 
an age-dependent vulnerability in terms of the extent of cognitive impairment following 
injury.  
 This age dependency was also shown in a model of lateral diffuse injury using a 
silicone impactor tip. This injury produced gross tissue alterations in the P11 animal in 
the form of cortical, white matter, and subcortical atrophy as well as ventriculomegaly 
while this injury in the PND17 animals did not produce any overt tissue damage 
(Raghupathi and Huh, 2007).  Both age groups showed evidence of axonal injury in the 
white matter tracts and the thalamus, but PND11 animals showed increased astroglial 
reactivity and only PND11 animals demonstrated a spatial learning impairment at 28 days 
post-injury. This model of diffuse injury also produces a robust microglia/macrophage 
response accompanied by degeneration in the cortex, white matter, hippocampus, and 
thalamus (Hanlon et al., 2016b) (Chapters 3 & 4). 
 Impact to the intact dura in neonatal rabbits (PND5-7) produced similar results to 
those produced in the mouse and rat. The injury resulted in severe lesion at the impact 
site that, over time, affected the white matter and subcortical structures.  Microglial 
reactivity was significantly increased in the white matter at 7 days post-injury.  The 
animals also showed decreased neurobehavioral function and a deficit in novel object 
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recognition memory (Zhang et al., 2015). Impact to the intact dura in piglets of different 
ages (5 days, 1 month, 4 months) showed that injury to the older animal produced a 
greater extent of cell loss (Duhaime et al., 2000).  
 
 Despite vast differences in the brains of rodents and larger mammals such as pigs, 
pediatric injury models in both types of animals have successfully modeled the pathology 
associated with different types and severities of human pediatric traumatic brain injury 
such as tissue atrophy, ventriculomegaly, white matter injury, and inflammation.  Using 
models such as these to elucidate secondary mechanisms involved in these pathologies 
may provide relevant therapeutic targets to ameliorate further brain damage and 
functional impairment.    
 
1.3 MECHANISMS OF PEDIATRIC TRAUMATIC BRAIN INJURY 
 
1.3.1 Cell Death 
 
 Cell loss is apparent in children following TBI through volumetric analysis 
revealing evidence of tissue atrophy (Verger et al., 2001, Wilde et al., 2005, Suskauer and 
Huisman, 2009).  In preclinical models of injury to the immature brain, evidence of cell 
death is apparent through the formation of lesions/cavitations, the presence of tissue 
atrophy, and through detection of markers associated with necrosis, apoptosis, and 
excitotoxicity (Bittigau et al., 1999, Tong et al., 2002, Huh et al., 2006, Huh and 
Raghupathi, 2007).  After injury, dysregulation of excitatory neurotransmission and 
calcium influx can result in cellular damage referred to as excitotoxicity (Choi, 1987) and 
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there is evidence that excitotoxicity can lead the cell down either apoptotic or necrotic 
cell death pathways (Portera-Cailliau et al., 1997, Huh and Raghupathi, 2009).  Evidence 
of excitoxicity has been confirmed in the human population through the discovery of high 
amounts of glutamate in the cerebrospinal fluid of children that sustained a severe TBI 
(Ruppel et al., 2001).    Because calpain is activated by rises in intracellular calcium 
concentrations, this cysteine protease has conventionally been associated with necrotic 
cell death and has been implicated in post-injury degeneration (Kampfl et al., 1997).  Our 
lab has demonstrated an increase in calpain-mediated spectrin breakdown products in the 
cortex, thalamus, and white matter out to 3 days following injury to the PND11 rat 
indicating a role for excitotoxicity and necrotic damage in the pathophysiology of injury 
to the immature brain (Huh et al., 2006).  There is some evidence, however, that calpain 
is also associated with apoptotic cell death and can affect aspects of the intrinsic 
apoptotic pathway through its ability to inactivate anti-apoptotic protein bcl-2 and 
activate caspase-3 (Harwood et al., 2005).  Apoptotic cell death may also play a role in 
neurodegeneration following injury to the developing brain as researchers observed 
increased DNA fragmentation, increased caspase 3 activity, and down-regulation of bcl-2 
after injury and discovered that these apoptotic markers were most severe in young PND3 
and PND7 brain-injured rats (Bittigau et al., 1999).  Directly targeting the dysregulation 
of excitatory neurotransmission with NMDA or AMPA receptor antagonists following 
traumatic brain injury in the adult have produced very promising positive results that 
range from neuroprotection to the amelioration of cognitive impairment (Hamm et al., 
1993, Belayev et al., 2001, Rao et al., 2001). The immature brain, however, responds 
differently to changes in excitatory neurotransmission because the circuitry depends on 
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activity for proper development (Giza et al., 2007).  This was further demonstrated by the 
observation that NMDA receptor antagonism increased delayed apoptosis in the 
developing brain following TBI (Pohl et al., 1999).  These results suggest that targeting 
alterations in excitatory neurotransmission following insult to the immature brain may 
exacerbate injury pathology.   
 While alterations in excitatory neurotransmission can cause cell death, neuronal 
damage can also be mediated by external forces such as alterations in the glial response 
following injury. Microglia, specifically, can release pro-inflammatory cytokines and 
harmful mediators such as nitric oxide that will cause cellular injury and may result in 
cell death (Loane and Byrnes, 2010).  Microglial involvement following traumatic brain 
injury will be discussed in more depth in section 1.4.  
 
1.3.2 Axonal Injury 
 
 Traumatic axonal injury is a hallmark pathology of pediatric TBI and is readily 
reproduced in pre-clinical models.  In the year following injury, children demonstrated a 
decreased percentage of white matter on follow-up MRI scans compared to uninjured 
age-matched controls (Ghosh et al., 2009).  In our model of closed head injury in the 
PND11 rat, we recently showed that there is severe atrophy in the white matter over time 
indicating the loss of damaged axons (Hanlon et al., 2016b).  Proposed secondary 
mechanisms behind axotomy following traumatic brain injury include ionic 
dysregulation, calpain-mediated proteolysis, impaired axonal transport, microtubule 
degradation, and neurofilament compaction (Pettus et al., 1994, Pettus and Povlishock, 
1996, Saatman et al., 1996, Okonkwo et al., 1998, Buki et al., 1999, Stone et al., 2001).  
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Impaired axonal transport can be visualized through the accumulation of amyloid 
precursor protein leading to axonal swelling and eventual disconnection and has been 
observed in models of contusive and diffuse injury in the immature brain (Raghupathi 
and Huh, 2007, DiLeonardi et al., 2009, Eucker et al., 2011, Huh et al., 2011).  In 
addition to structural alterations in the axon, there is also evidence that brain injury in the 
immature animal impairs signal conduction throughout white matter fiber bundles 
(Dileonardi et al., 2012).  So far, a viable treatment strategy for ameliorating white matter 
histopathology and functional deficits has not been identified (DiLeonardi et al., 2009, 
2012).  
 
1.4 MICROGLIA/MACROPHAGES AND THEIR ROLE IN 
TRAUMATIC BRAIN INJURY 
 
1.4.1 Microglia Biology 
 
Origin  
 Sources indicate that microglia make up approximately 10-15% of all the cells in 
the brain, but this number may vary across brain regions and species (Lawson et al., 
1990, Azevedo et al., 2009).  They are known as the resident macrophages of the CNS 
because they were once believed to originate from hematopoietic stem cells much like 
monocytes and peripheral macrophages due to their structural and functional similarities 
(Hickey and Kimura, 1988, Eglitis and Mezey, 1997).  With scientific advances in 
cellular fate mapping and genetic manipulations, however, recent studies have indicated 
that microglia originate from a special population of macrophages from the yolk sac prior 
to the vascularization of the brain (Ginhoux et al., 2010, Schulz et al., 2012).  It is evident 
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that in times of distress, however, peripheral cells can infiltrate the brain and assume 
microglial phenotype and function indicating that yolk sac-derived microglia and 
hematopoietically-derived peripheral macrophages share some similarities (London et al., 
2013).      
 
Activation  
 Microglia exist in three morphologically distinct phenotypes: resting, ramified, 
and activated.   Resting microglia are characterized by their thin cell bodies and long, 
complex processes.  The term “resting” may be misleading, however, as it implies that 
these microglia are inactive, but these cells are constantly scanning their environment and 
releasing mediators to aid in maintaining the integrity of the surrounding neuronal 
circuitry (Hanisch and Kettenmann, 2007).  Using two-photon microscopy and 
genetically modified mice with fluorescently tagged microglia, microglia were visualized 
in vivo and it was observed that the processes of resting microglia were extremely motile 
and exhibited cycles of extension and withdrawal (Nimmerjahn et al., 2005).  
Furthermore, the processes of resting microglia make direct connections with synapses 
suggestive of a role in synapse maintenance (Wake et al., 2009).  It has become evident 
that neuronal signaling in the healthy brain assists in keeping microglia in a surveilling or 
“resting” state (Kierdorf and Prinz, 2013).  Such signals include the interaction between 
neuronal membrane-bound CD200 and the CD200 receptor on microglia as CD200 
knockout mice exhibited increases in microglial number and activated morphology (Hoek 
et al., 2000). Additionally, neurons express cell surface proteins that signal to the 
microglia that they are healthy and do not need to be phagocytosed such as signal 
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regulatory protein alpha (SIRPα) (van Beek et al., 2005). As microglia detect 
perturbations in the environment, they undergo a morphological change. A cell that 
seems to be in the middle of this change and could go on to become fully activated or 
return to resting, depending on the signals in the microenvironment, is sometimes 
referred to as an “intermediately active” or “ramified” cell (Gomes-Leal, 2012). These 
cells exhibit enlarged cell bodies that are still elongated with a visible shortening of the 
processes.  Recently, cells that meet these criteria have been identified after injury as 
“rod” microglia, but it is unclear what function these types of cells have in the 
pathophysiology of injury (Taylor et al., 2014).  When a microglia becomes fully 
“activated” the processes retract and the cell soma becomes enlarged and rounded taking 
on an amoeboid morphology more similar to that of peripheral macrophages.  It is 
through this morphological change that the cells are believed to become highly mobile 
and phagocytic (Nimmerjahn et al., 2005).  Microglia can become activated in response 
to neuronal damage through the detection of cell membrane fragments, purines, and 
glutamate indicating that the neuron is releasing its cytosolic contents into the 
extracellular space. These can activate the triggering receptor expressed on myeloid cells 
2 (TREM2) thus signaling for the microglia to become active and phagocytose the dying 
cell (Neumann and Takahashi, 2007, Kierdorf and Prinz, 2013).  In addition to a change 
in morphology, these activating signals can also trigger the release of soluble mediators 
such as pro- and anti-inflammatory cytokines, chemokines, and nitric oxide that can have 
beneficial or deleterious effects on the surrounding cells (Biber et al., 2007).   
 
Synthesis and Release of Soluble Mediators 
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 While microglia are not the only cells in the brain that can synthesize and release 
pro- and anti-inflammatory mediators, the use of these mediators to maintain homeostasis 
and respond to CNS insult is well-characterized in microglia (Hanisch, 2002, Kettenmann 
et al., 2011, Smith et al., 2012, Nayak et al., 2014).  Microglia not only synthesize and 
release cytokines and chemokines, they also contain receptors for some of these 
molecules to act as regulatory mechanisms and, in the specific case of chemokine 
receptors, to aid in chemotactic migration (Kettenmann et al., 2011).  Some of the well-
characterized pro-inflammatory cytokines associated with microglial reactivity are 
interleukin-1β (IL-1β), tumor necrosis factor α (TNFα), interleukin-6 (IL-6) and 
interferon gamma (IFN-γ) (Ramesh et al., 2013).  Microglia utilize chemokines such as 
macrophage inflammatory proteins (MIPs: MIP-1α, MIP-1β, MIP-2, Mip-3β), 
Interleukin-8 (IL-8), macrophage colony stimulating factor (M-CSF), and monocyte 
chemoattractant protein-1 (MCP-1) to attract other microglia and migratory peripheral 
cells (including peripheral macrophages) to the site of damage (Hanisch, 2002).  
Microglia can also synthesize and release nitric oxide (NO) and the excitotoxic 
tryptophan metabolite quinolinic acid (QA) that can be extremely detrimental to cell 
survival (Boje and Arora, 1992, Bal-Price and Brown, 2001, Guillemin, 2012).  These 
pro-inflammatory, chemotactic, and potentially neurotoxic characteristics are associated 
with an M1 microglial phenotype that has emerged in the study of detrimental microglial 
contributions to CNS pathology (Heneka et al., 2014, Tang and Le, 2016).  Microglia can 
also release mediators that are considered beneficial or anti-inflammatory in order to 
dampen the spread of neuroinflammation within the brain and modulate neuronal 
circuitry. For example, in response to neuronal damage and upregulation of pro-
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inflammatory mediators, microglia will also release the endogenous interleukin-1 
receptor antagonist (IL-1ra) and the anti-inflammatory cytokine IL-10 (Hanisch, 2002).  
Similarly, microglia can release growth factors such as transforming growth factor beta 
(TGFβ) that has been shown to aid in neurogenesis (Battista et al., 2006).  This beneficial 
anti-inflammatory profile has been associated with the alternative activation state M2 in 
which the most popular marker is Arginase-1, an enzyme expressed by microglia that is 
associated with wound repair (Cherry et al., 2014).  While investigations into the M1/M2 
microglial polarization have seen a rise in recent years, some evidence has been put forth 
that indicates that microglia don’t exist in perfectly polarized activated states, but that 
they can express markers associated with either phenotype at the same time (Morganti et 
al., 2016).  However, some researchers don’t believe this M1/M2 polarization exists in 
microglia in the healthy or damaged brain (Ransohoff, 2016).        
 
Role in Development 
 Microglia play crucial roles in brain development and this may be a factor in the 
pathophysiology of TBI in the immature brain.  Microglia have been implicated in 
developmental cell death, vascularization, synapse formation, and neurogenesis (Pont-
Lezica et al., 2011).  While microglia have been shown to congregate to areas of 
apoptosis, they may do more than just arrive to engulf the dying cell.  When the 
microglial CD11b integrin was deleted in mice, there was a decrease in developmental 
cell death indicating that microglia may play an active role in mediating cell death in the 
hippocampus (Wakselman et al., 2008).  One of the biggest responsibilities that microglia 
have in the developing brain is synaptic pruning- a process by which unnecessary 
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synaptic connections are removed in order to strengthen and enhance necessary circuitry.  
This process was confirmed in the developing mouse brain as labeled post synaptic 
density proteins were observed within labeled microglia.  Additionally, when the 
fractalkine receptor was knocked down in developing mice, there was an increase in total 
post-synaptic density proteins and synaptic spine density, and a decrease in the frequency 
of spontaneous excitatory post synaptic currents (sEPSCs), indicating that fractalkine 
serves as an important mediator in microglial-neuronal interaction and without it, 
microglia do not properly execute their synaptic pruning responsibilities, resulting in 
immature connectivity (Paolicelli et al., 2011).  The confirmation of microglial 
involvement in synaptic pruning may have important implications for 
neurodevelopmental disorders in which aberrant connectivity results in behavioral 
dysfunction (i.e. autism or schizophrenia). Finally, microglial-associated mediators that 
have been identified as harmful pro-inflammatory molecules in the injured brain act as 
powerful neuromodulators that allow for the development of functional neuronal circuitry 
(McAfoose and Baune, 2009).  For example, IL-1 activity in the healthy brain seems to 
be necessary for hippocampal-dependent memory processes as blockade of this signaling 
resulted in memory impairment (Goshen et al., 2007). 
 
Role in ischemic brain injury in the neonate   
Hypoxic-ischemic (HI) injuries in the neonate produced microglial responses that 
were evident 4 hours after injury and peaked around 4 days, but evidence of activation 
still remained out to 14 days post-insult (McRae et al., 1995, Ivacko et al., 1996).  
Similarly, HI in 7-day-old rats resulted in acute increases in inflammatory mediators such 
39 
 
as IL-1β and TNFα and prolonged expression of microglial/macrophage marker MHC1 
out to 42 days post-injury (Bona et al., 1999).  This injury also induced increases in 
chemokine expression indicating that hypoxic-ischemic injury was sufficient to mount an 
inflammatory response involving chemotactic migration of immune cells (Cowell et al., 
2002).  The use of anti-inflammatory therapeutics in HI have produced mixed results with 
some studies citing significant rescue of injury-induced damage and others claiming that 
these therapies exacerbate damage in the developing brain.  Similar to results in adult 
TBI, blockade of IL-1 signaling reduced gliosis, myelin loss, and improved motor 
outcomes such as impairments in overall locomotion and limb dexterity following HI 
injury and inflammatory insult initiated by administration of lipopolysaccharide (LPS) 
(Girard et al., 2012).  Antibiotics with anti-microglial properties such as doxycycline and 
minocycline have been shown to alleviate injury-induced damage to neurons and 
oligodendrocytes as well as alleviate neurological dysfunction following HI injury (Arvin 
et al., 2002, Jantzie et al., 2005, Cai et al., 2006).  However, in a model of HI injury in the 
neonate mouse, minocycline administration significantly increased lesion volume (Tsuji 
et al., 2004).  In a model of neonatal stroke, cellular depletion of microglia also 
exacerbated lesion area (Faustino et al., 2011).  Finally, in contrast to results in the adult, 
progesterone treatment in neonatal rats following HI exacerbated injury-induced 
hemispheric damage.  Interestingly this exacerbation was only observed in rats injured on 
PND7 and PND14, but not those injured on PND21 emphasizing that treatments may not 
function through the same mechanisms in young animals compared to older animals 
(Tsuji et al., 2012). 
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Age-dependent effects of microglial priming prior to brain injury 
 The endotoxin lipopolysaccharide (LPS) activates microglia in both neonate and 
adult animals (Hoogland et al., 2015).  In the adult brain, LPS-induced microglial 
activation prior to cryogenic injury resulted in neuronal protection as LPS-treated brain-
injured mice demonstrated fewer TUNEL-labeled cells in the injured cortex (Chen et al., 
2012).  Interestingly, even when mice were exposed to LPS in utero, neuroprotection was 
conferred when they sustained a hypoxic-ischemic injury on PND70 (Wang et al., 2007).  
LPS preconditioning in adult mice also protected neurons from TNFα-induced damage 
following stroke (Rosenzweig et al., 2007) and reduced contusion volume and motor 
deficits following TBI (Longhi et al., 2011).  Preconditioning prior to weight-drop brain 
injury reduced gliosis and axonal injury in the corpus callosum in adult rats (Turner et al., 
2017). These results indicate a neuroprotective role for LPS preconditioning and 
microglial priming in the context of injury to the adult brain.  In the immature brain, 
however, LPS preconditioning has had mixed results in models of hypoxic-ischemic (HI) 
injury and these conflicts appear to be dependent on the timing of LPS delivery and the 
length of HI exposure. When LPS (0.3 mg/kg) was delivered 24 hours prior to a 50-
minute HI insult, it reduced brain injury as measured by regional morphologic analysis.  
When this same dose of LPS was delivered 6 hours or 72 hours before either a 20-minute 
or 50-minute HI insult, however, brain injury was significantly increased (Eklind et al., 
2005).  In a different study, 0.3 mg/kg LPS 24 hours prior to a 2-hour insult resulted in a 
high mortality rate, but 0.05 mg/kg LPS 24 hours prior decreased acute post-insult 
microglia/macrophage activation and NOS production as well as reducing long-term 
brain damage and ameliorating learning and memory deficits in adulthood (Lin et al., 
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2009).  When LPS was administered in utero and HI was induced at PND5 or 9, treated 
pups demonstrated exacerbated brain injury, reduced myelin, and increased caspase-3 
activity (Wang et al., 2007).  These inconsistent results emphasize the complexity of 
microglial/macrophage activity during development, especially in the context of injury. 
 
1.4.2 Clinical Evidence for Microglial Involvement in Pediatric TBI 
 
 The microglial response in children following traumatic brain injury is often 
monitored via serum biomarker analysis.  As previously mentioned, microglia release a 
host of different pro- and anti-inflammatory mediators, growth factors, and neurotoxic 
chemicals that can be monitored post-injury (Woodcock and Morganti-Kossmann, 2013).  
In assessments of cytokines concentrations in the CSF following severe TBI in children, 
cytokines IL-1β, IL-6, and IL-10 were elevated indicating an increase in pro-
inflammatory signaling but also an endogenous increase in anti-inflammatory signaling to 
combat the injury (Bell et al., 1997, Buttram et al., 2007).  Additionally, there seemed to 
be an age-dependency in the observed levels of IL-10 with children under the age of 4 
producing significantly higher levels of IL-10 irrespective of injury severity (Bell et al., 
1997).  Additionally, chemokines IL-8 and MIP-1α were also increased indicating 
migratory signaling to other immune cells (Buttram et al., 2007).  Children that sustain 
severe traumatic brain injury also have significantly higher concentrations of quinolinic 
acid in their CSF indicating high levels of microglia/macrophage activation in the brain 
following injury (Berger et al., 2004).  While children that sustain severe injuries seemed 
to be more likely to mount a measurable immune response, there was evidence that 
children that sustained mild TBIs had significantly higher concentrations of IL-6 in their 
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CSF indicating a role for inflammation in a range of different injury severities (Berger et 
al., 2009).             
 
1.4.3 Microglial Reactivity Following TBI 
 
Adult TBI  
In models of TBI in the adult, cellular microglial activation has been detected in 
both grey and white matter following different severities of injury (Csuka et al., 2000, 
Raghavendra Rao et al., 2000, Igarashi et al., 2007, Venkatesan et al., 2010, Wang et al., 
2014) and increases in the production of inflammatory mediators have been observed 
(Shohami et al., 1994, Fan et al., 1995, 1996, Stover et al., 2000, Song et al., 2002, Natale 
et al., 2003, Israelsson et al., 2008).  Treatments targeting this immune response in the 
adult brain following TBI have been rather successful in mediating injury-induced cell 
death and functional impairment indicating a role for microglial activation and 
inflammation in the neurodegenerative mechanisms following injury.  Progesterone 
treatment following traumatic brain injury in the adult rat decreased IL-1β and TNFα 
expression and has been associated with a decrease in apoptotic markers and 
improvement on a spatial learning and memory task (He et al., 2004, Djebaili et al., 
2005).  Minocycline administration has been shown to decrease microglial reactivity and 
was associated with similar reductions in apoptosis and functional impairments following 
TBI (Sanchez Mejia et al., 2001, Kovesdi et al., 2012, Siopi et al., 2012).  Finally, 
blockade of harmful pro-inflammatory IL-1 signaling can significantly reduce neuronal 
damage and ameliorate cognitive dysfunction (Toulmond and Rothwell, 1995, Sanderson 
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et al., 1999).  In the immature brain, the microglial response has been thoroughly 
investigated following non-impact hypoxic-ischemic brain injury.  
 
Neonate TBI       
Very few studies have been conducted investigating microglial reactivity and the 
role of inflammation following impact to the developing brain.  In adolescent mice 
(PND35), a mild impact resulted in an increase in microglial reactivity in only the corpus 
callosum at 24 hours, but there were no differences in labeling between brain-injured 
animals and sham-injured controls at 3 months post-injury and this initial increase was 
not associated with volumetric changes or increases in cell death (Semple et al., 2016).  
In a model of moderate contusive injury in the PND21 mouse, microglial activation was 
apparent in the ipsilateral cortex around the lesion, the CA2 region, CA3 region and 
dentate gyrus of the hippocampus, and the thalamus out to 7 days post-injury.  All of 
these regions also demonstrated evidence of fluoro-jade B-positive (FJB+) degenerating 
cells in the same time frame (Tong et al., 2002).  This injury also resulted in enhanced 
infiltration of leukocytes and neutrophils as these cell types were elevated in the brains of 
animals injured on PND21 compared to brain-injured adult animals (Claus et al., 2010).  
After injury to the neonatal rabbit (PND5-7), researchers characterized a robust 
microglial response in the white matter of brain-injured animals that was associated with 
both an increase in microglial cell number and a morphologic activation that was heaviest 
at 3 days post-injury, but persisted to 21 days and may be associated with persistent 
cognitive deficits (Zhang et al., 2015).  While neuroinflammation has been identified as a 
target for pediatric TBI, there are still only a few studies targeting this cascade or the 
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microglial response following impact-based trauma to the immature brain (Potts et al., 
2006).  Brain-injured neonatal mice that were deficient in neutrophil elastase (released by 
activated neutrophils recruited from the periphery) demonstrated a decrease in cell death 
and markers of oxidative stress as well as functional recovery in spatial learning and 
memory assessment. Acutely targeting neutrophil elastase with an inhibitor, however, 
only reduced acute cell death and had no effect on long-term behavioral outcomes 
emphasizing the complexity of targeting aspects of the neuroinflammatory cascade 
following injury to the immature brain (Semple et al., 2015).  Because neutrophils can be 
recruited by chemotactic signals released by microglia (specifically IL-8 and MIP-2), 
these results also still indicate that microglial reactivity is pivotally involved in this 
process (Hanisch, 2002, Kobayashi, 2008).  Finally, our lab has demonstrated that 
repetitive trauma to the PND11 rat induces dense microglia/macrophage reactivity in the 
cortex, corpus callosum, and thalamus that is associated with neurodegeneration, axonal 
injury, and spatial learning and memory deficits.  Acute treatment with minocycline in 
this model only resulted in a decrease in activated microglia/macrophages in the corpus 
callosum at 3 days post-injury and had no effect on neurodegeneration or axonal injury, 
but exacerbated spatial memory deficits in the second post-injury week (Hanlon et al., 
2016a).   
 
The microglial response following impact injury to the immature brain is not 
simply a replica of the response that occurs in adults or in models of non-impact brain 
injury.  The role of microglial activation following injury to the developing brain needs 
further investigation, especially if anti-inflammatory treatments are going to be used in 
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brain-injured children. This thesis aims to characterize the cellular microglia/macrophage 
response in a model of neonatal traumatic brain injury and to investigate its role in 
neuropathological alterations and long-term functional impairments through the use of 
post-injury microglia/macrophage manipulations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
 
 
 
 
 
 
 
CHAPTER 2: STATEMENT OF SPECIFIC AIMS 
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Traumatic brain injury (TBI) is a leading cause of death and disability in children 
with those aged 0-4 having the highest incidence of emergency room visits due to TBI 
(Faul et al., 2010).  Children that survive their injuries exhibit long-term pathologic 
changes such as atrophy and ventriculomegaly and demonstrate a wide array of 
functional impairments (Wilde et al., 2005, Ghosh et al., 2009).  Evidence of 
neuroinflammation in brain-injured children has been documented and may play a pivotal 
role in the perpetuation of injury-induced neuronal damage and behavioral impairments 
(Berger et al., 2004, Buttram et al., 2007, Berger et al., 2009).  Our lab has demonstrated 
that closed head injury in the PND11 rat resulted in atrophy, indicative of cell 
loss/degeneration, ventricle enlargement, axonal injury, and spatial learning and memory 
deficits thus reproducing the pathology observed in human pediatric TBI (Raghupathi 
and Huh, 2007).  We have preliminary evidence that this injury produces a 
microglia/macrophage response, but the characterization of this response and its effects 
on pathology and behavioral alterations has yet to be elucidated.  Inflammation following 
pediatric TBI has also been identified as a potential target for therapeutic intervention 
(Potts et al., 2006) as anti-inflammatory treatments have been successful in ameliorating 
cell death and behavioral dysfunction in models of TBI in the adult (Sanchez Mejia et al., 
2001, He et al., 2004, Siopi et al., 2012).  The evidence for the success of anti-
inflammatory interventions in the developing brain following non-impact injury is 
conflicting as some report neuroprotection and others report exacerbation of injury-
induced pathology (Arvin et al., 2002, Tsuji et al., 2004, Cai et al., 2006, Carty et al., 
2008, Faustino et al., 2011, Tsuji et al., 2012).  Investigating the microglia/macrophage 
response and using different manipulations targeting either the entire cell or the activation 
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state will not only illuminate its role in post-injury pathology and behavioral alterations, 
but it will also shed light on the efficacy of targeting post-injury microglia/macrophage 
activation in the immature brain.       
SPECIFIC AIM 1:  
Part A: Characterize the post-injury microglia/macrophage response and investigate 
novel functional deficits in axonal conduction and cortical electrophysiology. Hypothesis: 
The microglia/macrophage response will overlap regionally and temporally with 
neurodegeneration, axonal injury, and axonal degeneration suggesting a role for 
microglia/macrophages in these post-injury pathologies.  Brain-injured animals will 
exhibit deficits in cortical activity and axonal conduction in regions where degeneration 
and microglia/macrophage reactivity are present.    
Part B: Elucidate the role of microglia/macrophages in post-injury pathology and 
functional deficits using clodronate-mediated microglia/macrophage depletion.  
Hypothesis: Clodronate-treated brain-injured animals will demonstrate a decrease in 
degeneration and axonal injury that will ameliorate deficits in cortical field potential, 
axonal conduction, and spatial learning and memory.  
SPECIFIC AIM 2:  
Investigate the role of microglia/macrophage activation in post-injury pathology and 
functional deficits by using minocycline to reduce activated (amoeboid) 
microglia/macrophages. Hypothesis: Minocycline treatment will decrease 
microglia/macrophage activation while simultaneously decreasing neurodegeneration and 
axonal injury.  Minocycline-treated animals will also demonstrate improvements in 
cortical activity and spatial learning and memory. 
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SPECIFIC AIM 3:  
Part A: Expand the functional profile of our injured animals beyond that of spatial 
learning and memory and neuronal activity within the impact site to include relevant 
behavioral assessments in the chronic post-injury period (anxiety, working memory, 
seizures, motor) and a characterization of neuronal activity a region that does not 
demonstrate post-injury cellular pathology. Hypothesis:  Brain-injured will demonstrate 
increased anxiety, working memory impairment, an increased susceptibility to seize, and 
deficits in locomotion. Animals will not exhibit alterations in neuronal activity in the 
frontal cortex, indicating a role for degeneration and microglia/macrophage reactivity in 
post-injury neuronal activity.    
Part B: Investigate the role of acute microglia/macrophage manipulations on behavioral 
impairment in the chronic post-injury period. Hypothesis: The acute neuroprotection 
afforded by clodronate-mediated depletion and minocycline-mediated decreased 
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reactivity hypothesized in Aims 1 and 2 will aid in attenuating chronic post-injury 
behavioral impairment.  
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CHAPTER 3: CHARACTERIZATION OF THE 
MICROGLIA/MACROPHAGE RESPONSE FOLLOWING TBI IN 
THE NEONATE RAT AND THE EFFECTS OF LOCAL 
MICROGLIA/MACROPHAGE DEPLETION 
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3.1 ABSTRACT 
 
 Neuroinflammatory mediators and markers of microglia/macrophage activation 
have been identified in the cerebrospinal fluid of children that have sustained traumatic 
brain injuries indicating that these immune cells may play a significant role in the 
pathophysiology of the injury.  In this study, microglia/macrophage reactivity was 
assessed following injury to the PND 11 rat.  Injury produced a robust 
microglia/macrophage response in the cortex, thalamus, and subiculum at 3 days post-
injury that was sustained out to 4 weeks.  This microglia/macrophage reactivity was 
associated with the sustained presence of FJB(+) profiles in all of these regions.  
Interestingly, cortical activity was only altered at 3 days post-injury despite the sustained 
presence of FJB-labeled cells.  Microglia/macrophage reactivity was also observed in the 
corpus callosum and lateral white matter tracts out to 4 weeks post-injury and was 
associated with evidence of axonal degeneration (FJB) and axonal injury (APP).  
Similarly, axons in the white matter of brain-injured animals showed both conduction and 
transport deficits.  Peri-injury microglia/macrophage depletion was conducted via 
clodronate injection to investigate the role of microglia/macrophages in these various 
post-injury pathologies.  At 15 days post-injury, microglia/macrophages showed evidence 
of repopulation but exhibited a strange rod-like phenotype in brain-injured animals that 
progressed to an increase in activated amoeboid cells by 35 days post-injury.  This 
coincided with an increase in FJB labeling in all regions.  In the cortex, this increase in 
FJB labeling was also associated with hyperactivity.  Clodronate, which has largely been 
identified as selectively targeting microglia/macrophages, also decreased astrocytic 
reactivity indicating non-specific targeting.  Interestingly, despite an increase in FJB(+) 
53 
 
profiles in the white matter, axonal injury and axonal conduction deficits were unaffected 
by microglia/macrophage depletion.  Finally, brain-injured animals treated with 
clodronate did not show attenuation or exacerbation of injury-induced spatial learning 
and memory deficits at 2 or 4 weeks post-injury.  Sham-injured animals treated with 
clodronate, however, showed a mild, but transient spatial learning deficit indicating a role 
for glia in physiological cognitive development.  While these results support the notion 
that post-injury microglia/macrophage activation is needed for the maintenance of 
neuropathology, the depletion may have been too severe of an intervention and further 
investigation is warranted.  
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3.2 INTRODUCTION 
 
Pediatric traumatic brain injury (TBIs) is a devastating health problem that can 
result in long-term pathologic and functional alterations that can significantly affect 
quality of life (Annegers et al., 1998, Ewing-Cobbs et al., 2000, Schwartz et al., 2003, 
Keenan et al., 2004, Anderson et al., 2005, Ewing-Cobbs et al., 2008, Max et al., 2015).  
While advocating for injury prevention in children is admirable, it is essential that targets 
are identified and therapeutics are developed aimed at halting the secondary damage 
associated with biochemical cascades following injury (Greve and Zink, 2009).  
Neuroinflammation has been identified as a potential therapeutic target following 
pediatric TBI as evidence has emerged that the increased presence of pro-inflammatory 
mediators in the cerebrospinal fluid of brain-injured children may correlate with injury 
severity and may be exacerbated in young children (≤ 4 years of age) (Amick et al., 2001, 
Potts et al., 2006, Buttram et al., 2007, Berger et al., 2009).  These inflammatory 
mediators are associated with a cascade that involves microglia/macrophage activation 
post-injury and specific evidence for this reactivity has also been observed in the CSF of 
traumatically injured children (Berger et al., 2004, Loane and Kumar, 2016).   
Microglia/macrophage reactivity has been identified in pediatric traumatic brain 
injury models using rodents and rabbits, but their role in the pathophysiology of pediatric 
trauma remains unclear (Zhang et al., 2015, Chhor et al., 2016).  Additionally, microglia 
play a large role in proper brain development indicating that their role in injury to the 
developing brain may be more complex than their role following injury to the fully-
developed adult brain (Graeber and Streit, 2010, Loane and Byrnes, 2010).  Targeting the 
microglia/macrophage response following hypoxic-ischemic (HI) injury to the 
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developing brain, however, has produced results that are very similar to the success 
reported in the use of anti-microglia/macrophage treatments following TBI in the adult 
indicating that an anti-microglia/macrophage therapeutic may provide neuroprotection in 
an impact-based model of pediatric brain injury (Sanchez Mejia et al., 2001, Arvin et al., 
2002, He et al., 2004, Djebaili et al., 2005, Cai et al., 2006, Plane et al., 2010).  
In our model of TBI to the PND11 rat, injury results in tissue atrophy, axonal 
injury, and prolonged spatial learning and memory deficits (Raghupathi and Huh, 2007).   
We have limited preliminary evidence that indicates that this injury also results in 
microglia/macrophage reactivity.  One of the goals of this study to characterize the 
cellular microglial response following injury as it relates to neurodegeneration, axonal 
pathology, and alterations in neuronal activity.  The second goal of this study is to 
investigate how these pathologies are altered in the absence of an acute 
microglia/macrophage response through the use of clodronate-mediated 
microglia/macrophage depletion.  Clodronate (dichloromethylene-bisphosphonate, 
Cl2MBP) can be packaged in liposomes to specifically target and induce the apoptosis of 
phagocytic cells and is commonly used to target peripheral macrophages (Lehenkari et 
al., 2002, van Rooijen and van Kesteren-Hendrikx, 2003).  It has shown efficacy in 
depleting microglia from mixed cultures and in the limited use of this compound in the 
brain, it has been successful in significantly decreasing the total number of microglia 
(Faustino et al., 2011, Drabek et al., 2012, Kumamaru et al., 2012, Asai et al., 2015).  
Based on the previous work targeting the microglia/macrophage response in both adults 
(TBI) and neonates (HI), it is our hypothesis that by removing the 
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microglia/macrophages, we will block their detrimental contribution to secondary injury 
and observe an amelioration of injury-induced neuropathology and functional deficits.  
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3.3 MATERIALS AND METHODS 
 
3.3.1 Brain Injuries 
 
 All surgical procedures were done in accordance with the rules and regulations of 
the Institutional Animal Care and Use Committee at Drexel University College of 
Medicine.  On postnatal day 11, male and female Sprague Dawley rat pups (Charles 
River Laboratories, Wilmington, MA) were randomly assigned to injury conditions 
(Sham-Injured, N=; Brain-Injured, N=).  Animals were placed in a nose cone and 
anesthetized using 5% isoflurane and a 2cm incision slightly left of the midline was made 
to expose the skull.  Once exposed, the periosteum was cleared away and a small mark 
was made on the skull over the left parietal cortex midway between the bregma and 
lambda sutures to indicate the impact site.  Four minutes after the start of anesthesia 
exposure, animals were removed from the nose cone, placed in plastic rodent restrainer 
(Braintree Scientific, Braintree, MA), and moved to the stage of the controlled cortical 
impact device (CCI, Custom Design and Fabrication, Richmond, VA, Fig. 3.1).  The 
piston tip (5mm silicone impactor tip) was zeroed over the previously made mark and 
then electrically driven into the intact skull at velocity of 5m/s with an injury depth of 
3mm and a dwell time of 100ms.  Sham-injured animals were treated exactly the same as 
brain-injured animals but did not undergo impact.  Animals were allowed to right 
themselves before being placed back under anesthesia to be sutured. Surgical procedure 
and recovery occurred on heating pads to maintain the animals’ body temperatures.  Post-
surgery, animals recovered in a separate cage for at least 30 minutes before being placed 
back with the mother.      
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3.3.2 Fluoro-Gold Injections 
 
 Fluoro-Gold (2%, Fluorochrome) was injected into the left cortex of both 
sham-injured and brain-injured animals 14 days post-injury.  Animals were initially 
placed under 5% isoflurane anesthetic for the incision and situating the animal in blunt-
tipped stereotactic jaw bars.  The anesthetic was tapered down to 2-3% for the duration of 
the surgery.  A 10-μl glass syringe (Hamilton, Franklin, MA) and a microsyringe 
injection pump (Micro-4, World Precision Instruments, Sarasota, FL) were used to 
withdraw 5μl of the working Fluoro-Gold solution into the syringe.  After zeroing  the tip 
at bregma and moving the tip to the desired coordinates, the spot was marked and a burr 
hole was drilled into the skull.  The dura was punctured using a 26 1/2 gauge needle, the 
needle was zeroed at the dura, and was lowered into the brain.  The needle was left 
stationary in the brain for 2 minutes prior to the beginning of infusion.  The compound 
was delivered at a rate of 1μl/minute for a total of 2μl in 2 minutes. The syringe was left 
stationary in the brain for 5 minutes after the completion of infusion before being raised 
slowly from the brain to minimize draw back.  Animals were removed from the jaw bars, 
sutured, and moved to the recovery cage. All surgical procedures and recovery occurred 
on circulating heating pads to maintain body temperature and the animals were allowed 
to recover for 30 minutes before being returned to their home cages.  
 
3.3.3 Clodronate Administration 
 
 Liposome-encapsulated clodronate or empty control liposomes were 
administered to both sham-injured and brain-injured animals 24 hours after injury on 
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postnatal day 12.  Animals were initially placed under 5% isoflurane anesthetic for suture 
removal, cleaning and reopening of the incision site, and situating the animal in blunt-
tipped stereotactic jaw bars.  The anesthetic was tapered down to 1-2% for the duration of 
the injection surgery.  Separate 100-μl glass syringes (Hamilton, Franklin, MA) and a 
microsyringe injection pump (Micro-4, World Precision Instruments, Sarasota, FL) were 
used to withdraw 30μl of Clodrosome® (liposome-encapsulated clodronate) or 
Encapsome® (empty liposomes, Encapsula NanoSciences, Brentwood, TN).  The syringe 
was zeroed at the intersection of the bregma and midline sutures and moved into position 
for burr hole markings (cortical injection: 1.5mm posterior to bregma and 1.7mm lateral 
to the midline; thalamic injection: 3.5mm posterior to bregma and 1.7mm lateral to the 
midline).  Two burr holes were made in the skull in the targeted areas and the dura was 
punctured with a 26 1/2 gauge needle.  Once zeroed in the burr hole, the needle was 
lowered 1.7mm into the cortex and left still for 2 minutes before the pump was switched 
on.  The compound was delivered at a rate of 1μl/minute for a total of 10μl in 10 minutes. 
The syringe was left stationary in the brain for 5 minutes after the completion of infusion 
before raised slowly from the brain to minimize draw back. The syringe was then moved 
and zeroed over the burr hole for the thalamic injection and lowered 3.7mm into the 
brain.  The same procedure was repeated as described for the cortical injection.  Once the 
syringe was removed from the brain, the animal was taken out of the jaw bars and 
sutured.  All surgical procedures and recovery occurred on circulating heating pads to 
maintain body temperature and the animals were allowed to recover for at least an hour 
before being returned to the mother. 
 
60 
 
3.3.4 Histology and Immunohistochemistry 
 
At the appropriate time points, animals were anesthetized (sodium pentobarbital, 
60mg/kg, i.p.) and perfused transcardially with 4% paraformaldehyde. Brains were left in 
the skull in paraformaldehyde for 24 hours before being extracted from the skull, post-
fixed for an additional 24 hours, and placed in 30% sucrose at 4°C until the time of 
slicing. Brains were sliced on a freezing-stage sliding microtome after being flash frozen 
in 2-methyl butane at -40°C.  Twelve sets of coronal sections (40-45μm thick) were taken 
starting approximately at the bregma suture to 5-6mm posterior to bregma. Depending on 
the age of the animal, each set of sections contained 12-16 sections and were stored in 
5ml vials filled with cryoprotectant (30% ethylene glycol, 30% glycerol) at -20°C until 
use.  Adjacent sets of sections were mounted on gelatin-coated slides and stained for 
Fluoro-Jade B (FJB) or Nissl-myelin (2% Cresyl Violet and 0.2% Cyanine R) (Hanlon et 
al., 2016).  Sections from FG brains were mounted and allowed to dry in the dark before 
being coverslipped with DPX mounting media. Using free-floating 
immunohistochemistry protocols, additional separate sets of sections (full or half vials) 
were evaluated for microglia/macrophages using antibodies for anti-ionized calcium-
binding adaptor molecule 1 (Iba1, Wako, Richmond, VA, 1:20,000) and CD68 (Clone 
ED1, BioRad, formerly AbD Serotech, Hercules, CA, 1:500), astrocytes using glial 
fibrillary acidic protein (GFAP, Sigma, St. Louis, MO: 1:5,000) and traumatic axonal 
injury using a polyclonal antibody to the C-terminal end of amyloid precursor protein 
(APP, Zymed, San Francisco, CA, 1:2,000).  For anti-APP immunohistochemistry, 
antigen retrieval was executed by incubation with 10mM sodium citrate (pH 6.5) in a 
60ºC water bath for 20 minutes.  Primary antibody binding was detected using 
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biotinylated donkey anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA, 1:1000 
for APP and 1:500 for Iba1) or biotinylated donkey anti-mouse IgG (Jackson 
ImmunoResearch, West Grove, PA, 1:500 for ED-1 and GFAP).  Antibody binding was 
visualized using the ABC Elite System with diaminobenzidine (Vector Laboratories, 
Burlingame, CA).   
 
3.3.5 Quantification Methods for Histology and Immunohistochemistry 
 
The areas of the cortex (from midline to rhinal fissure) of the injured hemisphere 
and white matter (corpus callosum, cingulum and lateral aspects up to the rhinal fissure) 
were measured in Nissl-myelin-labeled sections via manual tracing using Image J 
software (NIH) (Hanlon et al., 2016). Quantification in the cortex (layers 2 through 5 of 
the retrosplenial, motor and somatosensory cortices), hippocampus (dorsal subiculum) 
and thalamus (dorsolateral and lateral geniculate nuclei), and  was conducted by counting 
labeled profiles (Iba1, ED-1, FJB) in 3-5 high power field (HPF) images (20x 
magnification) per section across 3-5 non-adjacent sections; Iba1(+) profiles that 
exhibited an activated morphology were counted and presented as a percent of total 
Iba1(+) profiles in that region.  ED-1(+) profiles were counted as separate phenotypes: 
amoeboid morphology (enlarged, rounded cells with few to no visible processes) and rod 
morphology (elongated cells with thick cell bodies and few to no visible processes).  
Fluoro-Jade B(+) profiles (regardless of size) and amoeboid/rod ED-1(+) profiles were 
counted in 3 HPF images (20x magnification) per section that covered the area between 
the corpus callosum, cingulum and the lateral aspects of the white matter up to the rhinal 
fissure across 3-5 sections.  Because of the density of Iba1 labeling in the white matter, 
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clear cellular bodies could not be distinguished in order to conduct reliable cell counting.  
For this reason, we used a thresholding approach from digitized images (Image J, NIH) 
and the labeled area was divided by the corresponding total area measured in the Nissl-
myelin stained sections to address severe atrophy in the white matter (Hanlon et al., 
2016).  GFAP labeling was quantified in the cortex using this same measured 
thresholding technique except the labeled area was not measured as a function of the 
nissl-myelin-stained cortical area due increased confidence in the cortical boundaries in 
GFAP-labeled sections as opposed to white matter boundaries in Iba1-labeled sections.  
APP-labeled profiles were quantified in the white matter and thalamus using a modified 
grid analysis method (DiLeonardi et al., 2009) where the presence of APP(+) profiles 
were marked in a 6x5 grid overlaid onto 20x images (Photoshop). In the white matter, 3 
images across 5 sections (15 images) where analyzed and in the thalamus, 3 images 
across 3 sections (9 images) were analyzed.       
 
3.3.6 Compound Action Potential Electrophysiology 
 
 Compound action potential (CAP) electrophysiology was conducted as previously 
described (Reeves et al., 2005, DiLeonardi et al., 2009).  Briefly, animals were 
anesthetized with 5% isoflurane, decapitated, and the brain was rapidly removed and 
placed in oxygenated (95% O2/5% CO2) ice-cold artificial cerebrospinal fluid (aCSF) 
(130 mM NaCl, 24 mM NaHCO3, 10 mM glucose, 3.5mM KCl, 1.25 mM Na2H2PO4, 1.5 
mM MgSO4 .7H2O, 2mM CaCl2.2H2O).  The brain was adhered to the vibratome block 
using superglue and the block was placed with the ventral surface of the brain facing the 
blade in the vibratome bath chamber.  The bath chamber was filled with ice-cold aCSF 
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and was continuously oxygenated.  Coronal slices were cut at a thickness of 450μm 
starting at bregma and ending at approximately 4mm posterior to bregma. After 1 hour of 
incubation at room temperature, slices were moved to the aCSF-filled recording chamber 
where they were continuously bathed with fresh aCSF for the duration of recording.  A 
bipolar, tungsten stimulating electrode (with an inter-tip distance of approximately 
350μm) was placed in the injured (left hemisphere) corpus callosum and a pulled glass 
recording pipette filled with aCSF was placed in the corpus callosum approximately 1mm 
away from the stimulating electrode.  Potentials were evoked using constant current 
pulses (200μs duration) from a Master-8 pulse stimulator (A.M.P.I, Jerusalem, Israel) at 
increasing intensities (manual current stepping) and recorded using an Axoclamp 2B 
amplifier.  A maximum current was found for each slice and input/output curves were 
constructed using decreasing 200μA current steps from the maximum.  The amplitude of 
the N1 (myelinated) component was measured as the difference (in millivolts) between 
the top of first positive peak and the trough of the first negative peak.  The amplitude of 
the N2 component (unmyelinated) was measured as the difference (in mV) between the 
trough of the second negative peak and baseline.  The conduction velocity was measured 
as the difference in time between the stimulating artifact and the first negative peak (N1) 
or second negative peak (N2) at max stimulus amplitude.   All quantitative analysis was 
made on representative waveforms that were the average of 4 sweeps at that particular 
stimulus intensity and presented as an input/output curve. Data in the clodronate study 
was presented as bar graphs at the max stimulus amplitude.  
 
 3.3.7 Cortical Evoked Field Potential Electrophysiology 
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Animals were anesthetized with 5% isoflurane, decapitated, and the brain was 
rapidly removed and placed in oxygenated (95% O2/5% CO2) ice-cold artificial 
cerebrospinal fluid (aCSF) (130 mM NaCl, 24 mM NaHCO3, 10 mM glucose, 3.5mM 
KCl, 1.25 mM Na2H2PO4, 1.5 mM MgSO4 .7H2O, 2mM CaCl2.2H2O).  The brain was 
adhered to the vibratome block using superglue and the block was placed with the ventral 
surface of the brain facing the blade in the vibratome bath chamber.  The bath chamber 
was filled with ice-cold aCSF and was continuously oxygenated.  Coronal slices were cut 
at a thickness of 450μm starting at 1.5 mm anterior to bregma and ending at 
approximately 4mm posterior to bregma. After a 1 hour incubation (30 minutes at 37°C 
and 30 minutes at room temperature), slices were moved to the aCSF-filled recording 
chamber where they were continuously bathed with fresh aCSF for the duration of 
recording.  A bipolar, tungsten stimulating electrode (World Precision Instruments, 
Sarasota, FL) was placed in layer 2 of the injured cortex and a pulled glass recording 
pipette filled with aCSF was placed in layer 5 of the same cortex (not directly 
underneath- offset by approximately 300μm).  Potentials were evoked using constant 
current pulses (200μs duration) from a Master-8 pulse stimulator (A.M.P.I, Jerusalem, 
Israel) at increasing intensities (manual current stepping from 0-1000μA) and recorded 
using an Axoclamp 2B amplifier.  Slices reacted similarly to current input and 
demonstrated a plateau around 800μA therefore all data is presented at this current 
intensity. The amplitude of the signal was measured as the difference (in millivolts) 
between baseline and the middle of the primary peak, the latency of the signal was 
measured as the difference in time (ms) between the beginning of the stimulus artifact 
and the middle of the primary peak, and the duration of the signal was measured as the 
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duration/width (ms) of the peak at 50% of the measured amplitude.  All quantitative 
analysis was made on representative waveforms that were the average of 5 sweeps at that 
particular stimulus intensity (800μA for representation of data).  
 
3.3.8 Spatial Learning and Memory Morris Water Maze Assessment 
 
 Spatial learning was assessed on days 10-13 and 28-31 in separate groups of 
animals in the clodronate study (Fig. 3.2B).  Animals were trained over 4 days to find the 
location of the hidden platform submerged approximately 1cm below the surface of the 
water as previously described (Hanlon et al., 2016a, Hanlon et al., 2016b).  On each day, 
animals completed 4 different trials (60s each) being released from 4 different points 90° 
apart around the edge of the maze (i.e. north, south, east, west).  The water was kept 
relatively cool at 18-20°C to motivate the animals to find the platform in order to escape 
the swimming task.  The latency to find the hidden platform was averaged across trials 
for each day and presented as a learning curve across 4 days.  On the 5
th
 day of 
assessment (day 14 or day 32), the platform was removed from the pool and animals were 
tracked using an overhead camera and Accutrak software (AccuScan Instruments Inc, 
Columbus, OH) for two 60-second trials to assess time spent in zones closest (platform) 
or furthest (peripheral) away from the former location of the platform.  Following the 
probe trials, animals were subjected to a visible platform trial in which the platform was 
placed back in the water, the water level was lowered so that the top inch of the platform 
was exposed, and a flag was adhered to the top of the platform.  These data were 
analyzed in terms of latency to the platform in order to detect if the animals had any type 
of visual deficits.   
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3.3.9 Statistical Analysis 
 
 All statistics were performed using Statistica 7 (StatSoft, Tulsa OK). All data are 
presented as mean ± standard error of the mean. Outcome measures were compared 
across groups (sham-injured empty-lip, brain-injured empty-lip, sham-injured clod-lip, 
brain-injured clod-lip) as a function of time (when applicable) and sex (when there were 
adequate numbers of each sex per group) using appropriate analyses of variance 
(ANOVA). Outcomes only involving two groups (i.e. sham vs. injured at one time point) 
were analyzed using independent samples t-tests. For spatial learning and memory, injury 
(sham vs. injured) and treatment (empty-lip vs. clod-lip) were used as separate 
independent factors.  When necessary, post-hoc analyses were performed using the 
Newman-Keuls test and a value of p≤0.05 was considered significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
3.4 RESULTS 
 
3.4.1 Microglia/macrophage reactivity and associated neuropathology in grey 
matter regions 
 
Traumatic brain-injury in the neonate rat resulted in sustained microglia/macrophage 
reactivity 
 Iba1 labeling in the cortex of sham-injured animals (Fig. 3.3A-C) revealed 
microglia that demonstrated a resting phenotype (Fig. 3.3G).  These cells had small cell 
bodies (Fig. 3.3H, black arrow) and long, elaborate processes (Fig. 3.3H, white arrows).  
Over time from 3 days (Fig. 3.3A) to 28 days (Fig. 3.3C), it seemed that the processes 
associated with these cells became longer and more complex which may suggest a 
developmental maturation of the microglia between post-natal day 14 (3 days post-
surgery) and post-natal day 39 (28 days post-surgery).  Iba1 labeling in the injured cortex 
of brain-injured animals (Fig. 3.3D-F) was dense and contained cells that demonstrated 
an activated phenotype (Fig. 3.3H).  These cells had enlarged, rounded cell bodies (Fig. 
3.3H, dashed outline) and very few short, thick processes (Fig. 3.3H, white arrows).  
These morphologic changes were observed in microglia/macrophages beginning around 
the anterior edge of the impact site (approximately in line with the bregma suture, Fig. 
3.1B) and extending through the impact site.  Reactivity in the cortex was observed in the 
retrosplenial cortex and in layers 2-5 of the motor and somatosensory cortices.  Although 
the labeling was most intense at 3 days post-injury (Fig. 3.3D), evidence of cellular 
reactivity was still present 4 weeks after the injury (Fig. 3.3F).   
 Using an ED-1 antibody (CD68), we were able to specifically label activated 
microglia/macrophages.  This antibody recognizes a lysosomal glycoprotein and its 
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expression levels may correlate with phagocytic activity (Damoiseaux et al., 1994).  ED-
1 labeling was scarcely observed in the cortex of sham-injured animals (Fig. 3.4A-C) and 
overlapped regionally and temporally with the observed Iba1 labeling in brain-injured 
animals (Fig. 3.4D-F).  The activated ED-1(+) microglia exhibited two distinct 
phenotypes: amoeboid-shaped cells (Fig. 3.4G) and rod-shaped cells (Fig. 3.4H).  The 
amoeboid cells were intensely labeled, rounded, and  had few, if any, visible processes 
(Fig. 3.4G).  The rod-shaped cells had an elongated, thick cell body with short, thick 
processes (Fig. 3.4H).  Because both of these phenotypes were identified as active 
through ED-1 labeling, our quantitative analyses of ED-1(+) labeling will account for 
these morphologies separately.  Microglia/macrophage reactivity (as assessed by both 
Iba1 and ED-1 labeling) was also present in the thalamus and hippocampus in the 
hemisphere ipsilateral to the injury (not shown).  In the thalamus, activated cells were 
present in the lateral nuclei, specifically the dorsolateral thalamus and the lateral 
geniculate nucleus.  Labeling in the hippocampus was restricted to the dorsal subiculum.  
Obvious increases in cellularity or morphologic activation was not observed in the 
hemisphere contralateral to the injury.          
 
Microglia/macrophage reactivity was associated with Fluoro-jade B (FJB) labeling 
 FJB(+) cells were observed in grey matter regions (cortex, thalamus, subiculum) 
that also exhibited increases in microglia/macrophage reactivity indicating an association 
between neuronal damage and microglia/macrophage reactivity.  Sham-injured animals 
do not exhibit any FJB(+) labeling in any region at any time post-injury (Fig. 3.5A).  
Labeled cells in the cortex were large and exhibited layered distribution indicative of 
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neurons (Fig. 3.5B-D).  Evidence of neuronal degeneration was still observed out to 28 
days post-injury (Fig. 3.5D).  FJB labeling in the subiculum also demonstrated neuronal 
morphology while labeling in the thalamus was more varied and contained a mix between  
neuronal morphology and small, punctate profiles indicative of axonal degeneration (not 
shown).   
   
Neuronal activity in the cortex within the impact site is altered at 3 days post-injury 
 Evoked field potential recordings were taken from layer 5 of the motor cortex at 
the level of bregma at 3, 7, and 21 days post-injury (Fig. 3.6).  From our histologic 
analyses, we know that this is the approximate beginning of the rostral-caudal 
distribution of cellular microglia/macrophage reactivity and neurodegeneration.  At 3 
days post-injury, signals from brain-injured animals were visibly smaller than those from 
sham-injured animals (Fig. 3.6A).  Quantification of the size of the signal revealed a 
significant effect of injury (F1,28=18.54, p<0.001), time (F2,28=12.19, p<0.001), and an 
interaction between injury and time (F2,28=11.82, p<0.001, Fig. 3.6B).  There was no 
significant interaction between injury, time, and sex (F2,28=2.47, p=0.10).  Post-hoc 
analysis of the interaction between injury and time revealed a developmental decrease in 
amplitude between 3, 7, and 21 days in sham-injured animals (p<0.001).  At 3 days post-
injury, brain-injured animals had significantly smaller signals compared to sham-injured 
animals (p<0.001), but this effect was transient and the signals were recovered to sham 
level at 7 (p=0.32) and 21 (p=0.85) days post-injury.  In quantification of the latency of 
the signal, there was no significant interaction between injury and time (F2,28=1.88, 
p=0.17) despite an apparent increase in the latency of the signals from brain-injured 
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animals at 3 days (Fig. 3.6C).  There was also no significant interaction between injury, 
time, and sex of the animal (F2,28=0.13, p=0.87).  The duration or width of the signal was 
also assessed and quantification  revealed a significant effect of time (F2,28=5.91, p<0.01) 
that indicated that the signals were wider at 7 days compared to 3 (p<0.01) and 21 days 
(p<0.05) irrespective of injury status (Fig. 3.6D).  There was no significant interaction 
between injury and time (F2,28=1.84, p=0.18) or between injury, time, and sex (F2,28=1.86, 
p=0.17).   
 Further within the impact site, approximately 3mm behind bregma, evoked field 
potentials were recorded from the motor cortex (Fig. 3.7).  This area demonstrated heavy 
microglia/macrophage reactivity and neurodegeneration.  Interestingly, signals from 
brain-injured animals did not appear to differ from sham-injured animals (Fig. 3.7A).  
Quantification of the amplitude of the signals revealed a significant effect of time 
(F2,24=5.24, p<0.05) that indicated a developmental decrease in the size of the signals 
between 3 and 21 days (p<0.05) irrespective of injury status (Fig. 3.7B).  There was no 
significant interaction between injury and time (F2,24=0.23, p=0.80) or between injury, 
time, and sex (F2,24=0.37, p=0.70).  Assessment of the latency of the signal also 
demonstrated no significant interactions (F2,24=0.91, p=0.42, Fig 3.7C).  Quantification of 
the duration of the signal revealed a significant interaction between injury, time, and sex 
(F2,24=4.41, p<0.02), but post hoc analysis revealed no significant effects (Fig. 3.7D).      
 
3.4.2 Microglia/macrophage reactivity and white matter pathology 
 
Microglia/macrophage reactivity was sustained in the white matter up to 28 days post-
injury 
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 ED-1(+) microglia/macrophages were observed in the white matter in both sham-
injured (Fig. 3.8A-C) and brain-injured animals (Fig. 3.8D-F).  ED-1(+) 
microglia/macrophages were distributed throughout the white matter in both hemispheres 
in sham-injured animals at 3 days post-surgery (PND14, Fig. 3.8A), but their presence 
was minimal by 28 days post-surgery (PND39, Fig. 3.8C).  In brain-injured animals, 
activated microglia/macrophages were present in the corpus callosum, cingulum, and 
lateral white matter tracts at 3 (Fig. 3.8D), 15 (Fig. 3.8E), and 28 (Fig. 3.8F) days post-
injury.  Both amoeboid and rod phenotypes were observed.  
 
Microglia/macrophage reactivity in the white matter was associated with axonal 
degeneration and axonal injury 
 Sham-injured animals demonstrated no evidence of FJB labeling in the white 
matter (Fig. 3.9A), but FJB(+) profiles were observed in the white matter of brain-injured 
animals (Fig. 3.9B-D).  Labeling in the white matter was diffuse and the labeled profiles 
were small and punctate indicative of axonal segments (Tong et al., 2002, Huh et al., 
2008).  FJB(+) profiles were heavily evident at 3 (Fig. 3.9B) and 15 (Fig. 3.9C) days 
post-injury, but were not as apparent 4 weeks post-injury (Fig. 3.9D) despite the fact that 
microglia/macrophage activation is still observed at this time point (Fig. 3.8F).  
Accumulation of amyloid precursor protein (APP) was apparent at 3 days post-injury in 
the corpus callosum, cingulum, and lateral white matter tracts where there was also 
evidence of axonal degeneration and microglia/macrophage reactivity (Fig. 3.9F).  Sham-
injured animals do not exhibit any evidence of APP labeling (Fig. 3.9E).    
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Axonal conduction deficits were observed in the corpus callosum of brain-injured 
animals 
 In addition to the observed axonal degeneration and axonal injury, we have 
previously reported that injury to the PND11 rat results in progressive atrophy of the 
white matter tracts (Raghupathi and Huh, 2007).  Axonal conduction was assessed in the 
injured corpus callosum at 1 day (prior to white matter atrophy) and 14 days post-injury 
(Fig. 3.10).  At 1 day post-surgery (PND12) sham-injured animals demonstrated large 
deflections indicative of strong signaling from both the myelinated (N1) and 
unmyelinated (N2) axons in the fiber tract (Fig. 3.10A).  Signals from brain-injured 
animals at 1 day post-injury were obviously smaller than those from sham-injured 
animals (Fig. 3.10A).  Separate repeated measures ANOVAs analyzing the amplitudes of 
the myelinated (N1) and unmyelinated components over 5 current steps revealed 
significant effects of injury (N1: F1,32=14.77, p<0.01; N2: F1,32=9.65, p<0.05), current 
step (N1: F4,32=28.95, p<0.001, N2: F4,32=29.34, p<0.001), and an interaction between 
injury and current step (N1: F4,32=5.99, p<0.01; N2: F4,32=4.56, p<0.01, Fig. 3.10B,C).  
Post hoc analysis revealed that both the myelinated (Fig. 3.10B) and unmyelinated (Fig. 
3.10C) portions of the signal from brain-injured animals was significantly smaller than 
sham-injured animals irrespective of current injection (p<0.05).  At 14 days post-injury, 
brain-injured animals demonstrated smaller signaling from myelinated fibers (N1), but 
did not seem to be deficient in signaling from the unmyelinated fibers (N2) (Fig. 3.10D).  
Assessment of the amplitude of the signals from the myelinated component revealed 
significant effects of injury (F1,28=8.85, p<0.05), current step (F4,28=25.54, p<0.001), and 
an interaction between  injury and current step (F4,28=4.04, p<0.05) that indicated that 
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brain-injured animals were still deficient in signaling from myelinated fibers at 14 days 
post-injury (p<0.05, Fig. 3.10E).  The deficit in the signaling from the unmyelinated 
fibers observed at 24 hours post-injury, however, was recovered by 14 days (injury: 
F1,28=0.22, p=0.66; current step: F4,28=18.79, p<0.001; injury x current step: F4,28=0.99, 
p=0.43, Fig. 3.10F ).  There were no differences in conduction velocity for either 
component at either time point (24 hours: N1, t(9)=0.77; p=0.46, N2, t(9)=0.78; p=0.45; 
14 days: N1, t(7)=-0.01; p=0.99, N2,  t(7)=-0.04; p=0.97; Fig. 3.10G).        
 
Brain-injured animals demonstrated deficits in axonal transport 2 weeks after injury 
 Axonal transport was assessed by injecting a retrograde tracer (Fluoro-Gold) into 
the left hemisphere of sham-injured and brain-injured animals at 14 days post-injury (Fig. 
3.11).  Despite the fact that there is evidence of FJB(+) cells in the cortex at this time, 
uptake of the tracer was similar in the injected cortex between brain-injured (Fig. 3.11B) 
and sham-injured animals (Fig. 3.11A).  Labeled cells were present in the cortex 
contralateral to the injection 5 days post-injection (Fig. 3.11C,D).  Sham-injured animals 
demonstrated heavy labeling indicating strong transport of the tracer (Fig. 3.11C).  While 
there were labeled cells in the contralateral cortex of brain-injured animals, the transport 
did not seem to be as efficient compared to the sham-injured animals (Fig. 3.11D)  This 
observation was confirmed by quantification as brain-injured animals had significantly 
fewer labeled cells in the contralateral cortex compared to sham-injured animals (t(5)=-
4.73; p<0.01).   
      
3.4.3 Clodronate-mediated microglia/macrophage depletion in the cortex 
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Depletion and repopulation of Iba1(+) and ED-1(+) microglia/macrophages in the 
cortex 
 Sham-injured (Fig. 3.12A-C) and brain-injured (Fig. 3.12D-F) animals that 
received the empty liposomes demonstrated typical labeling and reactivity.  At 3 days 
post-injury, sham-injured animals (Fig. 3.12G) and brain-injured animals (Fig. 3.12J) that 
received the clodronate liposomes demonstrated very few labeled microglia/macrophages 
in the cortex around the site of injection.  By 15 days post-injury, however, labeling in 
sham-injured animals appeared normal.  While microglia/macrophages were appearing in 
the cortex of brain-injured clod-lip animals at 15 days post-injury, the total number still 
seemed decreased compared to brain-injured animals that received the empty liposomes 
and the microglia/macrophages demonstrated an interesting rod-like phenotype (Fig. 
3.12K).  By 35 days, the brain-injured animals that were injected with clodronate seemed 
to demonstrate a higher level of morphologically “active” microglia/macrophages (Fig. 
3.12L).  Assessment of total Iba1(+) microglia/macrophages in the cortex at 15 and 35 
days revealed significant effects of status (F3,26=33.02, p<0.001), time (F1,26=87.73, 
p<0.001), and an interaction between status and time (F3,26=7.61, p<0.001, Fig. 3.12M).  
Post hoc analysis revealed that brain-injured animals that received the empty liposomes 
had significantly more Iba1(+) microglia/macrophages in the cortex compared to their 
corresponding sham-injured group and the brain-injured animals that received the 
clodronate at both 15 and 35 days (p<0.05).  Sham-injured animals that received the 
clodronate did not differ from those that received the empty liposomes at either 15 
(p=0.73) or 35 days (p=0.56).  Similarly, the total number of microglia/macrophages in 
the cortex of brain-injured animals that received clodronate did not differ from the total 
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number in the corresponding sham group at either time point (15d, p=0.93; 35d, p=0.06).  
There was no significant interaction between status, time, and sex (F3,26=0.34, p=0.80). 
 With the appearance of the rod-shaped microglia/macrophages in brain-injured 
animals that received the clodronate at 15 days post-injury (Fig. 3.12K) and the apparent 
increase in activated cells at 35 days post-injury (Fig. 3.12L), we evaluated 
microglia/macrophage activation following clodronate depletion using ED-1 labeling 
(Fig. 3.13).   Sham-injured animals that received the empty liposomes demonstrated 
activated microglia/macrophages in the cortex, but this was restricted to the area of 
injection at 3 days post-injury (Fig. 3.13A) and dissipated over time (Fig. 3.13B,C).  
Brain-injured animals that received the empty liposomes demonstrated typical cortical 
labeling (Fig. 3.13D-F).  Sham-injured animals injected with the clodronate demonstrated 
very little labeling across all three time points (Fig. 3.13G-I).  Brain-injured animals that 
received the clodronate had few labeled cells in the cortex at 3 days post-injury (Fig. 
3.13J), demonstrated an increase in rod-shaped microglia/macrophages at 15 days post-
injury (Fig. 3.13K), and seemed to have an increase in total labeling at 35 days post-
injury (Fig. 3.13L).  Quantification of amoeboid-shaped microglia/macrophages revealed 
a significant effect of status (F3,34=18.89, p<0.001), time (F2,34=4.53, p<0.05), and an 
interaction effect between status and time (F6,34=7.81, p<0.001, Fig. 3.13M).  Brain-
injured animals treated with the empty liposomes had significantly higher numbers of 
amoeboid microglia/macrophages at 3 days compared to the corresponding sham-injured 
group (p<0.001) and the brain-injured animals that received the clodronate (p<0.001).  
These effects were not sustained to 15 and 35 days post-injury.  There was no difference 
in the numbers of amoeboid microglia/macrophages in the cortex of sham-injured 
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animals at any time point. Interestingly, at 35 days post-injury, brain-injured animals that 
had sustained acute microglia/macrophage depletion demonstrated a significant increase 
in the number of activated amoeboid-shaped microglia/macrophages in the cortex 
compared to the corresponding sham-injured group (p<0.01) and brain-injured animals 
that received the empty liposomes (p<0.05) indicating a rebound effect in 
microglia/macrophage activation following acute depletion.  Quantification of rod-shaped 
microglia/macrophages showed a significant effect of status (F3,34=6.70, p<0.01) and an 
interaction between status and time (F6,34=4.71, p<0.01, Fig. 3.13M).  Post hoc analysis 
revealed mild effects with brain-injured animals that received the empty liposomes 
demonstrating a significant increase in rod-shaped microglia/macrophages at 3 days post-
injury compared to sham-injured animals (p<0.01), but this effect was not sustained to 15 
or 35 days post-injury.  Additionally, starting at 15 days post-injury, there seemed to be 
an increase in rod-shaped cells in brain-injured animals that received the clodronate, but 
these counts did not reach significance compared to the corresponding sham-injured 
group (p=0.10) or the brain-injured animals that received the vehicle (p=0.13).  There 
was no significant interaction between status, time, and sex for either amoeboid 
(F6,34=0.16, p=0.98) or rod (F6,34=0.80, p=0.57) microglia/macrophages.                                                  
 
Effect of clodronate administration on GFAP(+) astrocytic reactivity in the cortex 
 Brain-injured animals that received the empty liposomes showed a visible 
increase in GFAP immunoreactivity in cortex at 3 days post-injury (Fig. 3.14B).  Animals 
treated with clodronate, however, seemed to show a decrease in the density of astrocytes 
in the cortex regardless of injury status (Fig. 3.14C,D).  This was confirmed by a 
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thresholding analysis to assess the percentage of the cortex that exhibited GFAP(+) 
immunoreactivity.  A one-way ANOVA revealed a significant effect of status 
(F3,12=28.89, p<0.001, Fig. 3.14E) that indicated that brain-injured animals that received 
the empty liposomes had increased astrocytic reactivity compared to the corresponding 
sham-injured animals (p<0.01).  Sham-injured animals that received the clodronate 
showed a significant decrease in GFAP immunoreactivity compared to sham-injured 
animals that received the empty liposomes (p<0.05).  Similarly, brain-injured animals 
treated with clodronate had a significantly decreased percent area of labeling compared to 
brain-injured empty-lip animals (p<0.001) and there was no difference in reactivity 
between sham-injured and brain-injured clod-lip animals (p=0.72).   
 
Effect of microglia/macrophage depletion on neurodegeneration in the cortex 
 Sham-injured animals were assessed for FJB(+) reactivity as they demonstrated 
evidence of labeling around the sites of injection at 3 days post-injury (Fig. 3.15A,G) but 
the appearance of FJB(+) profiles in sham-injured animals dissipated over time (Fig. 
3.15B,C,H,I).  Brain-injured animals treated with clodronate (Fig. 3.15J-L) demonstrated 
visible increases in FJB(+) labeling in the cortex at all time points compared to sham-
injured animals and those that received the empty liposomes (Fig. 3.15D-F).  
Quantification revealed a significant effect of status (F3,35=61.91, p<0.001, Fig. 3.15M) 
that indicated that brain-injured animals treated with clodronate had significantly 
increased numbers of FJB(+) profiles in the cortex compared to the corresponding sham-
injured animals (p<0.001) and brain-injured empty-lip animals (p<0.01) regardless of 
time post-injury.  Importantly, there was no difference in FJB labeling between sham-
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injured animals (p=0.30).  There was no interaction between status, time, and sex 
(F3,35=0.56, p=0.76).      
 
Effect of acute microglia/macrophage depletion on neuronal activity in the chronic post-
injury period 
 Cortical activity at the bregma level did not show any differences between sham- 
and brain-injured animals at 21 days post-injury (Fig. 3.6) and this lack of difference was 
confirmed at 4 weeks post-injury (Fig. 3.16).  Additionally, acute clodronate 
administration did not affect activity in this region as there were no significant effects of 
status for measurement of amplitude (F3,24=0.41, p=0.75, Fig. 3.16A), latency (F3,24=0.84, 
p=0.49, Fig. 3.16B), or duration (F3,24=0.25, p=0.86, Fig. 3.16C) of the signals.  
Additionally, there were no interactions between status and sex for any measure 
(amplitude: F3,24=0.76, p=0.53; latency: F3,24=0.89, p=0.46; duration: F3,24=1.55, p=0.23).  
Further into the impact site, at -3mm behind bregma, signals from brain-injured animals 
that received clodronate appeared much larger than those from sham-injured animals or 
brain-injured animals that received the empty liposomes (Fig. 3.17A).  Quantification of 
the amplitude of signal revealed a significant effect of status (F3,24=3.45, p<0.05, Fig. 
3.17B) that confirmed this observation as the signals from brain-injured clod-lip animals 
were significantly larger than those from sham-injured clod-lip animals (p<0.05) and 
brain-injured clod-lip animals (p<0.05).  There were no differences in the amplitude of 
the signals from sham-injured animals (p=0.90) or between sham-injured empty-lip and 
brain-injured empty-lip animals (p=0.53).  Analysis of the amplitude of signal showed a 
significant effect of status (F3,24=4.71, p<0.05, Fig. 3.17C) that interestingly indicated 
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that signals from brain-injured animals treated with the empty liposomes were faster than 
the signals from the corresponding sham-injured animals (p<0.05).  This observation was 
not extended to sham- and brain-injured animals that received the clodronate (p=0.12).  
There were no differences in the duration of the signals (F3,24=1.41, p=0.27, Fig. 3.17D) 
and no interactions between status and sex for any measure (amplitude: F3,24=0.39, 
p=0.76; latency: F3,24=1.23, p=0.32; duration: F3,24=0.69, p=0.56).      
 
3.4.4 Clodronate-mediated microglia/macrophage depletion in the white matter 
 
 Clodronate was injected into the deeper layers of the cortex so that diffusion of 
the substance would also target the subcortical white matter.  Both sham-injured and 
brain-injured animals injected with clodronate demonstrated severe depletion in the 
corpus callosum, cingulum, and lateral white matter  at 3 days post-injury (Fig. 3.18C,D).  
Quantification of Iba1 immunoreactivity in the white matter at 15 and 35 days revealed a 
significant interaction between status and time (F3,26=15.10, p<0.001, Fig. 3.18E) that 
indicated that brain-injured empty-lip animals had a significantly higher percentage of 
labeled white matter compared to sham-injured empty lip animals at 15 (p<0.001) and 
still demonstrated a mild increase at 35 days (p=0.06).  Brain-injured empty lip animals 
also demonstrated significantly higher levels of Iba1 immunoreactivity in the white 
matter compared to brain-injured clod-lip animals at 15 days (p<0.001) but this effect 
was not sustained out to 35 days (p=0.53).  There was no interaction between status and 
sex (F3,26=0.87, p=0.47).    
 Sham-injured animals demonstrated a small amount of APP immunoreactivity in 
the white matter at 3 days post-injury due to the intracerebral injection (Fig. 3.18F,H).  
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Brain-injured animals demonstrated robust APP labeling in the white matter irrespective 
of microglia/macrophage depletion (Fig. 3.18G,I).  Grid analysis quantification of APP 
labeling revealed a significant effect of status (F3,14=59.64, p<0.001, Fig. 3.18J) that 
indicated that brain-injured animals had more APP labeling compared to sham-injured 
animals regardless of treatment (p<0.001), but that there were no differences between 
sham-injured (p=0.15) and brain-injured groups (p=0.57).  While depletion of 
microglia/macrophages in the white matter did not affect axonal injury, it had a 
significant effect on FJB(+) labeling in the white matter (Fig. 3.18K).  Quantification of 
the number of FJB(+) profiles in the white matter revealed a significant effect of status 
(F3,25=14.70, p<0.001, Fig. 3.18K) that indicated that brain-injured animals treated with 
clodronate had significantly more FJB(+) profiles compared to sham-injured clod-lip 
animals (p<0.001) and brain-injured empty-lip animals (p<0.001).  There was no 
significant interaction between status, time, and sex (F3,25=0.60, p=0.62).  Additionally, 
there was no difference compound action potential electrophysiology between brain-
injured empty-lip and brain-injured clod-lip animals at 7 days post-injury (Fig. 3.18L).  
Analysis of the signals revealed no significant difference in the size of the myelinated 
(N1) and unmyelinated (N2) components of the signal (N1: t(5)=1.48, p=0.20; N2: 
t(5)=1.43, p=0.21).            
 
3.4.5 Clodronate-mediated microglia/macrophage depletion in the thalamus 
 
 Similar to the cortex, Iba1(+) and ED-1(+) microglia/macrophages were 
effectively depleted in the thalamus of both sham-injured and brain-injured animals at 3 
days post-injury (images not shown).  Analysis of total Iba1(+) microglia/macrophages at 
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15 and 35 days revealed a significant interaction between status and time (F3,26=2.94, 
p≤0.05, Fig. 3.19A) that indicated that brain-injured empty-lip animals had significantly 
more microglia/macrophages in the thalamus compared to sham-injured empty lip and 
brain-injured clod-lip animals at both 15 (p<0.001) and 35 days (p<0.05) post-injury.  
There was no difference between sham-groups and either time point (15d: p=0.82, 35d: 
p=0.64) and the number of microglia/macrophages in the thalamus of brain-injured clod-
lip animals was back to sham level at 15 days post-injury (p=0.89).  Quantification of 
ED-1-labeled amoeboid microglia/macrophages in the thalamus also revealed a 
significant interaction effect between status and time (F6,34=11.94, p<0.001, Fig. 3.19B).  
Post-hoc revealed a significant effect of injury on amoeboid microglia/macrophages as 
brain-injured empty-lip animals had significantly more amoeboid microglia/macrophages 
compared to sham-injured empty-lip animals at 3 and 15 days post-injury (p<0.001).  
This effect, however, was lost by 35 days (p=0.73).  Brain-injured clod-lip animals had 
significantly fewer amoeboid microglia/macrophages than brain-injured empty-lip 
animals at 3 days post-injury (p<0.001) but this effect was not present at 15 days 
(p=0.10) and was reversed at 35 days with brain-injured clod-lip animals having 
significantly more amoeboid microglia/macrophages in the thalamus compared to both 
sham-injured clod-lip animals (p<0.01) and brain-injured empty-lip (p<0.05).  
Quantification of rod microglia/macrophages also revealed a significant interaction 
between status and time (F6,34=7.06, p<0.001, 3.19B), but this effect only indicated that 
brain-injured animals that received the empty liposomes had significantly more rod 
microglia/macrophages compared to sham-injured animals and did not show a significant 
increase in rod microglia/macrophages in the brain-injured clod-lip animals over time.  
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Additionally there was no effect of sex on Iba1 labeling (F3,26=0.80, p=0.51), ED-1(+) 
amoeboid microglia/macrophages (F6,34=0.45, p=0.84) or ED-1(+) rod 
microglia/macrophages (F6,34=0.16, p=0.99).   
 Fluoro-jade B labeling in the thalamus was significantly increased in brain-injured 
animals that sustained acute microglia/macrophage depletion.  A significant interaction 
between status and time (F6,35=5.54, p<0.001, Fig. 3.19C) revealed that brain-injured 
animals that received clodronate had significantly more FJB(+) profiles in the thalamus 
than both the corresponding sham group and brain-injured empty-lip animals at all times 
post-injury (p<0.05).   There were no differences between sham-injured animals at any 
time point and brain-injured empty lip animals demonstrated a significant increase in 
FJB(+) profiles compared to the corresponding sham group at 3 and 15 days post-injury 
(p<0.001) that was reduced to only a mild increase at 35 days (p=0.06).  There was no 
effect of sex on FJB labeling in the thalamus (F6,35=1.47, p=0.22).  Despite a decrease in 
activated microglia/macrophages and an increase in FJB labeling in the thalamus of 
brain-injured clod-lip animals at 3 days post-injury, there was no difference in axonal 
injury present in the thalamus.  A significant effect of status (F3,14=35.44, p<0.001, Fig. 
3.19D) revealed that both brain-injured groups had significantly more APP(+) labeling in 
the thalamus compared to sham-injured animals (p<0.001), but there was no effect of 
clodronate administration (p=0.88).  
 
3.4.6 Clodronate-mediated microglia/macrophage depletion in the subiculum 
 
 Through diffusion of the compound from the thalamic injection, we were able to 
also decrease microglia/macrophages in the subiculum of the hippocampus (Fig. 
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3.20A,C).  Quantification of Iba1(+) microglia/macrophages in the subiculum at 15 and 
35 days post-injury revealed a significant interaction effect between status and time 
(F3,26=14.00, p<0.001, Fig. 3.20A) that indicated that brain-injured animals that received 
the empty lip had significantly more Iba1(+) microglia/macrophages than both sham-
injured animals and brain-injured clod-lip animals at 15 days post-injury, but there was 
no differences between any groups at 35 days post-injury.  Like in the cortex and 
thalamus, the total number of microglia/macrophages in the subiculum was back to sham  
level in brain-injured animals that received the clodronate by 15 days post-injury.  
Significant interactions between status and time were observed for amoeboid (F6,33=8.48, 
p<0.001) and rod (F6,33=4.97, p<0.01, Fig. 3.20C) microglia/macrophages in the 
subiculum.  Post hoc analysis revealed that, similar to the cortex and thalamus, amoeboid 
microglia/macrophages were significantly increased in the subiculum at 35 days post-
injury compared to sham-injured and brain-injured empty-lip animals (p<0.001).  This 
effect, however, may be due to sex as an interaction between status, time, and sex 
(F6,33=3.71, p<0.01) revealed that brain-injured clod-lip females had significantly more 
amoeboid microglia/macrophages in the subiculum than all other groups at 35 days post-
injury.  The only significant effect on rod microglia/macrophages in the subiculum 
occurred at 3 days post-injury as brain-injured animals that received the empty liposomes 
had significantly more rod microglia/macrophages in the subiculum compared to both 
sham-injured and brain-injured animals that received the clodronate (p<0.05).  There was 
no effect of sex on Iba1 immunoreactivity (F3.26=0.98, p=0.42) or ED-1(+) rod 
microglia/macrophages (F6,33=0.31, p=0.93) in the subiculum.  
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 Like in the cortex and thalamus, FJB reactivity was increased in the subiculum of 
brain-injured animals that received the clodronate at 3, 15, and 35 days post-injury (Fig 
3.20B).  This was confirmed by a significant effect of status (F3.36=29.13, p<0.001) that 
indicated that brain-injured animals that received the empty liposomes had significantly 
more FJB(+) profiles in the subiculum compared to the corresponding empty-lip sham-
injured group (p<0.01), but that brain-injured animals that received the clodronate had 
significantly more FJB(+) profiles than both the corresponding clod-lip sham-injured 
group (p<0.001) and the empty-lip brain-injured group (p<0.001) irrespective of time 
post-injury. There was no effect of sex on FJB reactivity in the subiculum (F3.36=0.95, 
p=0.47). 
 
3.4.7 Effect of microglia/macrophage depletion on injury-induced spatial learning 
and memory impairment 
 
 Spatial learning and memory was assessed in separate groups of animals on post-
injury days 10-14 (Fig. 3.21A,B) and 28-32 (Fig. 3.21C,D).  On days 10-14 sham-injured 
animals that received the empty liposomes performed much like what we’ve observed in 
the previous use of this test (Raghupathi & Huh, 2007).  Sham-injured animals that 
received the clodronate, however, seemed to be performing similarly to the brain-injured 
empty-lip animals and brain-injured animals that received the clodronate seemed to be 
performing slightly worse than both the clod-lip shams-injured animals and the brain-
injured empty-lip animals.  These differences, however, were subtle and there was no 
significant effect of injury or treatment on spatial learning (F1,51=2.22, p=0.15; F1,51=2.67, 
p=0.12 , Fig. 3.21A).  In the probe trial, brain-injured animals spent more time in the 
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peripheral zone furthest away from the platform compared to sham-injured animals 
irrespective of treatment, but this effect did not reach full significance (F1,17=4.01, 
p=0.06, Fig. 3.21B).  Brain-injured animals did, however, spend significantly less time in 
the platform zone compared to sham-injured animals (F1,17=4.67, p<0.05) and there was 
no significant effect of injury or treatment on performance in the visible platform trial 
(F1,17=0.002, p=0.97).  When animals were assessed on post-injury days 28-32, brain-
injured animals were significantly impaired in their ability to locate the hidden platform 
compared to sham-injured animals irrespective of treatment   (F1,45=8.59, p<0.05, Fig. 
3.21C).  There was no effect of clodronate administration on spatial learning at this time 
point.  In the probe trial, there was no effect of injury or treatment on the amount of time 
spent in the peripheral zones (F1,15=0.09, p=0.76, Fig. 3.21D), but brain-injured animals 
spent less time in the platform zone than sham-injured animals (F1,15=4.67, p<0.05) 
indicating a retention deficit irrespective of clodronate administration. There was no 
effect of injury or treatment on the visible platform trial (F1,15=2.02, p=0.18).    
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3.5 DISCUSSION 
 
 Following closed head injury to the neonate rat, microglia/macrophage reactivity 
was observed as a function of increased cellularity and morphologic transformation in the 
cortex, thalamus, subiculum, and white matter of brain-injured rats.  
Microglia/macrophage reactivity closely associated with neurodegeneration, axonal 
degeneration, and evidence of axonal injury.  While we hypothesized that 
microglia/macrophage depletion would ameliorate neuropathology and functional 
deficits, we discovered that the loss of microglia/macrophages around the time of injury 
actually caused a sustained exacerbation of neuropathology that included increased 
microglia/macrophage activation in the chronic post-injury period.  This increase in 
neuropathology altered neuronal activity, but did not affect spatial learning and memory 
ability.   
 The temporal and regional similarities between microglia/macrophage reactivity 
and neurodegeneration and axonal injury suggest that microglia/macrophages are 
involved in these processes.  Microglia have been shown to associate with apoptotic cells 
during development and closely associate with fluoro-jade B labeling in a model of 
contusive injury to the PND21 mouse (Pont-Lezica, et al., 2001; Tong et al., 2002).   It is 
unclear, however, whether microglia/macrophages actively perpetuate cell death and 
axonal injury or whether they are simply activated in those regions in order to clear out 
the damaged cells.  There is evidence to suggest that microglia initially become activated 
in response to neuronal damage, but can then remain activated and perpetuate further 
damage through the release of toxic mediators (Loane and Kumar, 2016).   
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In the white matter, microglia play a role in providing trophic support to 
oligodendrocyte precursor cells to aid them through differentiation into a mature 
myelinating oligodendrocyte and therefore these cells share a very close spatial 
relationship (Domingues et al., 2016).  When activated by an insult, both microglia and 
astrocytes can inhibit this maturation thus causing oligodendrocyte damage and 
myelination deficits (Peferoen et al., 2014, Domingues et al., 2016).  Oligodendrocyte 
death has been observed following TBI in the adult rat and HI injury in the neonate rat 
(Liu et al., 2002, Lotocki et al., 2011).  It is possible that the fluoro-jade B labeling we 
observed in the white matter may be indicative of both axonal fragments and dying 
oligodendrocytes.   Labeling specifically for oligodendrocytes, oligodendrocyte precursor 
cells, and myelin basic protein will allow us to elucidate a stronger spatial and temporal 
relationship between microglial activation and oligodendrocyte damage. 
This study suggests that removal of microglia/macrophages around the time of the 
injury is actually deleterious to the immature brain as clodronate administration resulted 
in a severe and sustained increase in neurodegeneration.  The increase in FJB(+) profiles 
observed at 3 days post-injury following microglia/macrophage depletion may be 
indicative of a lack of phagocytosis of damaged cells following injury.  In the chronic 
post-injury period, however, brain-injured animals that received clodronate exhibited 
increased microglia/macrophage activation associated with increased degeneration in 
several brain regions suggesting this secondary wave of activation may play an active 
role in the observed degeneration. This is supported by the fact that neuronal activity was 
altered in brain-injured animals that received the clodronate.  In brain-injured animals 
that did not undergo microglia/macrophage depletion, neuronal activity was not altered in 
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the hindlimb region of the motor cortex at 4 weeks post-injury despite the sustained 
presence of injury-induced neurodegeneration.  When neurodegeneration and 
microglia/macrophage reactivity were increased in this region, the signals showed 
evidence of hyperactivity indicating dysfunction of neuronal circuitry and deleterious 
effects of acute microglia/macrophage depletion in the developing brain.   
 While the number of total Iba1(+) microglia/macrophages returned to sham-injury 
level by 2 weeks post-injury, the repopulated microglia/macrophages in brain-injured 
animals demonstrated a rod-like phenotype.  Rod-like microglia/macrophages have been 
observed following TBI in the adult rat and our current study has identified that these  
microglia/macrophages are an activated phenotype as evident by ED-1 immunoreactivity, 
but it is unclear whether or not they play a specific role in post-injury pathology (Taylor 
et al., 2014).  There is some evidence to suggest that rod-like microglia are highly 
proliferative and can rapidly transformation to amoeboid shape (Tam and Ma, 2014).  It 
is possible that the increase in rod-like microglia/macrophages in clodronate-treated 
brain-injured animals is indicative of microglia/macrophage proliferation and some of 
these rod-like cells go on to become amoeboid-shaped microglia/macrophages at 35 days 
post-injury.  
 While acute microglia/macrophage depletion did increase FJB(+) labeling in the 
white matter at 15 and 35 days post-injury, this was not associated with a simultaneous 
increase in microglia/macrophage reactivity suggesting a different mechanism.  As 
indicated with the original time course, more study into the specific effect of microglial 
depletion on oligodendrocytes is necessary, especially with the increase in FJB(+) 
profiles observed in the white matter in the chronic post-injury period.  Axonal injury and 
89 
 
axonal conduction were unaffected by treatment with clodronate.  These results support 
published observations using inducible microglial depletion in a model of repetitive TBI 
in adult mice.  Brain-injured animals in which microglia were genetically depleted did 
not show any alterations in silver staining, APP accumulation, or neurofilament labeling 
in the white matter compared to brain-injured animals containing intact microglia 
(Bennett and Brody, 2014).  
 There are two published studies that detail the use of clodronate-mediated 
microglial depletion in the brain following an insult (Faustino et al., 2011, Drabek et al., 
2012).  In a model of hypothermic cardiac arrest in adult rats, clodronate administration 
effectively decreased the number of microglia in the hippocampus of injured rats, but did 
not result in amelioration of cell death (Drabek et al., 2012).  Clodronate-mediated 
depletion exacerbated lesion size following stroke in the neonatal rat (Faustino et al., 
2011) emphasizing the importance of microglia in response to injury to the developing 
brain.  In the present study, we also demonstrated that clodronate is not specific to 
microglia/macrophages in the brain.  Clodronate administration resulted in a decrease in 
the density of astrocytes in the cortex in both sham- and brain-injured animals.  In 
culture, liposomal clodronate was effective in removing microglia without affecting 
astrocytes (Kumamaru et al., 2012).  Additionally, GFAP-labeled astrocytes in the brain 
did not take up fluorescently-tagged empty liposomes (Faustino et al., 2011).  The fact 
that clodronate affected astrocytes in our study makes separating the role of 
microglia/macrophages and astrocytes in post-injury pathology difficult as it has been 
shown that depletion of astrocytes can also result in neuronal damage (Lima et al., 2014).  
Also, the whole-cell depletion of microglia/macrophages may be too harsh of a 
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manipulation in the developing brain and a more targeted approach (such as utilizing 
anti-inflammatory drugs) may be more effective in ameliorating post-injury pathology.        
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3.6 FIGURE LEGENDS 
 
Figure 3.1 Controlled cortical impact injury device.  Image of the controlled cortical 
impact device (A) depicting the convex-shaped silicone impactor tip (inset).  Photo of a 
14-day-old rat brain overlaid with a 5mm circle depicting the region of direct impact (B).  
 
Figure 3.2 Experimental Timeline.  Timeline for the time course (A) and clodronate 
studies (B).  
 
Figure 3.3 Iba1-labeled microglia/macrophages in the cortex.  Representative 
photomicrographs of Iba1(+) microglia/macrophages in the cortex of sham-injured (A-C) 
and brain-injured (D-F) animals at 3 (A,D), 15 (B,E), and 28 (C,F) days post-injury.  
Representative photomicrograph s of a resting microglia/macrophage characterized by a 
thin cell body and long, elaborate processes (G) and an activated microglia/macrophage 
characterized by an enlarged cell body with few short, thick processes (H). Scale bar (F) 
= 100 μm, scale bar (H) = 10 μm,  
 
Figure 3.4 ED-1-labeled microglia/macrophages in the cortex.  Representative 
photomicrographs of activated ED-1(+) microglia/macrophages in the cortex of sham-
injured (A-C) and brain-injured (D-F) animals at 3 (A,D), 15 (B,E), and 28 (C,F) days 
post-injury.  Representative photomicrographs of an amoeboid microglia/macrophage 
characterized by a round cell body and few, if any, visible processes (G) and a rod  
microglia/macrophage characterized by an  elongated, thick cell body and short processes 
(H).  Scale bar (F) = 100 μm, scale bar (H) = 10 μm,  
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Figure 3.5 Time course of neurodegeneration in the cortex.   Representative 
photomicrograph depicting no positive labeling in the cortex of sham-injured animals 
(A).  Representative photomicrographs of FJB(+) profiles in the cortex of brain-injured 
animals at 3 (B), 15 (C), and 28 (D) days post-injury.  Scale bar (F) = 100 μm.    
 
Figure 3.6 Evoked field potential recordings from the injured cortex at bregma.   
Representative traces from the bregma-level cortex of sham-injured and brain-injured 
animals at 3 days post-injury (A).  Quantification of signal amplitude (B), signal latency 
(C), and signal duration (D) in the bregma-level cortex at 3, 7, and 21 days post-injury.  
Error bars represent the standard error of the mean. *p≤0.05 compared to corresponding 
sham-injured group.  
 
Figure 3.7 Evoked field potential recordings from the injured cortex 3mm posterior 
to bregma.  Representative traces from the -3mm cortex of sham-injured and brain-
injured animals at 3 days post-injury (A).  Quantification of signal amplitude (B), signal 
latency (C), and signal duration (D) in the bregma-level cortex at 3, 7, and 21 days post-
injury.  Error bars represent the standard error of the mean.   
 
Figure 3.8 ED-1-labeled microglia/macrophages in the white matter.  Representative 
photomicrographs of activated ED-1(+) microglia/macrophages in the white matter of 
sham-injured (A-C) and brain-injured (D-F) animals at 3 (A,D), 15 (B,E), and 28 (C,F) 
days post-injury.  (F) = 100 μm, scale bar. 
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Figure 3.9 Time course of neurodegeneration in the white matter.   Representative 
photomicrograph depicting no positive labeling in the white matter of sham-injured 
animals (A).  Representative photomicrographs of FJB(+) profiles in the white matter of 
brain-injured animals at 3 (B), 15 (C), and 28 (D) days post-injury.  Representative 
photomicrographs of APP labeling in the white matter of sham-injured (E) and brain-
injured (F) animals at 3 days post-injury.  Scale bar (D,F) = 100 μm.    
 
Figure 3.10 Compound action potential electrophysiology in the corpus callosum.  
Representative traces from the corpus callosum of sham-injured and brain-injured 
animals 24 hours post-injury (A).  Quantification of the amplitude of the myelinated (N1) 
portion of the signal (B) and the unmyelinated portion (N2) of the signal (C) at 24 hours 
post-injury across five 200 μA current steps.  Representative traces from the corpus 
callosum of sham-injured and brain-injured animals 14 days post-injury (D).  
Quantification of the amplitude of the myelinated (N1) portion of the signal (E) and the 
unmyelinated portion (N2) of the signal (F) at 14 days post-injury across five 200 μA 
current steps.  Quantification of the conduction velocity for signals from the myelinated 
and unmyelinated axons in the fiber track at 24 hours and 14 days post-injury (G).  Error 
bars represent the standard error of the mean.  *p≤0.05 compared to corresponding sham-
injured group.  
 
Figure 3.11 Transport of Fluoro-Gold across the corpus callosum at 14 days post-
injury.  Representative photomicrographs of the injection site in the left cortex of sham-
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injured (A) and brain-injured (B) animals and FG(+) profiles in the cortex contralateral to 
the injection (right cortex) of sham-injured (C) and brain-injured (D) animals.  
Quantification of FG(+) profiles in the right cortex (E). *p≤0.05 compared to 
corresponding sham-injured group.  Error bars represent the standard error of the mean. 
Scale bar (B) = 200 μm, scale bar (D) = 100 μm.    
 
Figure 3.12 Iba1(+) microglia/macrophages in the cortex following clodronate-
mediated depletion.  
Representative photomicrographs of sham-injured (A-C) and brain-injured (D-F) animals 
injected with the empty liposomes and sham-injured (G-I) and brain-injured (J-L) 
animals treated with the clodronate liposomes at 3 (A,D,G,J), 15 (B,E,H,K), and 35 
(C,F,I,L) days post-injury.  Quantification of total Iba1(+) microglia/macrophages in the 
cortex at 15 and 35 days (M). Error bars represent the standard error of the mean . 
*p≤0.05 compared to corresponding (time-matched) sham-injured group, #p≤0.05 
compared to corresponding (time-matched) brain-injured empty-lip animals.  Scale bar 
(L) = 100 μm.   
 
Figure 3.13 ED-1(+) microglia/macrophages in the cortex following clodronate-
mediated depletion.  Representative photomicrographs of sham-injured (A-C) and brain-
injured (D-F) animals injected with the empty liposomes and sham-injured (G-I) and 
brain-injured (J-L) animals treated with the clodronate liposomes at 3 (A,D,G,J), 15 
(B,E,H,K), and 35 (C,F,I,L) days post-injury.  Quantification of ED-1(+) 
microglia/macrophages exhibiting amoeboid and rod morphologies at 3, 15 and 35 days 
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(M). Error bars represent the standard error of the mean.  *p≤0.05 compared to 
corresponding (time-matched) sham-injured group, #p≤0.05 compared to corresponding 
(time-matched) brain-injured empty-lip animals.  Scale bar (L) = 100 μm.   
 
Figure 3.14 GFAP(+) astrocytes in the cortex following clodronate-mediated 
microglia/macrophage depletion.  Representative photomicrographs of sham-injured 
(A) and brain-injured (B) animals injected with the empty liposomes and sham-injured 
(C) and brain-injured (D) animals treated with the clodronate liposomes at 3 days post-
injury.  Quantification of the percent area of GFAP labeling in the cortex at 3 days post-
injury (E). Error bars represent the standard error of the mean . *p≤0.05 compared to 
corresponding sham-injured group, #p≤0.05 compared to brain-injured empty-lip 
animals.  @p≤0.05 difference between sham-injured groups.  Scale bar (L) = 100 μm.   
 
Figure 3.15 FJB(+) profiles in the cortex following clodronate-mediated 
microglia/macrophage depletion. Representative photomicrographs of sham-injured 
(A-C) and brain-injured (D-F) animals injected with the empty liposomes and sham-
injured (G-I) and brain-injured (J-L) animals treated with the clodronate liposomes at 3 
(A,D,G,J), 15 (B,E,H,K), and 35 (C,F,I,L) days post-injury.  Quantification of total 
FJB(+) profiles in the cortex at 3, 15, and 35 days (M). Error bars represent the standard 
error of the mean.  Scale bar (L) = 100 μm.   
 
Figure 3.16 Cortical activity in the chronic post-injury period following acute 
clodronate-mediated microglia/macrophage depletion. Quantification of the amplitude 
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(A), latency (B), and duration (C) of signals taken from layer 5 of the motor cortex at 
bregma level 4 weeks post-injury. Error bars represent the standard error of the mean.  
 
Figure 3.17 Cortical activity within the impact site at 4 weeks post-injury following 
acute clodronate-mediated microglia/macrophage depletion.  
Representative traces from the -3mm motor cortex of sham-injured and brain-injured 
animals that received the empty liposomes and sham-injured and brain-injured animals 
that received the clodronate 4 weeks post-injury (A).  Quantification of signal amplitude 
(B), signal latency (C), and signal duration (D). Error bars represent the standard error of 
the mean.    *p≤0.05 compared to corresponding sham-injured group, #p≤0.05 compared 
to brain-injured empty-lip animals.   
 
Figure 3.18 White matter pathology following clodronate-mediated 
microglia/macrophage depletion.  Representative photomicrographs of Iba1(+) 
microglia/macrophages in the lateral white matter of sham-injured (A) and brain-injured 
(B) animals injected with the empty liposomes and sham-injured (C) and brain-injured 
(D) animals treated with the clodronate liposomes at 3 days post-injury.  Quantification 
of the percent area of Iba1 labeling in the white matter at 15 and 35 days post-injury (E).  
Representative photomicrographs of APP(+) profiles in the lateral white matter of sham-
injured (F) and brain-injured (G) animals injected with the empty liposomes and sham-
injured (H) and brain-injured (I) animals treated with the clodronate liposomes at 3 days 
post-injury.  Quantification of the percent positive boxes labeled with APP in the white 
matter at 3 days post-injury via grid analysis (J).  Quantification of FJB(+) profiles in the 
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white matter at 15 and 35 days post-injury (K).  Quantification of the size of the signals 
from the myelinated (N1) and unmyelinated (N2) components of the white matter fiber 
bundle at 7 days post-injury.  Data presented from the max stimulus amplitude (L).  Error 
bars represent the standard error of the mean. *p≤0.05 compared to corresponding sham-
injured group, #p≤0.05 compared to brain-injured empty-lip animals.  Scale bar (I) = 100 
μm.   
 
3.19 Effects of acute clodronate-mediated microglia/macrophage depletion on 
thalamic pathology.   Quantification of total Iba1(+) microglia/macrophages in the 
thalamus of sham-injured and brain-injured animals that received either the empty or 
clodronate liposomes at 15 and 35 days post-injury (A).  Quantification of ED-1(+) 
microglia/macrophages in the thalamus that exhibit amoeboid or rod morphologies at 3, 
15, and 35 days post-injury (B).  Quantification of FJB(+) profiles in the thalamus at 3, 
15, and 35 days post-injury (C).  Quantification of APP(+) profiles in the thalamus at 3 
days post-injury presented as the percent positive boxes that were positively labeled in 
the grid analysis (D).  Error bars represent the standard error of the mean. *p≤0.05 
compared to corresponding sham-injured group, #p≤0.05 compared to brain-injured 
empty-lip animals.   
 
3.20 Effects of acute clodronate-mediated microglia/macrophage depletion on 
pathology in the subiculum of the hippocampus.   Quantification of total Iba1(+) 
microglia/macrophages in the subiculum of sham-injured and brain-injured animals that 
received either the empty or clodronate liposomes at 15 and 35 days post-injury (A).  
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Quantification of FJB(+) profiles in the subiculum at 3, 15, and 35 days post-injury (B). 
Quantification of ED-1(+) microglia/macrophages in the thalamus that exhibit either the 
amoeboid or rod morphologies at 3, 15, and 35 days post-injury (C).  Error bars represent 
the standard error of the mean. *p≤0.05 compared to corresponding sham-injured group, 
#p≤0.05 compared to brain-injured empty-lip animals.   
 
3.21 Spatial learning and memory assessment at 2 different time points following 
acute clodronate-mediated microglia/macrophage depletion.  Assessment of spatial 
learning on days 10-13 post-injury in the Morris water maze presented as latency to find 
the hidden platform over 4 training days (A). Times spent in the peripheral and platform 
zones, and latency to the visible platform during the probe day on day 14 post-injury (B). 
Spatial learning assessment on days 28-31 post-injury (C) and probe trial assessments on 
day 32 post-injury (D).  Error bars represent the standard error of the mean. *p≤0.05 
compared to corresponding sham-injured group.  
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Figure 3.2 Experimental Timeline.   
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Figure 3.3 Iba1-labeled microglia/macrophages in the cortex.   
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Figure 3.4 ED-1-labeled microglia/macrophages in the cortex.   
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Figure 3.5 Time course of neurodegeneration in the cortex. 
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Figure 3.6 Evoked field potential recordings from the injured cortex at bregma.    
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Figure 3.7 Evoked field potential recordings from the injured cortex 3mm posterior 
to bregma.   
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Figure 3.8 ED-1-labeled microglia/macrophages in the white matter.   
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Figure 3.9 Time course of neurodegeneration in the white matter.    
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Figure 3.10 Compound action potential electrophysiology in the corpus callosum.   
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Figure 3.11 Transport of Fluoro-Gold across the corpus callosum at 14 days post-
injury.   
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Figure 3.12 Iba1(+) microglia/macrophages in the cortex following clodronate-
mediated depletion.  
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Figure 3.13 ED-1(+) microglia/macrophages in the cortex following clodronate-
mediated depletion.   
 
 
112 
 
Figure 3.14 GFAP(+) astrocytes in the cortex following clodronate-mediated 
microglia/macrophage depletion.   
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Figure 3.15 FJB(+) profiles in the cortex following clodronate-mediated depletion.  
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Figure 3.16 Cortical activity in the chronic post-injury period following acute 
clodronate-mediated microglia/macrophage depletion.  
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Figure 3.17 Cortical activity within the impact site at 4 weeks post-injury following 
acute clodronate-mediated microglia/macrophage depletion.  
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Figure 3.18 White matter pathology following clodronate-mediated 
microglia/macrophage depletion.   
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3.19 Effects of acute clodronate-mediated microglia/macrophage depletion on 
thalamic pathology.    
 
 
 
 
 
 
 
118 
 
3.20 Effects of acute clodronate-mediated microglia/macrophage depletion on 
pathology in the subiculum of the hippocampus.    
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3.21 Spatial learning and memory assessment at 2 different time points following 
acute clodronate-mediated microglia/macrophage depletion.   
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CHAPTER 4: ACUTE MINOCYCLINE TREATMENT FOLLOWING 
TRAUMATIC BRAIN INJURY IN THE NEONATE RAT 
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4.1 ABSTRACT 
 
The role of microglia/macrophages in the pathophysiology of injury to the 
developing brain has been extensively studied. In children under the age of 4 who have 
sustained a traumatic brain injury (TBI), markers of microglial/macrophage activation 
were increased in the cerebrospinal fluid and were associated with worse neurologic 
outcome. Minocycline is an antibiotic that decreases microglial/macrophage activation 
following hypoxic-ischemia in neonatal rodents and TBI in adult rodents thereby 
reducing neurodegeneration and behavioral deficits. In this study, 11-day-old rats 
received an impact to the intact skull and were treated for 3 days with minocycline. 
Immediately following termination of minocycline administration, 
microglial/macrophage reactivity was reduced in the cortex and hippocampus and was 
accompanied by an increase in the number of fluoro-Jade B profiles suggestive of a 
reduced clearance of degenerating cells. This effect was not sustained at 7 days post-
injury, but weeks (15 days and 4 weeks) after the injury minocycline treatment resulted in 
an increase in activated microglia/macrophages that coincided with an increase in 
neurodegeneration in the cortex and hippocampus of brain-injured animals.  This was 
also associated with hypoactivity as measured through evoked field potential in the cortex 
of brain-injured minocycline-treated animals.  Although microglial/macrophage reactivity 
was reduced in the white matter tracts and the thalamus at 3 days post-injury and 
subsequently increased in these regions in the weeks following injury, minocycline 
treatment did not affect axonal injury, axonal degeneration, or neurodegeneration.  
Injury-induced spatial learning and memory deficits were also not affected by 
minocycline and sex had minimal effects on either injury-induced alterations or the 
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efficacy of minocycline treatment. Collectively, these data demonstrate the differential 
effects of minocycline in the immature brain following impact trauma and suggest that 
minocycline may not be an effective therapeutic strategy for TBI in the immature brain. 
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4.2 INTRODUCTION 
 
With close to half a million children affected annually, traumatic brain injury 
(TBI) remains one of the most common causes of disability and death in infants and 
children (Langlois et al., 2005, Faul, 2010, Coronado et al., 2011).  The youngest age 
group (≤ 4 years old) exhibit worse outcome following moderate to severe TBI compared 
to older children (Anderson et al., 2005, Coronado et al., 2011). Pediatric TBI patients 
commonly exhibit traumatic axonal injury (TAI) and brain atrophy which are associated 
with prolonged cognitive deficits such as impairments of learning and memory, attention, 
and executive function (Duhaime and Raghupathi, 1999, Ewing-Cobbs et al., 2004, Tong 
et al., 2004, Anderson et al., 2005, Ewing-Cobbs et al., 2006, Catroppa et al., 2007, 
Catroppa et al., 2008, Anderson et al., 2009). Injury to the immature brain may also have 
adverse effects on the development of cognitive abilities (Babikian et al., 2015). 
Unfortunately, no specific therapies exist, with supportive care in the acute post-
traumatic period being the only current treatment option.  
  While the mechanisms underlying neuropathologic alterations following TBI in 
the immature brain are not completely understood, inflammation may play an important 
role in the sequelae of secondary injury. Activation of microglia, the resident immuno-
competent cells in the brain, and peripheral macrophage infiltration are thought to play an 
important role in the acute and chronic neurodegeneration observed following brain 
injury (Kreutzberg, 1996, Nimmerjahn et al., 2005, Hanisch and Kettenmann, 2007, 
Ransohoff and Perry, 2009, Graeber and Streit, 2010, Beynon and Walker, 2012). 
Markers of microglial/macrophage activation such as sCD163, ferritin, and interleukins-
6,-8 and -10 were increased in cerebrospinal fluid (CSF) from children after TBI with 
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more prominent increases observed in the youngest age group (≤ 4 years of age), 
suggesting that these patients may be at higher risk for worse neurologic outcome (Bell et 
al., 1997, Whalen et al., 2000, Newell et al., 2015). In neonatal rodents, hypoxic-ischemia 
(HI) or ischemia resulted in robust microglial/macrophage activation (McRae et al., 1995, 
Ivacko et al., 1996, Denker et al., 2007, Vexler and Yenari, 2009, Ferrazzano et al., 
2013). Increased microglial reactivity in the injured hemisphere following TBI in the 
immature mouse brain corresponded to areas containing degenerating neurons and was 
associated with an expansion of the cortical lesion and spatial learning deficits (Tong et 
al., 2002, Pullela et al., 2006). In addition, microglial reactivity has also been observed in 
the white matter tracts that was associated with an increase in tissue loss of the injured 
hemisphere and working and recognition memory deficits in a rabbit model of pediatric 
TBI (Zhang et al., 2015). These data suggest that microglial/macrophage activity may be 
involved in ongoing pathogenesis following TBI in the immature brain and may 
potentially serve as a therapeutic target.  
Minocycline is a second generation tetracycline derivative antibiotic with anti-
inflammatory properties, effectively crosses the blood-brain barrier after systemic 
administration and has demonstrated neuroprotection in many models of brain injury and 
neurodegenerative diseases (Elewa et al., 2006, Kim and Suh, 2009, Plane et al., 2010, 
Garrido-Mesa et al., 2013). Following neonatal rodent models of HI, minocycline 
decreased microglial activation which was associated with a reduction in injury-induced 
neuronal damage, oligodendroglial cell death, hypomyelination, white matter atrophy and 
locomotor deficits (Cai et al., 2006, Fan et al., 2006, Carty et al., 2008, Cikla et al., 
2016). In a model of pediatric cardiac arrest, acute treatment with minocycline reduced 
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microglial activation along with neurodegeneration and apoptosis (Tang et al., 2010). 
Treatment with minocycline following TBI in the adult mouse resulted in a reduction of 
microglial activation and proliferation which was associated with a decrease in pro-
inflammatory cytokine response, cerebral edema, lesion volume and attenuation of 
locomotor and spatial memory deficits (Homsi et al., 2009, Homsi et al., 2010, Siopi et 
al., 2011, Siopi et al., 2012). Similarly, minocycline administration following moderate-
severe contusive trauma to the adult rat brain reduced microglial activation and improved 
behavioral function (Abdel Baki et al., 2010, Lam et al., 2013). In contrast, minocycline 
did not attenuate cell death, axonal injury or tissue loss despite reducing active microglia 
following either diffuse brain trauma in the adult mouse (Bye et al., 2007) or repetitive 
brain trauma in the neonate rat (Hanlon et al., 2016a). Depleting the brain of its resident 
microglia exacerbates cell death following neonatal stroke (Faustino et al., 2011) but 
appears to not affect the extent of white matter injury following TBI (Bennett and Brody, 
2014). It must be noted that not all effects of minocycline can be attributed to its effects 
on reducing microglial/macrophage activation following brain injury. Fox et al., (2005) 
observed that minocycline administration following focal ischemia in the neonate rat did 
not reduce the extent of microglial activation but did reduce the volume of injury. 
Although microglial activation was not evaluated, minocycline treatment reduced both 
apoptotic and excitotoxic cell death  following HI in the neonatal rat (Arvin et al., 2002), 
reduced caspase activation following contusive brain trauma in the adult mouse (Sanchez 
Mejia et al., 2001) and attenuated inflammatory protein expression in a rat model of mild 
blast TBI (Kovesdi et al., 2012). By contrast, minocycline worsened injury-induced 
infarction and tissue atrophy in a mouse model of HI (Tsuji et al., 2004). Collectively, 
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these data underscore the complicated relationship between injury-induced 
microglial/macrophage activation and ensuing brain damage. 
With the goal of understanding the role of microglial/macrophage activation in 
neonatal brain trauma, the present study sought to test the hypothesis that minocycline 
treatment following TBI will attenuate microglial/macrophage reactivity along with 
neuronal and axonal degeneration leading to decreases in brain atrophy and a reversal of 
spatial learning and memory deficits. The effects of both short-term (3 days) 
administration of minocycline (45mg/Kg/dose) were tested in a well characterized model 
of single TBI in the 11-day-old rat. This injury results in neuronal and axonal 
degeneration, TAI, microglial/macrophage reactivity, tissue atrophy and cognitive 
deficits that last up to 4 weeks post-injury (Raghupathi and Huh, 2007). 
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4.3 MATERIALS AND METHODS 
 
4.3.1 Brain Injury and Minocycline Administration 
 
 Animals were injured as described in chapter 3.3.1. Immediately following the 
injury, animals were randomly assigned to receive a 45mg/Kg dose of minocycline 
hydrochloride (Sigma, St. Louis MO) dissolved in phosphate-buffered saline (PBS), or 
vehicle (PBS, 0.2mL/Kg) via an intraperitoneal (i.p.) injection. Sham-injured animals 
were also randomly assigned to receive either vehicle or minocycline. Minocycline or 
vehicle was injected every 12 hours for 3 days for a total of 6 injections (45 
mg/Kg/injection or 0.2 mL/Kg/injection). This dose and dosing paradigm was successful 
in reducing acute microglial/macrophage activation in neonate repetitive TBI (Hanlon et 
al., 2016a) and other models of neonate HI (Buller et al., 2009).  Animal numbers for 
each outcome are listed in Table 4.1.  
4.3.2 Intra-Cortical Fluoro-Gold Injections  
 
 Animals were injected with the retrograde tracer FluoroGold (2%, FluoroChrome) 
as previously described (Chapter 3.3.2).  For this study, however, the tracer was injected 
into the uninjured (right) cortex to address the potential confound that cells in the injured 
cortex were deficient in their uptake of the tracer.  
4.3.3 Histology and Immunohistochemistry 
 
 Animals were sacrificed at the appropriate time points according to methods 
described in chapter 3.3.4. Coronal sections were assessed for immunohistochemistry as 
previously described (Hanlon et al., 2016b) (Chapter 3.3.4). Briefly, coronal sections 
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were mounted on gelatin-subbed slides and subsequently stained with Nissl-Myelin or 
Fluoro-Jade B (FJB) for detection of gross tissue alterations and degeneration (Hanlon et 
al., 2016b).  Sections from FG brains were mounted and allowed to dry in the dark before 
being coverslipped with DPX mounting media. Microglia/macrophages were evaluated 
with free-floating immunohistochemistry using anti-ionized calcium-binding adaptor 
molecule 1 (Iba1, Wako, Richmond, VA, 1:20,000) and CD68 (Clone ED1, BioRad, 
formerly AbD Serotech, Hercules, CA, 1:500), astrocytes were visualized using glial 
fibrillary acidic protein (GFAP, Sigma, St. Louis, MO, 1:5,000), and traumatic axonal 
injury using a polyclonal antibody to the C-terminal end of amyloid precursor protein 
(APP, Zymed, San Francisco, CA, 1:2,000).   
 
4.3.4 Quantification of histology 
 
Quantification of histology was performed as previously described (Chapter 
3.3.5).  Exceptions include that APP(+) profiles in the white matter and thalamus were 
counted in 20x images instead of being analyzed with an overlaid grid analysis (15 
images in the WM and 9 images in the thalamus). Also, Iba1 labeling in the white matter 
was counted in 20x images when the density of labeling allowed (15 days post-injury).  
 
4.3.5 Cortical Evoked Field Potential Recordings 
 
 Evoked field potential recordings were taken from layer 5 of the motor cortex at 
bregma and 3mm posterior to bregma at 3 days and 4 weeks post-injury and quantified as 
previously described (Chapter 3.3.7).    
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4.3.6 Spatial Learning and Memory Assessment 
 
 Spatial learning and memory was assessed on post-injury days 10-14 as 
previously described (Chapter 3.3.8).  
 
4.3.7 Statistical Analysis 
 
 All statistics were performed using Statistica 7 (StatSoft, Tulsa OK). All 
data are presented as mean ± standard error of the mean. Sham-injured animals that 
received vehicle injections were not statistically different from those that were treated 
with minocycline in any of the various histologic and behavioral outcome measures and 
were therefore combined for statistical purposes. Outcome measures were compared 
across groups (sham, injured + vehicle, injured + minocycline) as a function of time 
(when applicable) and sex (when there were adequate numbers of each sex per group) 
using appropriate analyses of variance (ANOVA). When necessary, post-hoc analyses 
were performed using the Newman-Keuls test and a value of p≤0.05 was considered 
significant. Animal numbers for each outcome are listed in Table 4.1.   
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4.4 RESULTS 
 
4.4.1 Effects of acute minocycline treatment on histopathology and neuronal activity 
in the injured cortex. 
 
Minocycline treatment decreased microglial/macrophage reactivity while simultaneously 
increasing neurodegeneration in the cortex at 3 days post-injury.  
 In sham-injured animals and in brain-injured minocycline-treated animals, Iba1-
positive microglia/macrophages displayed processes suggestive of a “resting” phenotype 
(Fig. 4.2A and 4.2C, white arrows). Brain-injured animals that received either vehicle or 
minocycline injections contained “activated” microglia/macrophages, in which processes 
were fewer and/or shorter and cell bodies were larger (Fig. 4.2B and 4.2C, black arrows), 
in the retrosplenial cortex and through all layers of the motor and somatosensory cortices. 
Quantification of the number of Iba1(+) microglia/macrophages in the cortex at both 3 
and 7 days post-injury revealed an interaction effect between group and time 
(F2,20=13.73, p<0.001; Fig. 4.2G) with a post-hoc analysis indicating that both brain-
injured groups contained more microglia/macrophages compared to the time-matched 
sham-injured animals, and that minocycline-treated, brain-injured animals had 
significantly fewer total microglia/macrophages than brain-injured animals that received 
vehicle; the latter effect was only noted at 3 days post-injury (p<0.001), but not at 7 days 
post-injury (p=0.39; Fig. 4.2G). Sex, when used as an independent variable, demonstrated 
no interaction with group or time (F2,20=0.06, p=0.94). Similarly, quantitative analyses of 
activated microglia/macrophages revealed an interaction effect between group and time 
(F2,20=4.88, p<0.05; Fig. 4.2H) with the post-hoc analysis indicating that minocycline 
treatment was only effective in decreasing the proportion of activated 
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microglia/macrophages in brain-injured animals at 3 days post-injury (p<0.01); sex of the 
animals did not influence the interaction between group and time (F2,20=0.01, p=0.99).   
Activated microglia/macrophages were additionally labeled using an antibody to 
CD68/ED-1 at 3 days post-injury (Fig. 4.2D-F). The activated microglia/macrophages 
took on two types of morphologies: amoeboid cells that were enlarged and rounded and 
rod cells that exhibited thick, elongated cell bodies.  Both types of cells had few if any 
visible processes (Fig. 4.2F Insets).  Qualitative analysis revealed that minocycline-
treated brain-injured animals (Fig. 4.2F) appeared to have fewer ED-1-labeled cells in the 
cortex compared to brain-injured animals that received the vehicle (Fig. 4.2E). One-way 
ANOVA of the number of amoeboid cells revealed a significant effect of status 
(F2,6=12.08, p<0.01, Fig. 4.2L) and post hoc assessment revealed that brain-injured 
animals had significantly more amoeboid cells than sham-injured animals irrespective of 
treatment (p<0.01). Despite observed qualitative differences, there was no significant 
difference in the number of amoeboid cells between brain-injured minocycline-treated 
animals and those that received the vehicle (p=0.41).  Analysis of rod 
microglia/macrophages also revealed a significant effect of status (F2,6=17.27, p<0.01, 
Fig. 4.2L) that showed that brain-injured animals had significantly more rod 
microglia/macrophages compared to sham-injured animals (p<0.05).  The number of rod 
microglia/macrophages showed a trending decrease between brain-injured minocycline-
treated animals and those that received the vehicle (p=0.06).   
Astrocytic reactivity was visualized in the cortex using an antibody to glial 
fibrillary acidic protein (GFAP).  Low power area thresholding analysis was conducted 
due to the diffuse nature of the labeling (Fig. 4.2G-I). Analysis revealed a significant 
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effect of status (F2,8=53.27, p<0.001, Fig. 4.2M) that indicated a severe increase in the 
area of labeling in the cortex of brain-injured animals compared to sham-injured animals 
(p<0.001).  Minocycline treatment had no effect on astrocytic reactivity in the cortex 
(p=0.17).  
     In cortical areas that contained reactive microglia/macrophages and astrocytes, 
FJB-labeled degenerating neurons were observed (Fig. 4.3B and 4.3C); there were no 
FJB(+) profiles in the sham-injured animals (Fig. 4.3A). A three-way ANOVA revealed 
an interaction effect between treatment status and time (F1,17=14.47, p<0.01; Fig. 4.2I) 
and minocycline-treated, brain-injured animals had significantly more FJB+ profiles than 
brain-injured animals (p<0.001) at 3 days post-injury but not at 7 days post-injury 
(p=0.61); sex of the animals did not affect FJB reactivity in the cortex (F1,17=0.79, 
p=0.39). Impact to the intact skull of either the neonate male or the female rat did not 
result in an overt lesion or cavitation of the underlying cortex (Fig. 4.3E and 4.3F). 
Cortical layers in sham-injured (Fig. 4.3D) and in brain-injured animals that received 
vehicle (Fig. 4.3E) or minocycline (Fig. 4.3F) demonstrated typical cellular labeling.  
 
Acute minocycline treatment was associated with an increase in microglial/macrophage 
reactivity and an increase in neurodegeneration in the cortex at 15 days post-injury.  
 At 15 days post-injury, microglial/macrophage reactivity was still present in the 
cortex of brain-injured animals as evidenced by an increase in Iba1-labeled 
microglia/macrophages (Fig. 4.4A-C) and the presence of ED-1 labeled cells (Fig. 4.4D-
F). Analysis of the total number of microglia/macrophages revealed a significant effect of 
injury status (F2,9=16.19, p<0.01; Fig. 4.4J) and post hoc assessment demonstrated that 
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brain-injured animals had significantly more Iba1-labeled cells in the cortex compared to 
sham-injured animals (p<0.01). The number of total microglia/macrophages did not differ 
between minocycline-treated brain-injured animals and those that received the vehicle 
(p=0.21).  Analysis of amoeboid ED-1-labeled cells in the cortex also revealed a status 
effect (F2,9=22.54, p<0.001; Fig. 4.4K). Post hoc analysis showed that, while brain-
injured animals that received the vehicle appeared to have more labeled cells compared to 
sham-injured animals, the difference was not significant (p=0.08). Brain-injured 
minocycline-treated animals, however, had significantly more amoeboid ED-1-labeled 
cells compared to both sham-injured (p<0.001) and brain-injured vehicle animals 
(p<0.01).  Similarly, there was a significant effect of status in the analysis of the number 
of rod-shaped ED-1-labeled cells (F2,9=39.86, p<0.001; Fig. 4.4K).  There was no 
significant difference between sham-injured and brain-injured animals that received the 
vehicle (p=0.26), but minocycline-treated brain-injured animals had significantly more 
rod-shaped cells than both sham-injured (p<0.001) and brain-injured animals that 
received the vehicle (p<0.001). These results indicate that the acute treatment that 
initially decreased reactivity altered the microglial/macrophage response almost two 
weeks after the cessation of treatment.  Similar to the 3-day time point, FJB-labeled 
profiles were observed in brain-injured animals in the same areas of cortex as the 
microglial/macrophage reactivity (Fig. 4.4H,I) and there was no evidence of FJB labeling 
in the sham-injured animals (Fig. 4.4G).  When the total number of FJB-labeled profiles 
were analyzed, there was a significant effect of status (F1,6=37.01, p<0.01; Fig. 4.4L) that 
indicated that brain-injured minocycline-treated animals had significantly more FJB-
labeled profiles in the cortex than brain-injured animals that received the vehicle 
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(p<0.01).  These results indicate that the increase in neurodegeneration may be connected 
to the increase in microglial/macrophage reactivity.  
 
Increased microglial/macrophage reactivity and neurodegeneration in brain-injured 
minocycline-treated animals was sustained in the cortex out to 4 weeks post-injury.  
 At 4 weeks post-injury, there were very few ED-1-labeled cells in the cortex of 
sham-injured animals (Fig. 4.5A), but brain-injured animals demonstrated visible labeling 
irrespective of treatment (Fig. 4.5B,C).  Analysis of the amoeboid ED-1-labeled cells 
revealed a significant effect of status (F2,11=17.64, p<0.001; Fig. 4.5G) and post hoc 
assessment indicated that brain-injured animals had significantly more amoeboid cells 
than sham-injured animals (p<0.01), but that minocycline treatment had no effect on the 
number of amoeboid cells in the cortex (p=0.10).  There was no interaction between sex 
and injury status in the quantification of amoeboid microglia (F2,11=2.21, p=0.16)  There 
was also a significant status effect in the rod-like ED-1(+) cells (F2,11=10.23, p<0.01; Fig. 
4.5G) that indicated that both brain-injured animals that received the vehicle did not 
differ from sham-injured animals (p=0.11). Minocycline-treated brain-injured animals, 
however, had significantly more rod-like ED-1-labeled cells than both sham-injured 
(p<0.01) and brain-injured animals that received the vehicle (p<0.05).  Again, there was 
no interaction between injury status and sex of the animal in this measure (F2,11=0.18, 
p=0.84).  Similar to previous time points, both brain injured groups displayed FJB(+) 
profiles in the cortex (Fig. 4.5E,F) while there was no visible labeling in the cortex of 
sham-injured animals (Fig. 4.5D).  In quantifying the FJB-labeled profiles in the cortex, 
there was a significant effect of status (F1,7=18.08, p<0.01; Fig. 4.5H) indicating that 
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brain-injured minocycline-treated animals had significantly more FJB-labeled profiles in 
the cortex than brain-injured animals that received the vehicle. Interestingly, there was a 
mild interaction between sex and status (F1,7=5.92, p=0.05) that indicated that brain-
injured males treated with minocycline had significantly more FJB(+) profiles in the 
cortex than any other group (p<0.05).  
 
Minocycline treatment reversed hypoactivity in the cortex at bregma level at 3 days post-
injury.  
 The motor cortex at the bregma level marks the anterior portion of the impact site 
and contains FJB-labeled profiles and activated microglia.  At 3 days post-injury, brain-
injured animals that received the vehicle demonstrated visibly smaller evoked field 
potentials compared to sham-injured and brain-injured minocycline-treated animals 
(Figure 4.6A).  Quantitative analysis of the size of the signals from this region revealed a 
significant effect of status (F2,13=4.33, p<0.05; Fig. 4.6B).  Brain-injured animals treated 
with vehicle had significantly smaller signals than sham-injured animals (p<0.05). This 
deficit was rescued by treatment with minocycline as the signals from minocycline-
treated brain-injured animals were similar in size to those from sham-injured animals 
(p=0.49).  There was no interaction between sex and status (F2,13=0.20, p=0.82). There 
was no significant effect of status for the latency of signal (F2,13=0.75, p=0.49, Fig. 4.6C) 
or the duration of signal (F2,13=0.61, p=0.56, Fig. 4.6D). Also, there was no interaction 
between status and sex for either variable (latency: F2,13=0.37, p=0.70; duration: 
F2,13=0.67, p=0.53).  
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Acute minocycline treatment resulted in hypoactivity in the impact site at 4 weeks post-
injury.  
 Well within the impact site, 3mm posterior to the bregma suture, there was no 
effect of injury or sex on the amplitude (F2,12=0.26, p=0.26, Fig. 4.7B) or latency 
(F2,12=0.13, p=0.88, Fig. 4.7C) of the signals at 3 days post-injury. Interestingly, there 
was a significant status effect in the quantification of the duration of the signals 
(F2,12=10.68, p<0.01, Fig. 4.7D) that indicated that the signals from brain-injured animals 
had a longer duration than those from sham-injured animals (p<0.05). There was also an 
interaction between sex and status at 3 days post-injury (F2,12=9.81, p<0.01) and post hoc 
analysis revealed that brain-injured females that were treated with the vehicle had 
significantly longer durations than brain-injured males that were treated with the vehicles 
(p<0.05).  Oppositely, the duration of signal from brain-injured minocycline-treated 
females was significantly smaller than the duration of signal from brain-injured 
minocycline-treated males (p<0.01). There were no differences between sham-injured 
males and females at 3 days post-injury (p=0.65).  At 4 weeks post-injury, however, 
brain-injured minocycline-treated animals demonstrated visibly weaker signals than those 
from sham-injured and brain-injured animals that received the vehicle (Fig. 4.7A). 
Quantitative analysis of the signal amplitude revealed a significant effect of status 
(F2,10=11.25, p<0.01, Fig. 4.7B), but no significant interaction between status and sex 
((F2,10=1.77, p=0.22).  Further analysis showed that the signals from sham-injured 
animals did not differ from those from brain-injured animals that received the vehicle 
(p=0.29).  Brain-injured minocycline-treated animals, however, exhibited significantly 
smaller signals than those from sham-injured (p<0.01) and brain-injured vehicle animals 
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(p<0.05, Fig. 4.7A,B).  There was no significant effect of status or sex for the latency of 
the signal (F2,10=1.32, p=0.31, Fig. 4.7C), but there was an interaction effect between sex 
and status for the duration of the signals (F2,10=10.30, p<0.01, Fig. 4.7D).  Post hoc 
analysis, however, revealed that there were no significant differences between male and 
female animals within each group or across groups. These results indicate that acute 
minocycline treatment can have detrimental effects on neuronal activity even 4 weeks 
after the injury.      
 
4.4.2 Effects of minocycline treatment on microglial/macrophage reactivity and 
degeneration in the hippocampus.  
 
Minocycline treatment decreased in microglial/macrophage reactivity while 
simultaneously increasing neurodegeneration in the subiculum at 3 days post-injury. 
   Closed head impact in the neonate rat resulted in neurodegeneration and 
microglial/macrophage reactivity in the hippocampus and was restricted to the dorsal 
aspect of the subiculum. As observed in the cortex, most Iba1(+) microglia/macrophages 
in the sham-injured animals exhibited the typical “resting” morphology (Fig. 4.8A), 
whereas in the brain-injured animals activated microglia/macrophages were also 
observed (Fig.4.8B,C). Quantification of Iba1(+) microglia/macrophages only revealed a 
group effect (F2,20=8.44, p<0.01; Fig. 4.8J), with more microglia/macrophages in brain-
injured animals compared to sham-injured animals (p<0.001); however there was no 
difference between the two brain-injured groups (p=0.77).  By contrast, analysis of the 
proportion of activated microglia/macrophages indicated an interaction effect between 
group and time (F2,20=9.45, p<0.01; Fig. 4.8K).  Brain-injured animals had a significantly 
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higher proportion of activated Iba1-labeled microglia/macrophages than sham-injured 
animals (p<0.001) and minocycline-treated brain-injured animals had a lower percent of 
activated microglia/macrophages than brain-injured animals that were injected with 
vehicle (p<0.001).  As was observed in the cortex, minocycline treatment only decreased 
the proportion of activated microglia/macrophages in brain-injured animals at 3 days 
post-injury (p<0.001) and not at 7 days post-injury (p=0.47). The sex of the animals did 
not affect either the total amount of Iba1 (+) microglia/macrophages (F2,20=0.30, p=0.74) 
or the proportion of activated microglia/macrophages (F2,20=0.34, p=0.72) in the 
subiculum.   
Sham-injured animals demonstrated very little ED-1 labeling in the subiculum 
(Fig. 4.8D) whereas brain-injured animals demonstrated both amoeboid and rod-shaped 
ED-1-labeled cells in the subiculum at 3 days post-injury (Fig. 4.8E,F).  While both 
brain-injured groups appeared to have more amoeboid cells than sham-injured animals 
and minocycline-treated brain-injured animals appeared to have significantly fewer 
amoeboid cells than brain-injured animals that received the vehicle, the status effect did 
not reach significance (F2,4=6.48, p=0.06, Fig. 4.8L).  This could, however, be due to the 
small sample sizes used for the ED-1 study at 3 days post-injury (N=4 animals/group).  
There was, however, a significant status effect when analyzing the number of rod-shaped 
ED-1-labeled cells in the subiculum at 3 days post-injury (F2,4=41.63, p<0.01).  Post hoc 
analysis revealed that both brain-injured groups had significantly more rod-shaped cells 
compared to sham-injured animals (p<0.05) and that brain-injured minocycline-treated 
animals had fewer rod-shaped cells than those treated with the vehicle (p<0.01) 
indicating an effect of treatment on this cellular subtype.                   
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Similar to the cortex, brain-injured animals exhibited FJB-positive labeling in the 
subiculum (Fig. 4.8H,I) whereas sham-injured animals showed no visible labeling (Fig. 
4.8G).  Quantification of FJB(+) profiles revealed an effect between treatment status and 
time (F1,17=44.45, p<0.001; Fig. 4.8M) with minocycline treatment increasing the number 
of FJB(+) cells at 3 days (p<0.001) but not at 7 days post-injury (p=0.48; Fig. 4.8M). Sex 
of the animals did not influence FJB reactivity in the subiculum (F1,17=1.43, p=0.25). 
 
Minocycline treatment resulted in increased microglial/macrophage reactivity and 
increased neurodegeneration in the subiculum at 15 days post-injury.    
 At 15 days post-injury, brain-injured animals still demonstrated visible increases 
in Iba1-labeled cells and contained labeled cells that displayed activated morphology 
whereas the labeled cells in sham-injured animals mostly exhibited resting morphologies 
(Fig. 4.9A).  Quantification of total Iba1-labeled microglia/macrophages showed a status 
effect (F2,9=22.82, p<0.001, Fig. 4.9J) in which brain-injured animals had significantly 
more labeled cells than sham-injured animals (p<0.001), but brain-injured minocycline-
treated animals had similar numbers of total Iba1-labeled cells compared to brain-injured 
animals that received the vehicle (p=0.26) indicating that there was no effect of treatment 
on total cellularity.  When slices were stained for activated microglia/macrophages using 
ED-1, sham-injured animals demonstrated very little labeling (Fig. 4.9D) while rod- and 
amoeboid-shaped cells were observed in the subiculum of brain-injured animals (Fig. 
4.9E,F).  Significant effects of status were observed for the counts of both amoeboid 
(F2,9=20.02, p<0.001) and rod cells (F2,9=11.84, p<0.01, Fig. 4.9K).  Brain-injured 
animals demonstrated more ED-1 labeling in the subiculum than sham-injured animals 
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for measures of both amoeboid and rod phenotypes (p<0.05).  Brain-injured animals 
treated with minocycline, however, had significantly more amoeboid cells in the 
subiculum compared to brain-injured animals that were injected with the vehicle 
(p<0.01), but there was no difference in the number of rod-like ED-1-labeled cells 
between brain-injured groups (p=0.12).  This increase in amoeboid 
microglia/macrophages in the subiculum appeared to coincide with an increase in FJB-
labeled profiles (Fig.4.9G-I,L). Quantification of FJB-positive profiles in the subiculum 
revealed a significant effect of status (F1,6=16.69, p<0.01, Fig. 4.9L) indicating that 
minocycline treatment was associated with an increase in FJB labeling in the subiculum 
of brain-injured animals.  
 
4.4.3 Effects of minocycline treatment on microglial/macrophage reactivity, 
degeneration, and axonal injury in the thalamus.          
 
Minocycline administration reduced microglial/macrophage reactivity, but exacerbated 
degeneration and had no effect on axonal amyloid precursor protein accumulation at 3 
days post-injury. 
In the thalamus of brain-injured animals, Iba-1 and ED-1-positive reactive 
microglia/macrophages were observed within the dorsolateral and lateral geniculate 
nuclei (Fig. 4.10B,C,E,F).  Microglia/macrophages in the thalamus of sham-injured 
animals demonstrated a resting phenotype visible through Iba1 labeling and very few ED-
1-labeled cells (Figure 4.10A,D).  Brain-injured animals, irrespective of treatment 
condition, had significantly more Iba(+) microglia/macrophages (F2,20=5.55, p<0.05; Fig. 
4.10G) and a significantly greater proportion of activated Iba1(+) microglia/macrophages 
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(F2,20=18.44, p<0.001; Fig. 4.10H) than sham-injured animals.  Brain-injured animals 
treated with minocycline had similar numbers of microglia/macrophages and a similar 
proportion of activated microglia/macrophages compared with brain-injured animals that 
received vehicle at both 3 and 7 days post-injury (total: 3 days, p=0.80; 7 days, p=0.79; 
proportion: 3 days, p=0.47; 7 days, p=0.35; Fig. 4.10G and 4.10H). Neither the total 
Iba1(+) microglia/macrophages (F2,20=0.10, p=0.90) nor the proportion of activated 
Iba1(+) microglia/macrophages (F2,20=0.79, p=0.47) was affected by the sex of the brain-
injured animals.  Quantification of ED-1 labeling at 3 days post-injury revealed 
significant effects of status for both amoeboid (F2,6=121.47, p<0.001, Fig. 4.10I) and rod 
(F2,6=37.34, p<0.001) microglia/macrophages.  Brain-injured animals had significantly 
more amoeboid (p<0.001) and rod (p<0.01) cells compared to sham-injured animals 
irrespective of treatment.  Brain-injured animals treated with minocycline, however, had 
fewer ED-1-labeled amoeboid and rod cells compared to brain-injured animals that 
received the vehicle (p<0.01) indicating that minocycline was specifically affecting 
activated microglia/macrophages and that using ED-1 staining may be more sensitive to 
detect these changes.   
Fluoro-Jade B(+) profiles were observed in the same thalamic nuclei as the 
activated microglia/macrophages in brain-injured animals (Fig. 4.11B,C).  FJB(+) 
profiles in the thalamus of brain-injured animals exhibited both large cellular 
morphologies and showed evidence of smaller, fragmented profiles indicative of axonal 
degeneration. Sham-injured animals did not demonstrate any FJB(+) profiles (Fig. 
4.11A). Quantification of FJB+ profiles revealed a significant effect of treatment status 
(F1,17=4.45, p<0.05) that indicated that minocycline-treated brain-injured animals had 
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significantly more FJB+ profiles compared to brain-injured animals that received vehicle 
irrespective of sex or time (p<0.05; Fig. 4.11G). There was, however, an interaction 
effect between sex and treatment status (F1,17=6.143, p<0.05) that demonstrated that 
female brain-injured animals that received the vehicle had fewer FJB+ reactivity than 
male animals that received the vehicle and female minocycline-treated animals (p<0.05). 
Evidence of traumatic axonal injury (TAI) as revealed by the presence of amyloid 
precursor protein (APP) accumulation within axons was observed only at 3 days post-
injury (Fig. 4.11E,F) and not in sham-injured animals (Fig. 4.11D). Analysis of the 
number of APP(+) profiles indicated no effect of treatment status (F1,7=0.12, p=0.74, Fig. 
4.11H). 
 
Minocycline treatment does not significantly affect microglial/macrophage reactivity and 
neurodegeneration in the thalamus at 15 days post-injury. 
 At 15 days post-injury, microglial/macrophage reactivity was evident in the 
thalamus of brain-injured animals using both Iba1 (Fig. 4.12B,C) and ED-1 (Fig. 
4.12E,F) labeling.  Much like the cortex and subiculum, Iba1-labeled 
microglia/macrophages in the thalamus of sham-injured animals displayed resting 
phenotype (Fig. 4.12A) and there were very few ED-1-labeled cells (Fig. 4.12D).  
Quantification of total Iba1-labeled microglia/macrophages showed a significant effect of 
injury status (F2,9=27.72, p<0.001, Fig. 4.12J) where brain-injured animals had 
significantly more microglia/macrophages than sham-injured animals (p<0.01).  The 
difference between brain-injured minocycline-treated animals and brain-injured animals 
that were injected with vehicle was trending on significant with the minocycline group 
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having slightly more microglia/macrophages than the vehicle group (p=0.06).  Significant 
effects of injury status were observed for both ED-1-labeled amoeboid (F2,9=11.62, 
p<0.01) and rod (F2,9=12.11, p<0.01, Fig. 4.12K) microglia/macrophages, but post hoc 
analysis indicated that there were no differences between brain-injured groups 
(amoeboid: p=0.28; rod: p=0.20).  There was no effect of status in the quantification of 
FJB(+) profiles in the thalamus indicating no difference between brain-injured groups 
(F1,6=0.05, p=0.83, Fig. 4.12L). 
 
      Minocycline treatment was associated with increased microglial/macrophage 
reactivity but no corresponding increase in neurodegeneration at 4 weeks post-injury.  
 At 4 weeks post-injury, brain-injured animals still showed dense ED-1 (Fig. 
4.13B,C) and FJB (Fig. 4.13E,F) labeling in the thalamus. Sham-injured animals showed 
no FJB labeling (Fig. 4.13D) and very little ED-1 labeling (Fig. 4.13A).  Analysis of ED-
1 labeling revealed significant effects of injury status for both amoeboid (F2,11=22.76, 
p<0.001) and rod  microglia/macrophages (F2,11=23.74, p<0.001, Fig. 4.13G), but no 
interaction between status and sex for either measure (amoeboid: F2,11=0.39, p=0.69; rod: 
F2,11=2.40, p=0.14).  Brain-injured animals had significantly more amoeboid and rod 
microglia/macrophages compared to sham-injured animals (p<0.01).  There was a 
significant effect of minocycline treatment as brain-injured animals treated with 
minocycline had significantly more amoeboid and rod microglia/macrophages compared 
to brain-injured animals that received the vehicle (p<0.05).  While brain-injured animals 
treated with minocycline appeared to have more FJB(+) profiles in the thalamus than 
those treated with vehicle, there was no significant effect of injury status (F1,7=3.78, 
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p=0.09) and no significant interaction between injury status and sex of the animal 
(F1,7=2.09, p=0.19). 
 
4.4.4 Effects of acute minocycline treatment on white matter pathology 
 
Minocycline-mediated reduction in microglial/macrophage reactivity had no effect on 
neurodegeneration and axonal injury in the white matter at 3 days post-injury. 
In sham-injured animals, Iba1-labeled microglia/macrophages in the corpus 
callosum, cingulum and white matter tracts below the site of impact were sparse and 
displayed a large number of processes (Fig. 4.14A). At 3 days post-injury, reactive 
microglia/macrophages (Fig. 4.14B and 4.14C) were observed as extremely dense 
labeling. Quantitative analysis of Iba1(+) immunoreactivity revealed an interaction effect 
between group and time (F2,20=86.23, p<0.001), wherein a post-hoc analysis indicated 
that both brain-injured groups had a significantly larger Iba1 immunoreactive area than 
that in sham-injured animals (p<0.001) and that minocycline-treated brain-injured 
animals had significantly smaller labeled areas at 3 days post-injury (p<0.001) but not at 
7 days post-injury (p=0.45) compared to brain-injured animals injected with vehicle (Fig. 
4.14G).  Brain-injured animals also exhibited ED-1(+) profiles in the white matter tracts 
(Fig. 4.14E,F).  At this time, sham-injured animals also exhibited visible ED-1 labeling in 
the white matter (Fig. 4.14D) although not to the degree of the brain-injured animals.  
There was a significant effect of status when quantifying amoeboid (F2,6=202.98, 
p<0.001), but not rod (F2,6=1.07, p=0.40, Fig. 4.14H) microglia/macrophages in the white 
matter at 3 days post-injury.  Post hoc analysis of the amoeboid cell count revealed that 
both groups of brain-injured animals had significantly more amoeboid cells compared to 
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sham-injured animals (p<0.001), but minocycline-treated brain-injured animals had 
significantly fewer amoeboid cells compared to those that received the vehicle (p<0.01).          
Fluoro-Jade B(+) profiles were observed at both 3 (Fig. 4.15B and 4.15C) and 7 
days post-injury (not shown) in a diffuse and punctate pattern suggestive of axonal 
degeneration; no FJB+ labeling was observed in sham-injured animals (Fig. 4.15A).  
Regions containing reactive microglia/macrophages and FJB labeling also demonstrated 
injured axons exhibiting intra-axonal accumulation of APP (Fig. 4.15E and 4.15F) 
whereas sham-injured animals did not exhibit APP immunoreactivity (Fig. 4.15D). 
Despite the effect on Iba1 and ED-1 immunoreactivity, there was no effect of 
minocycline treatment on FJB reactivity (F1,17=0.007, p=0.93; Fig. 4.15G) or the number 
of APP+ profiles in the white matter of brain-injured animals (F1,5=0.74, p=0.43; Fig. 
4.15H).  The sex of the animals failed to demonstrate any interaction effects with group 
or time with regards to Iba1 (F2,20=0.82, p=0.46), FJB reactivity (F1,17=0.01, p=0.93), or 
APP (F1,5=0.74, p=0.43) in the white matter tracts. The area of the white matter below the 
impact site in brain-injured animals was significantly smaller compared to that in sham-
injured animals at both 3 and 7 days post-injury (F2,20=10.90, p<0.001) and was 
unaffected by treatment with minocycline at either 3 days (p=0.47) or 7 days post-injury 
(p=0.77; Fig. 4.15H) and sex (F2,20=0.09, p=0.91). 
 
Axonal degeneration was unaffected by a minocycline-mediated increase in amoeboid 
microglia/macrophages in the white matter at 15 days post-injury.  
 At 15 days post-injury, Iba1(+) and ED-1(+) cells were counted in the white 
matter of sham-injured (Fig. 4.16A,D), brain-injured vehicle (Fig. 4.16B,E), and brain-
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injured minocycline (Fig. 4.16C,F) animals. No effect of injury status was observed in 
the total Iba1 counts (F2,9=2,02, p=0.17, Fig. 4.16J) indicating that there were no 
differences in the total number of Iba1(+) microglia/macrophages between sham-injured 
and brain-injured animals or between treatment conditions in the brain-injured group.  
Quantification of amoeboid and rod microglia/macrophages in ED-1-labeled sections, 
however, did reveal significant effects of injury status (amoeboid: F2,9=37.23, p<0.001; 
rod: F2,9=15.48, p<0.01; Fig. 4.16K).  Significantly more ED-1(+) 
microglia/macrophages were observed in brain-injured animals compared to sham-
injured animals irrespective of morphology (p<0.01), but minocycline treatment resulted 
in an increase in only amoeboid morphology when compared to brain-injured animals 
that received the vehicle (p<0.05; rod: p=0.37, Fig. 4.16K).  Very few FJB(+) profiles 
were observed in the white matter of brain-injured animals (Fig. 4.16H,I) at 15 days post-
injury and there were no positive profiles in the sham-injured animals (Fig. 4.16G).  
Despite observing corresponding increases in microglial/macrophage reactivity and 
FJB(+) profiles in the cortex and subiculum at this time point, the increase in amoeboid 
microglia/macrophages was not associated with an increase in FJB(+) profiles in the 
white matter of brain-injured minocycline-treated animals (F1,6=2.46, p=0.17, Fig. 
4.16L). 
 
Minocycline administration did not affect axonal transport in the third week post-injury 
 Both sham-injured and brain-injured animals demonstrated uptake of the tracer as 
evident by robust fluorescence in the injected cortex (Fig. 4.17A-C).  Fluoro-Gold (FG) 
was also present as diffuse labeling in the white matter (not shown).  In the cortex 
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contralateral to the injection (the left cortex), the morphology associated with FG(+) 
profiles appeared neuronal.  There was a visible increase in the number of FG(+) profiles 
in the cortex of sham-injured animals (Fig. 4.17D) compared to both brain-injured groups 
(Fig. 4.17E,F).  There did not, however, appear to be a difference between the brain-
injured groups.  Quantification revealed that sham-injured animals did have more FG(+) 
labeling in the cortex (69 ± 12 profiles) than brain-injured animals that received the 
vehicle (25 ± 12 profiles) and brain-injured minocycline-treated animals (26 ± 8 profiles), 
but this effect was only trending on significance perhaps due to the small sample size 
(F2,7=3.67, p=0.08, Fig. 4.17G).  
 
Axonal degeneration was not associated with alterations in microglial/macrophage 
reactivity out to 4 weeks post-injury. 
 ED-1(+) microglia/macrophages were still observed in the white matter of brain-
injured animals (Fig. 4.18B,C) at 4 weeks post-injury whereas there were very few 
labeled cells in the white matter of sham-injured animals (Fig. 4.18A).  Similar to the 15-
day quantification, there was a significant effect of injury status on ED-1(+) amoeboid 
microglia/macrophages in the white matter (F2,11=104.37, p<0.001). At 4 weeks, 
however, there was also a significant effect of injury status on rod 
microglia/macrophages (F2,11=16.75, p<0.001).  Post hoc analysis revealed that brain-
injured animals had significantly more ED-1(+) microglia/macrophages than sham-
injured animals irrespective of morphology (p<0.001) and that brain-injured minocycline-
treated animals had significantly more amoeboid (p<0.001) and rod (p<0.05) 
microglia/macrophages than brain-injured animals that were injected with the vehicle.  
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Also similar to the 15-day time point, there were very few FJB(+) profiles in the white 
matter of brain-injured animals (Fig. 4.18E,F) and no visible labeling in the sham-injured 
animals (Fig. 4.18D).  There were no differences in the number of FJB(+) profiles in the 
white matter between minocycline-treated brain-injured animals and those that received 
the vehicle (F1,7=0.30, p=0.60). Additionally, sex of the animal did not affect 
microglial/macrophage reactivity or neurodegeneration in the white matter (amoeboid: 
F2,11=2.60, p=0.12; rod: F2,11=0.34, p=0.72; FJB: F1,7=0.22, p=0.65).  
 
4.4.5 Effect of minocycline on injury-induced spatial learning and memory deficits.      
 
Minocycline administration does not affect spatial learning and memory impairments in 
the second post-injury week.  
Brain injury resulted in a spatial learning deficit based on the observation that 
brain-injured animals exhibited an increased latency to locate the hidden platform 
compared to sham-injured animals (Fig. 4.19A). A repeated measures ANOVA revealed 
main effects of injury status (F2,84=3.14, p=0.05) and training day (F3,84=35.51, p<0.001), 
but no interaction effect between status and training day (F6,84=0.97, p=0.45) or between 
group, training day, and sex (F6,84=1.02, p=0.42; Fig. 4.19A).  Post-hoc analysis indicated 
that sham-injured animals took a shorter amount of time to locate the hidden platform 
compared to brain-injured animals that received vehicle (p<0.05), but not those that 
received minocycline (p=0.06). However, both groups of brain-injured animals had 
similar latencies to the hidden platform across treatment days (p=0.42) indicating that 
minocycline treatment had no effect on injury-induced spatial learning deficits. The 
decreased efficiency in learning the location of the platform was associated with a 
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retention deficit based on the observation that brain-injured animals spent less time in the 
platform zone (F2,28=3.41 p<0.05; Fig. 4.19B) that was not affected by treatment or sex 
(F2,28=0.31, p=0.73). There was no difference in the amount of time spent in the 
peripheral zone between brain- and sham-injured animals (F2,28=2.61, p=0.09) possibly 
because female rats, irrespective of injury/treatment status, spent significantly more time 
in the peripheral zone compared to male rats (F1,28=4.21, p<0.05, Fig. 4.19B). 
Importantly, the learning and memory deficits appeared not to be due to problems in 
vision based on the lack of either a group or sex effect in the visible platform trial 
(F2,28=1.67, p=0.21; Fig. 4.19B) or problems in motor function based on similar swim 
speeds in sham- and brain-injured male and female rats (sham-injured: 23 ± 0.84 cm/s; 
brain-injured vehicle: 24 ± 1.39 cm/s; brain-injured minocycline: 21 ± 0.88 cm/s; 
F2,28=0.49, p=0.62). 
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4.5 DISCUSSION 
 
The present study demonstrates that short-term minocycline administration 
initiated immediately following closed head injury in the neonate rat reduced the total 
number of microglia/macrophages and microglial/macrophage activation when evaluated 
upon termination of treatment. This reduction was accompanied by an increase in the 
extent of neurodegeneration and was not sustained to 4 days after treatment ended.  In the 
weeks post-injury, however, acute minocycline treatment was associated with an increase 
in both neurodegeneration and microglial/macrophage reactivity and resulted in 
hypoactivity in a region of the injured motor cortex.  Moreover, there was no attenuation 
of spatial learning and memory deficits that were tested in the second week post-injury. 
Collectively, these data suggest that acute minocycline treatment may not be a viable 
strategy for TBI in the neonate. 
Short-term administration of minocycline (similar to the paradigm used in this 
study) has been found effective in decreasing microglial/macrophage activation following 
neonatal hypoxic ischemia (Cai et al., 2006, Fan et al., 2006, Lechpammer et al., 2008, 
Cikla et al., 2016), pediatric cardiac arrest (Tang et al., 2010), neonatal repetitive TBI 
(Hanlon et al., 2016a), and adult TBI (Bye et al., 2007, Homsi et al., 2010, Siopi et al., 
2011). The reduction in activated microglia/macrophages was accompanied by an 
attenuation of neuronal damage (Cikla et al., 2016), a decrease in asphyxia-induced 
neurodegeneration (Tang et al., 2010), and a reduction of lesion volume following TBI 
(Homsi et al., 2010). However, the association between microglial/macrophage activation 
and attendant neurodegeneration in brain injury is not quite clear-cut: minocycline 
treatment following TBI in the adult mouse decreased F4/80-labeled microglia that 
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exhibited the activated phenotype without affecting lesion volume or TUNEL labeling 
(Bye et al., 2007) whereas in a model of neonatal stroke minocycline failed to reduce 
microglial activation, but still had a beneficial effect on lesion volume (Fox et al., 2005). 
In contrast to all the above studies, the decrease in acute microglial activation observed in 
the present study was in fact, associated with an increase in the number of FJB+ neurons 
suggestive of either a lack of clearance of degenerating neurons or that microglia may 
play a more active role in neuronal survival following injury to the immature brain 
(Potter et al., 2009). This latter possibility is supported by the fact that depletion of 
microglia following stroke in neonatal rats causes an increase in lesion size (Faustino et 
al., 2011). Microglial/macrophage activation also occurs in white matter tracts following 
injury to either the neonate or the adult brain. In the neonate, HI-induced microglial 
activation and the concomitant oligodendrocyte cell death, myelin loss and decrease in 
white matter volume were attenuated by minocycline (Cai et al., 2006, Fan et al., 2006, 
Lechpammer et al., 2008). In the adult mouse, TBI-induced loss of corpus callosum 
volume was attenuated by minocycline treatment (Siopi et al., 2011). In contrast, short-
term administration of minocycline in the present study did not affect axonal injury, 
degeneration, or transport, an observation that was similar to those in a model of 
repetitive brain trauma in the neonate rat (Hanlon et al., 2016a) and closed head injury in 
the adult mouse (Homsi et al., 2010). In this regard, genetic ablation of microglia in the 
white matter did not reduce trauma-induced axonal injury (Bennett and Brody, 2014). 
A sustained effect on microglial/macrophage activation and neurodegeneration 
was not observed at 7 days post-injury after the treatment was terminated, but because we 
administered minocycline to the developing brain, it was worthwhile to assess if this 
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acute manipulation had any effect on neuropathology in the weeks after ending treatment.  
When we looked at microglial/macrophage reactivity and neurodegeneration out to 4 
weeks post-injury, we found that minocycline-treated brain-injured animals exhibited 
increases in both of these measures, specifically in the cortex and subiculum, and this 
may suggest that the microglia/macrophages are playing an active role in the observed 
neurodegeneration.  This increase in neurodegeneration and microglial/macrophage 
reactivity was associated with hypoactivity as measured by evoked field potential 
recordings at 4 weeks post-injury.  In contrast to our results, Fan et al. (2006) observed 
beneficial effects of minocycline 2 weeks after ending an acute treatment paradigm. 
Minocycline-treated brain-injured animals demonstrated a sustained decrease in 
microglial reactivity that was associated with decreased white matter damage and 
behavioral improvements.  These differential effects could be due to either dosing (Fan et 
al. used a pre-injury loading dose and only administered the drug once a day for 3 days) 
or the type of injury (HI vs TBI).  There are a few studies, however, that indicate that 
minocycline administration may cause deleterious effects when used in the immature 
brain. For example, an increase in lesion severity was observed in HI rats treated with 
minocycline (Tsuji et al., 2004).  Similarly, minocycline treatment exacerbated apoptosis 
caused by NMDA receptor antagonism (Inta et al., 2016).   
Minocycline, however, did not cause an attenuation or exacerbation of injury-
induced spatial learning and retention deficits in the second week post-injury. Consistent 
with these observations, minocycline did not affect motor deficits in brain-injured adult 
mice (Bye et al., 2007) or spatial learning and memory following HI in neonatal mice 
(Cikla et al., 2016) and TBI in adult rats (Kelso et al., 2011).  This lack of sustained 
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effect may be due to the fact that the half-life of minocycline in rodents is rather short (2-
3 hours) (Andes and Craig, 2002) or the fact that in the second week post-injury, 
minocycline administration resulted in an exacerbation of cellular neuropathology.  In 
contrast, a number of studies have demonstrated that minocycline reduced behavioral 
impairments days and weeks after treatment termination in HI-injured neonatal rats (Fan 
et al., 2006) and in adult mice following TBI (Homsi et al., 2010, Siopi et al., 2012). 
Again, it is possible that these differences may relate to the variability in dose and dosing 
paradigms, the type of injury and the age of the animal employed in the various studies.   
When appropriate, our statistical analyses included sex as an independent variable 
and led to the observation that sex did not consistently influence injury-induced 
microglial/macrophage reactivity, neurodegeneration or cognitive function. In this regard, 
a recent study reported that injury-induced increases in microglial numbers were not 
dependent on the sex of the injured neonate animal (Chhor, et al. 2016). However, injury-
induced mitochondrial dysfunction (Robertson and Saraswati, 2015), changes in neuronal 
structure (Semple, et al., 2016) and social recognition (Semple et al., 2016) were more 
apparent in male rats, whereas injury-induced deficits in play behavior was 
predominantly observed in female rats (Mychasiuk, et al., 2014). In our study, sex did not 
influence the effects of minocycline in the various outcomes, an observation that is in 
contrast to the effect of progesterone which was effective in reversing mitochondrial 
dysfunction only in male rat pups (Robertson and Saraswati, 2015). These observations 
underscore the importance of utilizing sex as a variable in histologic and behavioral 
analyses when treatment injury-induced alterations and efficacy of neuroprotective 
strategies are tested.  
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 The results described here have several limitations. First, while the efficacy of this 
dose has been well-documented (Buller et al., 2009), only a single dose (45 
mg/kg/injection) and dosing paradigm was utilized.  Adjusting the dose or extending the 
dosing paradigm may alter the chronic effects of minocycline. For example, neonatal 
mice that received a lower daily dose (22.5 mg/kg) of minocycline for 6 days showed 
improvement in white matter pathology following hypoxia-ischemia (Carty et al., 2008), 
raising the possibility that 45 mg/kg may be too high in the neonates.  And while no other 
study has shown the exacerbated chronic cellular pathology that we observed, it is 
possible that this is a consequence of the dose/dosing paradigm and further dose response 
studies are needed.   
Secondly, while minocycline was an effective tool in decreasing 
microglial/macrophage reactivity following injury, this compound has several off-target 
effects.  Minocycline deposits in the bones and teeth of treated patients causing 
discoloration (Douglas, 1963, Poliak et al., 1985, McCleskey et al., 2004, Sanchez et al., 
2004), and we routinely observe a bright yellow discoloration in the skulls of our 
minocycline-treated sham- and brain-injured rats (not shown).  Due to its ability to 
chelate calcium and deposit in teeth and bones, the drug is not typically recommended for 
use in pregnant women or young children (Buller et al.,2009).  Another common side 
effect of minocycline treatment is gastrointestinal disturbances due to its antibiotic 
properties (Goulden et al., 1996, Smith and Leyden, 2005) and alteration of the gut 
microbiome has been shown to influence neuroinflammation and behavioral processes 
such as cognition (Rea et al., 2016, Galland, 2014).  Additionally, minocycline treatment 
can cause a lupus-like autoimmune disorder referred to as minocycline-induced lupus 
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(MIL) that can have a wide array of detrimental effects including hepatitis, systemic 
inflammation resulting in arthritis, weight loss, and fatigue (Schlienger et al., 2000). 
While these side effects are commonly associated with chronic minocycline treatment in 
humans, it is still possible that the results we observed are confounded by systemic 
influences.  Minocycline administration has also caused neurological side effects as many 
chronic users complain of vertigo, ataxia, and headaches (Williams et al., 1974, Smith 
and Leyden, 2005).  Minocycline has also been shown to influence astrocytic reactivity 
and neuronal activity.  While we did not observe a treatment effect on injury-induced 
astrocytic reactivity at 3 days, administering minocycline prior to exposing mixed 
neuron-astrocyte cultures to Aβ significantly reduced astrocytic morphologic changes and 
Aβ-induced increases in pro-inflammatory cytokine release (Garwood et al., 2011). In a 
model using LPS challenge in adult rats, however, minocycline administration decreased 
both Iba1 and ED-1 expression without affecting GFAP expression (Yoon et al., 2012) 
indicating conflicting evidence for minocycline’s effects on astrocytic reactivity and may 
once again be attributable to differences in dosing.  Minocycline has also been shown to 
directly alter neuronal activity through modulation of glutamatergic neurotransmission 
thus making interpretation of minocycline’s effects on evoked field potential recordings 
difficult (Gonzalez et al., 2007).  For these reasons, the utilization of minocycline as both 
a tool for microglial/macrophage inhibition and a potential therapeutic should be 
carefully considered.  
Thirdly, only spatial learning and memory in the Morris water maze was used to 
test cognitive function, although minocycline has been effective in reducing deficits in 
this measure of cognition (Fan et al., 2006, Lam et al., 2013). Nevertheless, future studies 
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warrant the use of a wider range of functional outcomes that may allow researchers to 
better understand the differential effects of minocycline treatment following injury to the 
developing brain. Additional future investigations should investigate the effect of 
minocycline on microglial/macrophage phenotype as it has been documented that 
minocycline can selectively target the pro-inflammatory M1 phenotype (Kobayashi et al., 
2013) and similarly decrease harmful mediators associated with an M1 phenotype such as 
IL-1β and TNFα (Yrjanheikki et al., 1999, Wang et al., 2005, Bye et al., 2007, 
Wasserman and Schlichter, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
157 
 
4.6 FIGURE LEGENDS 
 
Figure 4.1 Experimental Timelines. (A) Schematic representing the treatment paradigm 
and histological/behavioral time points. (B) Schematic representing the treatment 
paradigm and electrophysiological time points.  
 
Figure 4.2 Glial reactivity in the injured cortex at 3 and 7 days post-injury following 
acute minocycline treatment.  Representative photomicrographs of Iba1 (A-C), ED-1 
(D-F), and GFAP (G-I) labeling in the cortex of sham-injured (A,D,G), brain-injured 
animals that received the vehicle (B,E,H) and minocycline-treated brain-injured animals 
(C,F,I) at 3 days post-injury.  Insets in panel F represent examples of ED-1 labeled 
microglia/macrophages in amoeboid or rod form. Quantification of total Iba1-labeled 
microglia/macrophages (G) and the percent activated microglia/macrophages (H) at 3 
and 7 days post-injury. Quantification of ED-1-labeled microglia/macrophages displaying 
amoeboid or rod morphology (L) and the percent area labeled with GFAP staining in the 
injured cortex (M) at 3 days post-injury. *p≤0.05 compared to corresponding sham-
injured group. #p≤0.05 compared to the brain-injured vehicle group. Error bars represent 
the standard error of the mean. Scale bar (F)= 100μm; Scale bar (F Insets) = 10μm; Scale 
bar (I) = 500μm.  
 
Figure 4.3 Degeneration and gross tissue pathology in the injured cortex at 3 and 7 
days post-injury following minocycline treatment.  Representative photomicrographs 
of FJB labeling in the cortex (A-C) and Nissl-Myelin-stained sections (D-F) of sham-
injured (A,D), brain-injured vehicle (B,E) and minocycline-treated brain-injured animals 
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(C,F) at 3 days post-injury.  Quantification of total FJB-labeled profiles in the cortex at 3 
and 7 days post-injury (G). #p≤0.05 compared to the brain-injured vehicle group. Error 
bars represent the standard error of the mean. Scale bar (C)= 100μm; Scale bar (F) =  
500μm μm.  
 
Figure 4.4 Histological outcomes in the injured cortex at 15 days post-injury 
following acute minocycline treatment.   Representative photomicrographs of Iba1 (A-
C), ED-1 (D-F) and FJB (G-I) labeling in the cortex of sham-injured (A,D,G), brain-
injured vehicle (B,E,H) and brain-injured minocycline-treated animals (C,F,I) at 15 days 
post-injury.  Quantification of total Iba1-labeled microglia/macrophages (J), ED-1 
labeled microglia/macrophages displaying amoeboid or rod morphology (K, insets), and 
total FJB-labeled profiles (L) in the cortex at 15 days post-injury. *p≤0.05 compared to 
corresponding sham-injured group. #p≤0.05 compared to the brain-injured vehicle group. 
Error bars represent the standard error of the mean. Scale bar (I)= 100μm.  
 
Figure 4.5 Histological outcomes in the injured cortex at 4 weeks post-injury 
following acute minocycline treatment.   Representative photomicrographs of ED-1 (A-
C) and FJB (D-F) labeling in the cortex of sham-injured (A,D), brain-injured vehicle 
(B,E) and brain-injured minocycline-treated animals (C,F) at 4 weeks post-injury.  
Quantification of ED-1-labeled microglia/macrophages displaying amoeboid or rod 
morphology (G), and total FJB-labeled profiles (H) in the cortex at 4 weeks post-injury. 
*p≤0.05 compared to corresponding sham-injured group. #p≤0.05 compared to the brain-
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injured vehicle group. Error bars represent the standard error of the mean. Scale bar (F)= 
100μm.  
 
Figure 4.6 Evoked field potential recordings from the injured cortex at bregma 
following acute minocycline treatment.   (A) Representative traces from the bregma-
level cortex of sham-injured, brain-injured vehicle, and brain-injured minocycline-treated 
animals at 3 days post-injury.  Quantification of signal amplitude (B), signal latency (C), 
and signal duration (D) in the bregma-level cortex at 3 days post-injury. *p≤0.05 
compared to corresponding sham-injured group.  
 
Figure 4.7 Evoked field potential recordings from the injured cortex at -3mm at 3 
days and 4 weeks following acute minocycline treatment.   (A) Representative traces 
from the -3mm level cortex of sham-injured, brain-injured vehicle, and brain-injured 
minocycline-treated animals at 4 weeks post-injury.  Quantification of signal amplitude 
(B), signal latency (C), and signal duration (D) in the -3mm-level cortex at 3 daysand 4 
weeks post-injury. *p≤0.05 compared to corresponding sham-injured group. 
 
Figure 4.8 Acute histological outcomes in the injured subiculum following 
minocycline treatment.  Representative photomicrographs of Iba1 (A-C), ED-1 (D-F), 
and FJB (G-I) labeling in the cortex of sham-injured (A,D,G), brain-injured vehicle 
(B,E,H) and minocycline-treated brain-injured animals (C,F,I) at 3 days post-injury.  
Quantification of total Iba1-labeled microglia/macrophages at 3 and 7 days post-injury 
(J), the percent activated Iba1-labeled microglia/macrophages at 3 and 7 days post-injury 
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(K), ED-1-labeled microglia/macrophages displaying amoeboid or rod morphology at 3 
days post-injury (L), and total FJB-labeled profiles in the cortex at 3 and 7 days post-
injury (M) .  *p≤0.05 compared to corresponding sham-injured group. #p≤0.05 compared 
to the brain-injured vehicle group. Error bars represent the standard error of the mean. 
Scale bar (F)= 100μm.  
 
Figure 4.9 Histological outcomes in the injured subiculum at 15 days post-injury 
following acute minocycline treatment.   Representative photomicrographs of Iba1 (A-
C), ED-1 (D-F) and FJB (G-I) labeling in the subiculum of sham-injured (A,D,G), brain-
injured vehicle (B,E,H) and brain-injured minocycline-treated animals (C,F,I) at 15 days 
post-injury.  Quantification of total Iba1-labeled microglia/macrophages (J), ED-1 
labeled microglia/macrophages displaying amoeboid or rod morphology (K), and total 
FJB-labeled profiles (L) in the subiculum at 15 days post-injury. *p≤0.05 compared to 
corresponding sham-injured group. #p≤0.05 compared to the brain-injured vehicle group. 
Error bars represent the standard error of the mean. Scale bar (I)= 100μm.  
 
Figure 4.10 Microglial/macrophage reactivity in the injured thalamus following 
minocycline treatment at 3 and 7 days post-injury.  Representative photomicrographs 
of Iba1 (A-C) and ED-1 (D-F) labeling in the thalamus of sham-injured (A,D), brain-
injured vehicle (B,E) and minocycline-treated brain-injured animals (C,F) at 3 days post-
injury.  Quantification of total Iba1-labeled microglia/macrophages (G) and the percent 
activated microglia/macrophages (H) at 3 and 7 days post-injury, and ED-1 labeled 
microglia/macrophages displaying amoeboid or rod morphology (I) in the thalamus at 3 
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days post-injury  *p≤0.05 compared to corresponding sham-injured group.  #p≤0.05 
compared to the brain-injured vehicle group Scale bar (F)= 100μm. 
 
Figure 4.11 Degeneration and axonal injury in the injured thalamus at 3 and 7 days 
post-injury following acute minocycline treatment.  Representative photomicrographs 
of FJB (A-C) and APP (D-F) labeling in the thalamus of sham-injured (A,D), brain-
injured vehicle (B,E) and minocycline-treated brain-injured animals (C,F) at 3 days post-
injury.  Quantification of total FJB-labeled profiles at 3 and 7 days post-injury (G) and 
the total APP-labeled profiles at 3 days post-injury (H).  Scale bar (F)= 100μm. 
 
Figure 4.12 Microglial/macrophage reactivity and degeneration in the injured 
thalamus at 15 days post-injury following acute minocycline treatment.   
Representative photomicrographs of Iba1 (A-C), ED-1 (D-F) and FJB (G-I) labeling in 
the thalamus of sham-injured (A,D,G), brain-injured vehicle (B,E,H) and brain-injured 
minocycline-treated animals (C,F,I) at 15 days post-injury.  Quantification of total Iba1-
labeled microglia/macrophages (J), ED-1 labeled microglia/macrophages displaying 
amoeboid or rod morphology (K), and total FJB-labeled profiles (L) in the thalamus at 15 
days post-injury. *p≤0.05 compared to corresponding sham-injured group. #p≤0.05 
compared to the brain-injured vehicle group. Error bars represent the standard error of the 
mean. Scale bar (I)= 100μm.  
 
Figure 4.13 Microglial/macrophage reactivity and degeneration in the injured 
thalamus at 4 weeks post-injury following acute minocycline treatment.   
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Representative photomicrographs of ED-1 (A-C) and FJB (D-F) labeling in the thalamus 
of sham-injured (A,D), brain-injured vehicle (B,E) and brain-injured minocycline-treated 
animals (C,F) at 4 weeks post-injury.  Quantification of ED-1-labeled 
microglia/macrophages displaying amoeboid or rod morphology (G), and total FJB-
labeled profiles (H) in the thalamus at 4 weeks post-injury. *p≤0.05 compared to 
corresponding sham-injured group. #p≤0.05 compared to the brain-injured vehicle group. 
Error bars represent the standard error of the mean. Scale bar (F)= 100μm.  
 
Figure 4.14 Effect of acute minocycline treatment on microglial/macrophage 
reactivity in the white matter at 3 and 7 days post-injury. Representative 
photomicrographs of Iba1 (A-C) and ED-1 (D-F) labeling in the white matter of sham-
injured (A,D), brain-injured vehicle (B,E) and minocycline-treated brain-injured animals 
(C,F) at 3 days post-injury.  Quantification the percent area of Iba-1 labeling at 3 and 7 
days post-injury (G) and ED-1-labeled microglia/macrophages displaying amoeboid or 
rod morphology at 3 days post-injury (H).  *p≤0.05 compared to corresponding sham-
injured group. #p≤0.05 compared to the brain-injured vehicle group. Error bars represent 
the standard error of the mean. Scale bar (F)= 100μm.  
 
Figure 4.15 Effect of acute minocycline treatment on degeneration and axonal 
injury in the white matter at 3 and 7 days post-injury. Representative 
photomicrographs of FJB (A-C) and APP (D-F) labeling in the white matter of sham-
injured (A,D), brain-injured vehicle (B,E) and minocycline-treated brain-injured animals 
(C,F) at 3 days post-injury.  Quantification of total FJB-labeled profiles at 3 and 7 days 
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post-injury (G), total APP-labeled profiles at 3 days post-injury (H), and white matter 
area at 3 and 7 days post-injury (I).  Error bars represent the standard error of the mean. 
Scale bar (F)= 100μm.  
 
Figure 4.16 Microglial/macrophage reactivity and degeneration in the injured white 
matter at 15 days post-injury following acute minocycline treatment.   Representative 
photomicrographs of Iba1 (A-C), ED-1 (D-F) and FJB (G-I) labeling in the white matter 
of sham-injured (A,D,G), brain-injured vehicle (B,E,H) and brain-injured minocycline-
treated animals (C,F,I) at 15 days post-injury.  Quantification of total Iba1-labeled 
microglia/macrophages (J), ED-1 labeled microglia/macrophages displaying amoeboid or 
rod morphology (K), and total FJB-labeled profiles (L) in the white matter at 15 days 
post-injury. *p≤0.05 compared to corresponding sham-injured group. #p≤0.05 compared 
to the brain-injured vehicle group. Error bars represent the standard error of the mean. 
Scale bar (I)= 100μm.  
 
Figure 4.17 Effect of minocycline on axonal transport of retrograde tracer Fluoro-
Gold in the third week post-injury.  
Representative photomicrographs of the injection site in the right cortex (A-C) and FG(+) 
profiles in the cortex contralateral to the injection (D-F) in sham-injured (A,D), brain-
injured vehicle (B,E), and brain-injured minocycline (C,F) animals.  Quantification of 
the number of FG(+) profiles in the cortex contralateral to injection (G).  Scale bar (C) = 
200μm, Scale bar (F) = 100μm.  
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Figure 4.18 Microglial/macrophage reactivity and degeneration in the injured white 
matter at 4 weeks post-injury following acute minocycline treatment.   
Representative photomicrographs of ED-1 (A-C) and FJB (D-F) labeling in the thalamus 
of sham-injured (A,D), brain-injured vehicle (B,E) and brain-injured minocycline-treated 
animals (C,F) at 4 weeks post-injury.  Quantification of ED-1-labeled 
microglia/macrophages displaying amoeboid or rod morphology (G), and total FJB-
labeled profiles (H) in the white matter at 4 weeks post-injury. *p≤0.05 compared to 
corresponding sham-injured group. #p≤0.05 compared to the brain-injured vehicle group. 
Error bars represent the standard error of the mean. Scale bar (F)= 100μm.  
 
Figure 4.19 Spatial learning and memory assessment following acute minocycline 
treatment.  (A) Latency to the hidden platform in sham-injured, brain-injured vehicle, 
and brain-injured minocycline animals over 4 days (post-injury days 10-13). (B) Probe 
trial assessment on post-injury day 14 with the platform removed from the maze. 
Quantification of time spent in the zones closest (platform) and furthest away (peripheral) 
from the former platform location and time it took to locate the platform when it was put 
back in the maze and made visible.  *p≤0.05 compared to corresponding sham-injured 
group. Error bars represent the standard error of the mean.  
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4.7 TABLES & FIGURES 
 
Table 4.1 Listing of animals used in statistical analysis for each outcome 
  Time point 
  3d 7d 15d 28d 
Outcome Group N N N N 
Iba1 Sham 4 3 4 
N/A Injured Vehicle 7 4 4 
Injured Minocycline 9 5 4 
ED-1 Sham 3 
N/A 
4 6 
Injured Vehicle 3 4 5 
Injured Minocycline 3 4 6 
GFAP Sham 4 
N/A N/A N/A Injured Vehicle 3 
Injured Minocycline 4 
NM (white 
matter area) 
Sham 4 3 
N/A N/A Injured Vehicle 7 4 
Injured Minocycline 9 5 
FJB Sham N/A N/A N/A N/A 
Injured Vehicle 7 4 4 5 
Injured Minocycline 9 5 4 6 
APP Sham N/A 
N/A N/A N/A Injured Vehicle 4 
Injured Minocycline 5 
Bregma E-phys Sham 7 
N/A N/A N/A Injured Vehicle 6 
Injured Minocycline 6 
-3mm E-phys Sham 7 
N/A N/A 
4 
Injured Vehicle 6 4 
Injured Minocycline 5 8 
Spatial 
Learning 
Sham 11 
Injured Vehicle 11 
Injured Minocycline 12 
Fluoro-Gold Sham 2 
Injured Vehicle 4 
Injured Minocycline 4 
Total Sham 37 
Injured Vehicle 41 
Injured Minocycline 50 
*Overlap in histology outcomes and spatial learning/15d histology 
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Figure 4.1 Experimental Timelines.  
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Figure 4.2 Glial reactivity in the injured cortex at 3 and 7 days post-injury following 
acute minocycline treatment.   
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Figure 4.3 Degeneration and gross tissue pathology in the injured cortex at 3 and 7 
days post-injury following minocycline treatment.   
 
 
 
 
 
 
 
 
 
169 
 
Figure 4.4 Microglial/macrophage reactivity and neurodegeneration in the injured 
cortex at 15 days post-injury following acute minocycline treatment.    
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Figure 4.5 Microglial/macrophage reactivity and neurodegeneration in the injured 
cortex 4 weeks post-injury following acute minocycline treatment.    
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Figure 4.6 Evoked field potential (EFP) recordings from the injured cortex at 
bregma following acute minocycline treatment.    
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Figure 4.7 EFP recordings from the injured cortex at -3mm at 3 days and 4 weeks 
following acute minocycline treatment.    
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Figure 4.8 Acute histological outcomes in the injured subiculum following 
minocycline treatment.   
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Figure 4.9 Microglial/macrophage reactivity and neurodegeneration in the injured 
subiculum at 15 days post-injury following acute minocycline treatment.    
 
 
 
175 
 
Figure 4.10 Microglial/macrophage reactivity in the injured thalamus following 
minocycline treatment at 3 and 7 days post-injury.   
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Figure 4.11 Degeneration and axonal injury in the injured thalamus at 3 and 7 days 
post-injury following acute minocycline treatment.   
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Figure 4.12 Microglial/macrophage reactivity and degeneration in the injured 
thalamus at 15 days post-injury following acute minocycline treatment.    
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Figure 4.13 Microglial/macrophage reactivity and degeneration in the injured 
thalamus 4 weeks post-injury following acute minocycline treatment.    
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Figure 4.14 Effect of acute minocycline treatment on microglial/macrophage 
reactivity in the white matter at 3 and 7 days post-injury.  
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Figure 4.15 Effect of acute minocycline treatment on degeneration and axonal 
injury in the white matter at 3 and 7 days post-injury.  
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Figure 4.16 Microglial/macrophage reactivity and degeneration in the injured white 
matter at 15 days post-injury following acute minocycline treatment.   
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Figure 4.17 Effect of minocycline treatment on axonal transport in the third week 
post-injury. 
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Figure 4.18 Microglial/macrophage reactivity and degeneration in the injured white 
matter at 4 weeks post-injury following acute minocycline treatment.    
 
 
 
184 
 
Figure 4.19 Spatial learning and memory assessment following acute minocycline 
treatment. 
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CHAPTER 5: LONG-TERM FUNCTIONAL DEFICITS 
FOLLOWING TBI IN THE NEONATE RAT 
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5.1 ABSTRACT 
 
 Children that survive traumatic brain injury can face life-long functional deficits 
in the form of cognitive impairments, motor deficits, alterations in mood-related 
behavior, and the development of seizure disorder.  The anatomical regions associated 
with certain functional changes may not exhibit cellular pathology in the form of 
microglial/macrophage reactivity or neurodegeneration, but that is not to say that 
neuronal physiology is not altered in these regions. In the 4
th
 post-injury week, brain-
injured animals demonstrated mild anxiety-like behavior in the elevated plus maze 
(EPM), a deficit in short-term working memory in a novel object recognition (NOR) 
assessment, increased seizure susceptibility, increased fine locomotion, and a deficit in 
forelimb motor control compared to sham-injured animals.  Additionally, neuronal 
activity was altered in the frontal motor cortex- a region that is outside of the impact site 
and demonstrates no cellular pathology. At 3 days post-injury, brain-injured animals 
exhibited evidence of hypoactivity in this region while at 21 days post-injury, brain-
injured animals demonstrated hyperactivity.  Systemic administration of the antibiotic 
minocycline reduced the working memory deficit, completely reversed the forelimb 
motor control deficit, and completely reversed the injury-induced hypoactivity at 3 days 
and the injury-induced hyperactivity at 4 weeks post-injury.  Depletion of 
microglia/macrophages within the impact site, however, had no effect on forelimb motor 
control or neuronal activity in the forelimb region of the motor cortex.  These results 
indicate that the systemic minocycline administration had whole-brain effects beyond just 
cellular pathology while the localized microglial/macrophage depletion was unable to 
affect pathology outside the impact site.  
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5.2 INTRODUCTION 
 
 Traumatic brain injury (TBI) sustained by young children has been shown to 
result in long-term behavioral disability.  Brain-injured children exhibit cognitive deficits 
in measures of working memory post-injury as well as demonstrate evidence of anxiety 
disorder (Treble et al., 2013; Max et al., 2015).  Children that sustained brain injuries 
between the ages of 0 and 15 years performed poorly in a task of visuospatial working 
memory when compared to age-matched uninjured controls (Treble et al., 2013).  
Additionally, research has indicated that children are at risk for the development of novel 
psychiatric disorders within the first year post-injury including severe personality 
changes and anxiety disorder (Max et al., 2015).  Motor deficits have also been identified 
as a long-term consequence of early childhood TBI as 25% of brain-injured children 
demonstrated deficient motor abilities in a longitudinal prospective study (Ewing-Cobbs 
et al., 1998).  Specifically, children that sustained brain injuries had difficulty completing 
an assessment of manual dexterity that involved placing pegs in the correct orientation in 
a peg board (Ewing-Cobbs et al., 2008).  Along with these alterations in functionality, 
children that sustain TBIs have an increased risk for developing post traumatic epilepsy 
(PTE) and seizure activity. Approximately 40% of children that sustained a TBI 
developed PTE and this was most strongly correlated to severe injuries in younger 
children (Arndt et al., 2013). 
 In pre-clinical models, injury-induced alterations in neuronal activity may 
manifest as functional changes.  Prince & Tseng (1993) demonstrated that an undercut 
cortical injury to the developing rat brain within the first 4 weeks of life resulted in 
hyperactivity 3 weeks following the injury and evidence of post-traumatic epileptic 
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activity.  Later, this group demonstrated that an undercut injury to the cortex of postnatal 
day (PND) 21 rats resulted in an epileptogenic phenotype in which there was increased 
neuronal firing in layer V of the affected cortex (Jin et al., 2006) and a deficit in 
inhibitory GABAergic signaling within the same area (Ma & Prince, 2012).  While this 
undercut model is a severe penetrating form of brain injury, evidence has emerged that 
impact-based brain trauma can result in alterations in neuronal activity leading to 
epileptogenesis.  Nichols et al. (2015) showed that CCI injury to the PND17 rat produced 
epileptoform discharges in the first two weeks following injury as measured by 
continuous EEG monitoring. Additionally, neurons within the impact site (in the peri-
injury region around the site of lesion) demonstrated increased bursting activity during 
slice recording within the 3
rd
 week post-injury.  These studies, however, did not assess 
the animal’s susceptibility to behavioral seizure and it is unclear if our injury to PND11 
rats creates vulnerability for altered activity that may lead to an increased susceptibility to 
seize.   
Injury-induced lesion or cavitation makes recording within the direct impact site 
difficult and in one such model using PND17 rats, alterations in neuronal activity in the 
cortex contralateral to the impact site were observed, indicating that regions outside of 
the impact site that are devoid of cellular pathology (in this case lesion) can be affected 
by the injury (Li et al., 2014).  Due to the fact that our PND11 closed head injury model 
does not result in a lesion or cavitation (Raghupathi & Huh, 2007), we were previously 
able to determine that the injury only resulted in a transient deficit in neuronal activity in 
the motor cortex at bregma level and not deeper within the impact site (Chapter 3).  It is 
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unclear, however, whether our injury induces alterations in activity outside of our impact 
site in regions that may be crucial for functional alterations.       
 Working memory deficits observed in the clinical population have also been 
recapitulated in pre-clinical animal models of pediatric TBI.  Rat pups that sustained an 
open controlled cortical impact injury on PND 17 demonstrated deficits in novel object 
recognition (NOR) memory 2 weeks post-injury (Schober et al., 2014).  A different 
laboratory observed similar results using open CCI injury in PND21 rat pups in which 
brain-injured animals explored the novel object significantly less than sham-injured 
animals 1 week post-injury (Scafidi et al., 2010).  Novel object recognition has been 
shown to be heavily dependent on the perirhinal cortex and the medial prefrontal cortex 
(short-term) or the hippocampus (long-term) (Barker et al., 2007; Antunes & Biala, 
2012).  In our injury model, there is no evidence of cellular pathology in the prefrontal or 
perirhinal cortices so the short-term NOR assessment will allow for further investigation 
into the diffuse nature of our injury. 
 Investigation into anxiety-like behavior following TBI to the immature brain has 
produced conflicting results.  Mice injured on PND21 demonstrated an increase in time 
spent in the open areas in the elevated zero maze compared to sham-injured mice 2 weeks 
post-injury indicating a decrease in anxiety-like behavior (Pullela et al., 2006).  This 
same group, however, later observed that their brain-injured mice demonstrated a form of 
social anxiety in adulthood as evidenced by decreased sociability in a resident-intruder 
and three-chamber test indicating that general anxiety and social anxiety may be affected 
differently after injury (Semple et al., 2012).  In a model of mild TBI in PND30 rats, 
brain-injured male rats demonstrated decreased anxiety-like behaviors as evident by a 
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decrease in closed arm time in the elevated plus maze and an increase in the percent time 
spent in in the middle of an open field arena while female brain-injured rats showed no 
differences from sham-injured animals in measures of anxiety-like behavior (Mychasiuk 
et al., 2014).  Rats that were injured via CCI on PND17, however, showed an increase in 
time spent in the dark portion of the elevated zero maze in adulthood indicating an 
anxious phenotype (Ajao et al., 2012).  Additionally, brain injury induced by controlled 
weight drop in a PND7 rat resulted in an anxiety-like phenotype as evidenced by a 
decrease in exploratory behavior in the center of an open field arena compared to sham-
injured animals 2 weeks after injury (Sonmez et al., 2007).  These mixed results may 
indicate that there is an age at injury effect with regards to the manifestation of anxiety-
like behaviors following injury to the immature brain and it is unknown whether our 
injury to PND11 rats will produce an increase or decrease in anxiety-like behavior. 
 Locomotor difficulties have been identified in both the acute and chronic post-
injury periods.  Adelson et al. (1997) observed motor deficits in rats that were injured on 
PND17 that were dependent on injury severity.  The severely injured group (100g weight 
drop) showed deficits on the balance beam and inclined plane task that persisted for 4 
days post-injury while the “ultra-severe” injury group (150g weight drop) demonstrated 
sustained deficits out to 10 days post-injury.  Focal injury to the frontal lobe in PND21 
mice resulted in long-term impairment in rotarod performance and open field rearing 
behavior at 2 months post-injury (Chen et al., 2013).  When PND21 mice were injured 
laterally over the parietal cortex, however, there was no difference between brain-injured 
and sham-injured animals in terms of rotarod and balance beam performance, but 
researchers observed a general hyperactivity as brain-injured animals demonstrated more 
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exploratory behavior in the open field task compared to sham-injured animals (Pullela et 
al., 2006).  We have previously demonstrated that our brain-injured animals do not 
exhibit a deficit in swim speed as measured in a Morris water maze (MWM) spatial 
learning task (Raghupathi & Huh, 2007), but have no information on terrestrial 
locomotion or limb dexterity in our animals. 
 While we previously demonstrated that anti-microglial/macrophage therapeutics 
(clodronate and minocycline) had no effect on injury-induced spatial learning and 
memory impairment (Chapters 3 & 4), other studies have shown positive effects of anti-
microglial/macrophage treatments, specifically minocycline, in other functional tasks.  
Minocycline administration has been particularly effective in reducing locomotion-based 
impairments following brain injury.  In a model of adult brain-injury, minocycline-treated 
mice showed marked improvement on the rotarod task 1-4 days after injury compared to 
brain-injured animals that received the saline vehicle (Sanchez-Mejia et al., 2001).  A 
similar model using adult mice also found that minocycline treatment improved 
performance on a ledged beam task 1-2 days after injury (Bye et al., 2007).  In a model of 
hypoxic-ischemia in rats on PND4, minocycline treatment immediately before injury and 
once a day for 3 days after the injury significantly reduced impairment in the wire 
hanging task starting at 1 week post-injury (Fan et al., 2006).  Modulation of microglial 
activation through CX3CR1 knockout, however, caused an exacerbation of injury-
induced locomotor deficits in the rotarod task in adult mice (Febinger et al., 2015) and 
microglial depletion in uninjured neonate rats (PND1 and PND4) can increase baseline 
locomotor activity (Nelson & Lenz, 2017).  It is unclear, however, whether acute anti-
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microglial/macrophage treatment can positively affect functional outcome in the chronic 
post-injury period following impact-based trauma to the neonatal rat brain.    
 In the current study, we aimed to expand the functional profile of our injury 
model to include assessments that are clinically relevant to the human brain-injured 
population and addressed the possibility that there may be alterations in neuronal activity 
outside of our direct impact site that could affect functional outcome.  Additionally, the 
current study investigated the use of acute anti-microglial/macrophage therapeutics in 
ameliorating long-term functional outcomes.                       
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5.3 MATERIALS AND METHODS 
 
5.3.1 Brain Injuries 
 
On postnatal day 11, male and female Sprague Dawley rat pups were randomly 
assigned to injury and treatment conditions.  Procedure was followed as described in 
section 3.3.1. Animals for the characterization study (Part A) are listed in table 5.1 and 
animals for the minocycline and clodronate studies (Part B) are listed in table 5.2.)          
 
5.3.2 Minocycline Treatment Paradigm 
 
Sham- and brain-injured animals were administered minocycline hydrochloride 
(45mg/kg/injection, Sigma, St. Louis, MO) or phosphate buffered saline vehicle (PBS, 
0.2 ml/kg/injection) immediately following the injury via intraperitoneal injection.  
Animals received subsequent injections every 12 hours for 3 days for a total of 6 
injections (Chapter 4.3.1, Fig. 5.1 B).      
 
5.3.3 Clodronate Administration Paradigm 
 
Sham- and brain-injured animals were randomly assigned to receive the liposome-
encapsulated clodronate or the empty liposomes and the previously stated procedure was 
followed (Chapter 3.3.3, Fig. 5.1 C).         
  
5.3.4 Cortical evoked field potential (EFP) electrophysiology and quantification 
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 Evoked field potential recordings were taken from layer 5 of the motor cortex 
1mm anterior to bregma (forelimb region of the motor cortex) at 3, 7, and 21 days post-
injury (characterization) , 3 days and 4 weeks (minocycline), or 4 weeks (clodronate) and 
quantified as previously described (Chapter 3.3.7).    
 
5.3.5 Behavior testing and analyses 
 
 Behavior assessments for the characterization study, the minocycline study, and 
the clodronate study were performed within the 4
th
 post-injury week (Fig. 5.1).  
 
Elevated Plus Maze 
 Animals were assessed for the presence of anxiety-like behaviors using the 
elevated plus maze (EPM). This plus maze sits approximately 3-ft off the ground and 
contains two enclosed arms and two completely open arms (Fig. 5.2 A).  Animals were 
placed in the neutral zone (intersect of the 4 arms) facing an open arm and left to explore 
the maze without distraction for 5 minutes.  The maze was cleaned with 70% ethanol in 
between animals.  Trials were videotaped and later analyzed for the time spent in the 
open arms (including both 2-paw and 4-paw entry), 4-paw open arm time, time spent in 
the closed arms, number of head dips, number of 2-paw entries into the open arms, 
number of 4-paw entries into the open arms, and the number of entries into the closed 
arms.  The idea behind this task is that animals that demonstrate a more anxious 
phenotype will more likely remain in the closed arms for a prolonged period of time and 
will not partake in risk-taking behaviors such as open arm entries and head dips (Walf 
and Frye, 2007).     
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Novel Object Recognition  
Both sham-injured and brain-injured animals were tested for short-term working 
memory using a novel object recognition (NOR) paradigm.  The test was performed in an 
open-top plastic enclosure and video recorded from above in order to visualize the entire 
field. Animals were subjected to two separate 10-minute habituation trials on the two 
days prior to testing in which the animals were left to explore the empty chamber (Fig. 
5.3 A). On the day of testing, two identical objects (glass bottles) were placed at opposing 
diagonal corners of the chamber and animals spent 5 minutes exploring the objects in a 
pre-test trial (Fig. 5.3 B).  The time spent exploring both objects was quantified in order 
to confirm that the animals spent an equal amount of time with the identical objects.  An 
hour after the pre-test trial, one of the glass bottles was replaced with a metal cylinder 
and the animals were allowed to once again explore the objects for 5 minutes (Fig. 5.3 
C). Again, the time spent exploring each object was quantified and presented as the 
percent time spent exploring either the original or novel object (object exploration 
time/total exploration time).  One sham-injured animal and one brain-injured animal had 
to be excluded from analyses because they did not reach the criterion for total exploration 
(15 seconds) in the test trial.   
 
Seizure Susceptibility 
 Seizures were induced using the GABAA antagonist flurothyl (bis[2,2,2-
trifluoroethyl] ether, Sigma-Aldrich, St. Louis, MO) (Wakamori et al., 1991; Krasowski, 
2000).  Animals were placed in a plexiglass chamber and flurothyl was dripped 
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(30μl/minute) onto a piece of filter paper within the chamber via a tube attached to a 1-ml 
syringe on a syringe pump (syringe pump model) (Fig. 5.4 A). Sessions were videotaped 
and the flurothyl was dripped into the chamber until the animal went into full tonic-clonic 
seizure.  At that point, the chamber was opened, the ether dissipated, and the seizure was 
halted naturally.  The videos were analyzed and the time to the first mycolonic jerk 
(latency to seize) and the timed length of the seizure were recorded.  Seizure length was 
characterized as the time from the beginning of full tonic clonic seizure until the animal 
stilled and regained awareness of surroundings (reaction to sound or movement outside 
the chamber).  
 
Activity Monitoring 
Sham-injured and brain-injured animals were monitored for locomotor activity 
using the SmartFrame Open Field Station monitoring system (Kinder Scientific, Poway, 
CA).  Animals were placed in chambers measuring 41cm x 41cm x 38cm equipped with a 
16x16 photobeam grid that recorded both lateral (ambulatory movement) and vertical 
(rearing) beam breaks.  Additionally, this system characterized any movement that did 
not qualify as a complete ambulatory beam break as a fine movement.  These movements 
can include twitches, grooming behavior, and tail flicks. Data was collected and 
condensed using MotorMonitor software (manufacturer and version) and presented as the 
number of beam breaks meeting the basic locomotion, fine locomotion, and rearing 
criteria during the entire 5-minute collection trial.   
 
Straight-path Swim Task 
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 Both sham-injured and brain-injured animals were trained to swim the length of 
the 48” aquarium in a straight path as previously described (Stoltz et al., 1999). The water 
in the tank was 18-20°C and to make sure the test rats could see the platform, a cue rat 
was placed on the platform and a flag was adhered to the side of the platform. During 
training the tank was separated into quarters to form the 4 training release points at 
varying distances from the platform (Fig. 5.6 A, dashed grey lines).  The animals were 
released from these points in order until they could swim the length of the tank in a 
straight path without turning or running into the sides.  On the day of the test (24 hours 
after training), animals were subjected to one acclimation trial released from the back of 
the tank in order to familiarize them with the task.  In all subsequent trials, animals were 
released from the back of the tank and recorded for quantification.  Animals were tested 
by cage and allowed to rest for 2 minutes in between trials.  When animals completed 3 
straight-path runs without turning or running into the walls of the tank, they were 
considered finished and returned to their home cage. Videos had to be slowed down to 
0.125x normal speed in order to accurately count both forelimb and hindlimb strokes.  
Data is presented as the average number of strokes across 3 runs.  
 
5.3.6 Statistical analyses 
 
 All statistical analyses were performed using Statistica software (Version 7.0, 
Tulsa, OK).  For the NOR pre-test, a 3-way ANOVA was run using status (sham/injured 
or sham/injured vehicle/injured minocycline), sex, and object number as independent 
variables to ascertain whether the animals had a preference for the placement of the 
objects. All other measures (NOR test, swim test, activity monitoring, EPM, seizure, and 
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cortical EFPs) were analyzed using two separate 2-way ANOVAs using status (status 
(sham/injured, sham/injured vehicle/injured minocycline, sham empty-lip/injured empty-
lip/sham clod-lip/injured clod-lip) and sex as independent variables.  When animal 
numbers did not allow for an adequate comparison of the sexes, one-way ANOVAs using 
status as the categorical predictor were used.  When appropriate, Newman-Keuls posthoc 
tests were performed with p≤0.05 being considered significant.     
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5.4 RESULTS 
 
5.4.1. Brain-injured animals exhibit a wide range of behavioral deficits in the 
chronic post-injury period.  
 
Brain-injured animals exhibited a mild increase in anxiety-like behavior 
 Brain-injured animals spent significantly more time (219 ± 7s) in the closed arm 
portions of the maze compared to sham-injured animals (184 ± 9s) (F1,19=9.32, p<0.01) 
indicative of anxiety-like behavior (Fig. 5.2 B).  This corresponded to a mild, but 
insignificant decrease in the number of entries the brain-injured animals made into the 
closed arms indicating that brain-injured animals may have been staying longer in the 
closed arms per entry (brain-injured: 11 ± 0.8 entries, sham-injured: 13 ± 0.9 entries, 
F1,19=3.46, p=0.08, Fig. 5.2 C).  Brain-injured animals demonstrated a decrease in both 
total open arm time and 4-paw open arm time, but these differences did not reach 
significance when compared to sham-injured animals (total open arm: brain-injured: 32 ± 
4s, sham: 45 ± 7s; F1,19=2.38, p=0.14; 4-paw open: brain-injured: 5 ± 2s, sham: 15 ± 5s: 
F1,19=3.08, p=0.10) (Fig. 5.2 D,E).  Brain-injured animals also demonstrated a decrease in 
the amount of times they made entries into the open arms with 4 paws that did not reach 
significance when compared to sham-injured animals (brain-injured: 0.9 ± 0.2 entries, 
sham-injured: 2 ± 0.5 entries; F1,19=4.17, p=0.06, Fig. 5.2 F).  Additionally, there was a 
mild, but insignificant decrease in the number of times brain-injured animals looked over 
the edge of the maze (head dips) (brain-injured: 8 ± 0.6 dips, sham-injured: 10 ± 1 dip, 
F1,19=2.58, p=0.12, Fig. 5.2 G).  Finally, there was no difference between brain-injured 
and sham-injured animals in the number of entries they made into the open arms with 
only 2 paws (brain-injured: 6 ± 0.8 entries, sham-injured: 7 ± 1 entry; F1,19=0.22, p=0.64, 
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Fig. 5.2 H).  There was no interaction between status and sex for any outcome measure 
(total closed arm time: F1,19=1.06, p=0.32; closed arm entries: F1,19=0.04, p=0.85, total 
open arm time: F1,19=0.09, p=0.76, 4-paw open arm time: F1,19=0.01, p=0.92, 4-paw 
entries: F1,19=0.05, p=0.82, head dips: F1,19=0.92, p=0.35, 2-paw entries: F1,19=2.14, 
p=0.16).  While the behaviors that demonstrate a lack of anxiety (open arm times and 
head dips) were not significantly different between groups, there were mild decreases in 
these behaviors in the brain-injured group and paired with the significant increase in 
closed-arm time, the brain-injured animals may exhibit a mildly anxious phenotype.          
         
Brain-injured animals demonstrated short-term working memory deficits at 4 weeks post-
injury. 
 In the pre-test trial for novel object recognition both sham-injured and brain-
injured animals spent similar amounts of time with both of the identical glass bottles 
(F1,34=0.55; p=0.46) indicating that the animals did not have a preference for a specific 
corner of the chamber (Fig. 5.3 D).  There was no interaction between injury status, sex, 
and bottle in the amount of exploratory time in the pre-test (F1,34=0.55; p=0.46).  In the 
test trial, brain-injured animals spent significantly less time exploring the novel object 
and significantly more time exploring the original object compared to sham-injured 
animals (F1,17=20.57; p<0.001; Fig. 5.3 E).  This indicated that the brain-injured animals 
did not retain the information learned from the pre-test trial and gave the original object a 
similar amount of attention as the novel object.  There was no interaction between injury 
status and sex in the amount of time spent exploring either the novel or original object 
(F1,17=0.94; p=0.35).          
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 Brain-injured animals demonstrated an increased vulnerability to seizure activity. 
 When subjected to vaporized flurothyl, both sham-inured and brain-injured 
animals seized (Fig. 5.4).  The first myoclonic jerk was defined as the first involuntary 
whole-body twitch in which the limbs splayed outward and was closely followed by full 
status seizure.  Brain-injured animals demonstrated an increased vulnerability to seizure 
activity as indicated by a significantly decreased latency to the myoclonic jerk compared 
to sham-injured animals (Brain-injured: 223 ± 8s, sham-injured: 259 ± 6s, F1,19=11.70, 
p<0.01, Fig. 5.4 B). Despite this increase in seizure susceptibility, the length of the 
seizure did not differ between brain-injured (154 ± 12s) and sham-injured (156 ± 12s) 
animals (F1,19=0.25, p=0.63, Fig. 5.4 C). There was no interaction between injury status 
and sex in either the latency to seize (F1,19=0.33; p=0.57) or the length of seizure 
(F1,19=0.25; p=0.63). These data indicate that there may be an injury-induced alteration in 
brain circuitry that makes the initiation of seizure activity more likely, but does not affect 
the propagation and cessation of the seizure activity. 
 
Brain-injured animals exhibited an increase in fine locomotion at 4 weeks post-injury. 
 Brain-injured animals broke a similar amount of beams that qualified for basic 
ambulatory locomotion compared to sham-injured animals (brain-injured: 889 ± 53, 
sham-injured: 948 ± 33; F1,19=1.89; p=0.19) indicating that injury did not cause a deficit 
in basic locomotion at 4 weeks post-injury (Fig. 5.5 A).  Similarly, brain-injured animals 
and sham-injured animals did not differ in the amount of vertical beam breaks indicative 
of rearing behavior (brain-injured: 23 ± 5, sham-injured: 32 ± 3; F1,19=1.86, p=0.19, Fig. 
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5.5 B). Analysis of the fine locomotor beam breaks, however, revealed an overall effect 
of injury status that indicated that brain-injured animals performed more fine motor beam 
breaks compared to sham-injured animals (brain-injured: 444 ± 22, sham-injured: 395 ± 
10; F1,19=4.24, p=0.05, Fig. 5.5 C).  This may be due to an increase in involuntary 
twitching or anxious grooming behavior at 4 weeks post-injury.  There was no interaction 
between injury status and sex in basic movement (F1,19=1.89; p=0.19), rearing behavior 
(F1,19=1.86; p=0.19), and fine movement (F1,19=2.62; p=0.12).     
 
Brain-injured animals demonstrated a deficit in forelimb motor control at 4 weeks post-
injury. 
 When swimming in a straight path, rats will typically keep their forelimbs 
immobile and use their hindlimbs to propel them forward (Stoltz et al., 1999).  This 
behavior was observed in our sham-injured animals (Fig. 5.6 B).  Animals that sustained 
a brain injury, however, used their forelimbs when swimming and this forelimb use was 
preferential to the limb contralateral (right forelimb) to the injury site (left hemisphere) 
(Fig. 5.6 C). When this limb use was quantified and analyzed, a two-way ANOVA 
(injury status x sex) revealed an effect of injury status that showed that brain-injured 
animals used their right forelimb significantly more than sham-injured animals (brain-
injured: 2.63 ± 0.52, sham-injured: 0.39 ± 0.16; F1,19=10.77, p<0.01, Fig. 5.6 D).  There 
was no interaction between sex and injury status (F1,19=1.53, p=0.23).  The use of the 
forelimb ipsilateral to the injury site (left forelimb), however, did not differ between 
brain-injured animals and sham-injured animals (brain-injured: 1.26 ± 0.49, sham-
injured: 0.52 ± 0.17; F1,19=1.56, p=0.30, Fig. 5.6 D) further supporting the preferential 
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use of the forelimb contralateral to the injury.  Additionally, the use of the right forelimb 
in the brain-injured animals did not seem to be a compensatory mechanism for any type 
of hindlimb deficit as there were no differences in hindlimb use between brain-injured 
and sham-injured animals (right hindlimb, brain-injured: 11.16 ± 0.56, sham-injured: 
11.19 ± 0.30, F1,19=0.004, p=0.95; left hindlimb, brain-injured: 11.00 ± 0.61, sham-
injured: 10.96 ± 0.44, F1,19=0.28, p=0.61, Fig. 5.6 E).     
 
5.4.2 Brain-injured animals demonstrated alterations in neuronal activity in the 
forelimb region of the frontal motor cortex.  
 
 In light of behavioral changes that implicate frontal cortex circuitry (NOR and 
forelimb motor deficits) evoked field potentials (EFPs) were recorded a millimeter 
anterior to bregma in the forelimb region of the motor cortex (Fig. 5.7 A).  This region is 
outside of the direct impact site and does not show any cellular pathology such as 
activated microglia/macrophages or degenerating FJB-labeled cells.  The amplitude, 
latency, and duration was quantified for each signal, averaged according to injury 
condition, and presented at a stimulus intensity of 800 μA (Fig. 5.7 D-F).  Brain-injured 
animals demonstrated altered activity in the forelimb region of the motor cortex that was 
indicative of hypoactivity at 3 days post-injury (Fig. 5.7 B) and hyperactivity at 21 days 
post-injury (Fig. 5.7 C). A 3-way ANOVA (status, sex, and time) analyzing the 
amplitudes of the signals revealed a significant interaction between status and time 
(F2,27=17.73; p<0.001), but no interaction between status, time, and sex (F2,27=1.35; 
p=0.28).  Post-hoc analysis of the interaction between status and time indicated that 
signals from brain-injured animals were significantly smaller in amplitude than signals 
204 
 
from sham-injured animals at 3 days post-injury (sham-injured, 0.55 ± 0.07mV; brain-
injured, 0.20 ± 0.02mV; p<0.01, Fig. 5.7 B,D).  There was no difference in the amplitude 
of the signals from sham-injured and brain-injured animals at 7 days post-injury (sham-
injured, 0.30 ± 0.07mV; brain-injured, 0.33 ± 0.05mV; p=0.71, Fig. 5.7 D), but at 21 days 
post-injury, the signals from brain-injured animals were significantly larger than those 
from sham-injured animals (sham-injured, 0.24 ± 0.04mV; brain-injured, 0.49 ± 0.08mV; 
p<0.05, Fig. 5.7 C,D).  Also, there was a developmental decrease observed in sham-
injured animals in which the signal amplitude at 3 days was significantly larger than at 7 
days (p<0.05) and 21 days post-injury (p<0.01).   
 Altered activity can also manifest as a difference in the time it takes the signal to 
arrive at the recording electrode after stimulation (latency, Fig. 5.7 E).  A 3-way ANOVA 
analyzing signal latencies revealed a significant interaction between status and time 
(F2,27=10.91; p<0.001).  Post-hoc analysis revealed that, at 3 days post-injury, the signals 
from brain-injured animals arrived much slower than the signals from sham-injured 
animals (sham-injured, 2.63 ± 0.34s; brain-injured, 4.46 ± 0.20s; p<0.05, Fig. 5.7 B,E).  
There was no difference in latency of signal between sham- and brain-injured animals at 
7 days (sham-injured, 3.93 ± 0.67s; brain-injured, 3.55 ± 0.23s; p=0.74, Fig. 5.7 E). At 21 
days post-injury, the signals from brain-injured animals arrived faster than those from 
sham-injured animals, but this difference did not reach significance (sham-injured, 3.62 ± 
0.20s; brain-injured, 2.3 ± 0.50s; p=0.07, Fig. 5.7 C,E).  There was no interaction 
between status, time, and sex in the latency of the signal (F2,27=0.71; p=0.50).  
Differences in the width of signal can also be indicative of altered activity in the region of 
interest. Analysis of the width of the signal showed no significant differences between 
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sham-injured and brain-injured animals at 3 days (sham-injured, 2.31 ± 0.45s; brain-
injured, 2.03 ± 0.32s), 7 days (sham-injured, 2.02 ± 0.19s; brain-injured, 2.17 ± 0.56s), or 
21 days post-injury (sham-injured, 1.80 ± 0.23s; brain-injured, 1.94 ± 0.21s; F2,27=0.17; 
p=0.84, Fig. 5.7 F).  There was also no significant interaction between status, time, and 
sex (F2,27=0.21; p=0.81).   
 
5.4.3 Systemic minocycline administration influenced functional outcomes at 4 
weeks post-injury. 
 
Treatment with minocycline improved the injury-induced working memory deficit 
 In the pre-test, sham-injured and brain-injured (irrespective of treatment) animals 
spent similar percentages of time with both objects and there was no interaction effect 
between status (sham-injured, brain-injured vehicle, brain-injured minocycline), sex, and 
bottle (F2,54=0.85; p=0.43, Fig. 5.8 A).  A 2-way ANOVA of the percent time spent with 
the novel and original object in the test trial revealed a significant effect of status 
(F2,27=16.98; p<0.001) and post-hoc testing indicated that sham-injured animals spent 
significantly more time with the novel object than both brain-injured groups (sham-
injured: 78 ± 2; brain-injured vehicle: 60 ± 1, p<0.001; brain-injured minocycline: 68 ± 3, 
p<0.01, Fig. 5.8 B).  The minocycline-treated brain-injured group, however, spent a 
significantly higher percentage of time with the novel object compared to the brain-
injured animals that received the vehicle (p<0.01) indicating that minocycline treatment 
had a positive effect on working memory in the 4
th
 post-injury week (Fig. 5.8 B).  There 
was no significant interaction between status and sex in the percent of time spent with the 
novel object (F2,27=2.04; p=0.15).     
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Minocycline treatment did not affect seizure activity 
 When exposed to flurothyl gas, 100% of animals seized.  Due to a low number of 
animals in this seizure study (Table 5.2), sex was not used as an independent variable for 
analysis.  A one-way ANOVA analyzing the latency to the first myoclonic jerk revealed a 
significant effect of injury status (F2,8=10.31; p<0.01) in which sham-injured animals 
(283 ± 8s) had significantly longer latencies than both brain-injured groups irrespective 
of treatment status (brain-injured vehicle: 230 ± 5s, p<0.01; brain-injured minocycline: 
225 ± 12s, p<0.01, Fig. 5.9 A) replicating the increased susceptibility observed in the 
brain-injured animals in the characterization study (Fig. 5.4 B).  Minocycline-treated 
brain-injured animals, however, did not differ from the brain-injured animals that 
received the vehicle (p=0.72) in terms of latency to seize. Similar to the characterization 
study, the length of the seizure did not differ between sham-injured animals and either 
brain-injured group (F2,8=0.26; p=0.78).   
 
 Minocycline treatment exacerbated the mild injury-induced increase in fine 
movement. 
 Similar to the characterization study, brain-injured animals did not show any 
differences in basic locomotion compared to sham-injured animals (sham-injured: 857 ± 
38 beam breaks, brain-injured vehicle: 892 ± 52 beam breaks, brain-injured minocycline: 
889 ± 42 beam breaks) and there was no significant interaction between status and sex 
(F2,42=1.58; p=0.22, Fig. 5.10 A).  Analysis of the fine movement revealed a significant 
effect of status (F2,42=5.27; p<0.01), but no interaction between status and sex 
(F2,42=2.93; p=0.06, Fig. 5.10 B).  Post-hoc analysis of the status effect indicated that 
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sham-injured animals made significantly fewer fine movement beam breaks (368 ± 11 
beam breaks) than minocycline-treated brain-injured animals (435 ±15 beam breaks, 
p<0.01), but did not differ from the brain-injured animals that received the vehicle (395 ± 
16 beam breaks, p=0.18).  Minocycline-treated brain-injured animals also made 
significantly more fine movement beam breaks compared to the brain-injured animals 
that received the vehicle (p<0.05, Fig. 5.10 B).  The effect on fine movement originally 
observed in the characterization study (Fig. 5.5 C) was very mild and was not repeated in 
the brain-injured animals that received the vehicle in this study.  This may be due to an 
increase in the number of animals in each group and the introduction of a third status 
group.  This increase in animals also revealed an injury-induced decrease in rearing 
behavior.  A 2-way ANOVA revealed a significant effect of status (F2,42=7.62; p<0.01) 
that showed that sham-injured animals made significantly more rearing beam breaks (29 
± 4 beam breaks) compared to brain-injured animals that received the vehicle (19 ± 3 
beam breaks, p<0.01) and brain-injured minocycline-treated animals (17 ± 2 beam 
breaks, p<0.01).  There was, however, a significant interaction between status and sex 
(F2,42=4.55; p<0.05) that indicated that sham-injured females made significantly more 
rearing beam breaks than any other group (p<0.01).   
 
Treatment with minocycline reversed injury-induced deficits in forelimb motor control     
 Forelimb motor control was quantified for all groups by counting the number of 
strokes taken with both of the forelimbs (contralateral to the injury = right forelimb, 
ipsilateral to the injury = left forelimb).  A 2-way ANOVA analyzing the number of 
strokes taken with the forelimb contralateral to the injury revealed a significant effect of 
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status (F2,18=9.65; p<0.01) and no interaction between status and sex (F2,18=0.46; p=0.64, 
Fig. 5.11). Post-hoc analysis of the status effect showed that brain-injured animals that 
received the vehicle took significantly more strokes with the forelimb contralateral to the 
injury (4 ± 0.65 strokes) compared to both sham-injured animals (0.62 ± 0.41 strokes, 
p<0.01) and brain-injured animals treated with minocycline (0.93 ± 0.37 strokes, p<0.01).  
Brain-injured animals treated with minocycline showed no difference in the number of 
strokes taken compared to sham-injured animals (p=0.68) indicating a treatment-induced 
rescue of the forelimb motor control deficit.  Similar to the characterization study, there 
was no difference in the number of strokes taken with the forelimb ipsilateral to the 
injury for any group (sham-injured: 0.62 ± 0.27 strokes, brain-injured vehicle: 1.54 ± 
0.26 strokes, brain-injured minocycline: 1.20 ± 0.27 strokes, F2,18=0.17; p=0.84).  
 
Minocycline treatment reversed injury-induced hypoactivity at 3 days post-injury and 
injury-induced hyperactivity at 4 weeks post-injury 
 At 3 days post-injury, analysis of the signal amplitude revealed a significant effect 
of status (F2,13=8.38; p<0.01) and no interaction effect between status and sex (F2,13=0.27; 
p=0.77).  Post-hoc analysis revealed that the previously-observed hypoactivity in brain-
injured animals in the characterization study (Fig. 5.7) was also observed in the brain-
injured animals that received the vehicle as their signals were significantly smaller than 
those from sham-injured animals (sham-injured: 0.48 ± 0.04 mV, brain-injured vehicle: 
0.23 ± 0.03 mV, p<0.01, Fig. 5.12 A, C).  Minocycline-treated brain-injured animals, 
however, had significantly larger signals compared to brain-injured animals that received 
the vehicle (0.44 ± 0.06 mV, p<0.01). Additionally, their signals do not differ from sham-
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injured animals (p=0.55), indicating a rescue of the injury-induced decrease in signal 
amplitude.  Analysis of signal latency at 3 days revealed a significant effect of status 
(F2,13=7.28; p<0.01) that indicated that brain-injured animals, irrespective of treatment, 
demonstrated increased latencies compared to sham-injured animals (sham-injured: 3.12 
± 0.23s; brain-injured vehicle: 3.97 ± 0.20s, p<0.05; brain-injured minocycline: 3.95 ± 
0.36s, p<0.05, Fig. 5.12 D). While minocycline treatment appeared to rescue the injury-
induced deficit in signal amplitude, brain-injured minocycline-treated animals did not 
show a recovery in injury-induced deficits in signal latency as the latencies of their 
signals did not differ from the latencies of the signals from brain-injured animals that 
received the vehicle (p=0.95).  There was an interaction between status and sex 
(F2,13=4.33; p<0.05) that indicated that male brain-injured minocycline-treated animals 
had significantly longer latencies compared to female brain-injured minocycline-treated 
animals (p<0.05).  Similar to the characterization study, there was no significant effect of 
status (F2,13=0.86; p=0.44) and no significant interaction between status and sex 
(F2,13=2.77; p=0.10) in terms of the signal duration (Fig. 5.12 E).  
 At 4 weeks post-injury, analysis of the signal amplitude showed a significant 
effect of status (F2,10=5.75; p<0.05) and no interaction between status and sex (F2,10=0.08; 
p=0.93).  Brain-injured animals that received the vehicle had significantly larger signals 
than sham-injured animals (sham-injured: 0.22 ± 0.02mV, brain-injured vehicle: 0.39 ± 
0.08mV, p<0.05), indicative of hyperactivity.  Signals from brain-injured minocycline-
treated animals (0.19 ± 0.02mV) were significantly smaller than those from brain-injured 
animals that received the vehicle (p<0.05) and did not differ from sham-injured animals 
(p=0.67), indicating that minocycline treatment rescued the injury-induced hyperactivity 
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observed in the chronic post-injury period (Fig. 5.12 B,C). Interestingly, there was no 
significant effect of status or significant interaction between status and sex in the latency 
of the signals indicating that any altered activity did not manifest in a change in signal 
latency (Fig. 5.12 D). There was also no significant effect of status (F2,10=0.18; p=0.84) 
or significant interaction between status and sex in the duration of the signals (F2,10=3.86; 
p=0.06).      
 
5.4.7 Acute microglial/macrophage depletion does not alter injury-induced deficits  
 
Clodronate administration does not alter forelimb motor control in the forelimb 
contralateral to the injury site but increased use in the forelimb ipsilateral to the impact 
 Both sham-injured and brain-injured animals treated with clodronate liposomes or 
empty liposomes were subjected to the straight path swim task in the 4
th
 week post-injury 
when an injury-induced deficit in forelimb motor control was previously observed (Fig. 
5.6).  Analysis revealed an effect of status (F3,27=11.12; p<0.001) but no interaction 
between status and sex (F3,27=0.42; p=0.74, Fig. 5.13).  Post hoc analysis indicated that 
brain-injured animals that received the empty liposomes used the forelimb contralateral 
to the injury significantly more than the sham-injured group that received the empty 
liposomes (sham-injured empty-lip: 0.44 ± 0.21 strokes; brain-injured empty-lip: 5.04 ± 
1.27 strokes, p<0.01).  Similarly, brain-injured animals that received the clodronate 
liposomes used the forelimb contralateral to the injury site significantly more than sham-
injured animals that received the clodronate liposomes (sham-injured clod-lip: 0.26 ± 
0.12 strokes; brain-injured clod-lip: 6.11 ± 1.28 strokes, p<0.001).  The number of 
strokes with the contralateral forelimb, however, did not differ between brain-injured 
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animals that received the empty liposomes and those that received the clodronate 
liposome treatment (p=0.41).  Also, the strokes taken by sham-injured animals did not 
differ between treatment conditions (empty-lip vs. clod-lip, p=0.89, Fig. 5.13).  
Interestingly, there was a significant effect of status in the use of the forelimb ipsilateral 
to the injury (F3,27=3.95; p<0.05).  Post-hoc assessment revealed that brain-injured 
animals that received clodronate liposomes took significantly more strokes with the 
forelimb ipsilateral to the injury (2.07 ± 0.22 strokes) compared to the sham-injured 
clodronate liposome group (1.04 ± 0.64 strokes, p=0.05)  and the brain-injured animals 
that received the empty liposomes (2.07 ± 0.22 strokes, p<0.05).  There was no 
significant interaction between status and sex for use of the forelimb ipsilateral to the 
injury (F3,27=2.06; p=0.13).    
 
Clodronate administration does not alter injury-induced hyperactivity in the forelimb 
region of the motor cortex at 4 weeks post-injury 
 Evoked field potentials in the clodronate study were only recorded in the chronic 
post-injury period after evidence of microglial/macrophage repopulation (Fig. 5.1).  
Signals from the forelimb region of the motor cortex of brain-injured animals were large 
compared to sham-injured animals irrespective of treatment (Fig. 5.14 A). Analysis of 
signal amplitude revealed a significant effect of status (F3,25=17.46; p<0.001) and no 
interaction between status and sex (F3,25=0.15; p=0.93).  Brain-injured animals that 
received the empty liposomes and brain-injured animals that received the clodronate 
liposomes had significantly larger signals than the corresponding sham-injured animals 
(sham-injured empty-lip: 0.21 ± 0.02 mV, brain-injured empty-lip: 0.40 ± 0.04 mV, 
212 
 
p<0.001; sham-injured clod-lip: 0.19 ± 0.02 mV, brain-injured clod-lip: 0.45 ± 0.04 mV, 
p<0.001; Fig. 5.14 B).  Signals from sham-injured animals that received the empty 
liposomes were similar in magnitude to the signals from sham-injured animals that 
received the clodronate liposomes (p=0.57).  Also, signals from brain-injured animals 
that received the empty liposomes did not differ in magnitude from the signals from 
brain-injured animals that received the clodronate liposomes (p=0.26).  Interestingly, 
there was no significant effect of status (latency: F3,25=0.49; p=0.69; duration: F3,25=0.27; 
p=0.85) or interaction between status and sex for the latency of the signal (F3,25=0.81; 
p=0.50, Fig. 5.14 C) or the duration of the signal (F3,25=0.37; p=0.77, Fig. 5.14 D).  
Together, these data indicate that the acute microglial/macrophage depletion within the 
impact site had no effect on neuronal activity in the forelimb motor cortex- a region that 
is anterior to the impact site.        
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5.5 DISCUSSION 
 
 The current study illustrated a wide range of behavioral deficits in the chronic 
post-injury period and demonstrated alterations in neuronal activity not related to cellular 
pathology.  Previous to this set of experiments, the only functional outcome assessed in 
our injury model was spatial learning and memory in the Morris water maze (Raghupathi 
& Huh, 2007).  In this study, brain-injured animals demonstrated mild increases in 
anxiety-like behavior in the elevated plus maze, an impairment in short-term novel object 
recognition memory, an increased susceptibility to seize, increased fine locomotion, and 
impairment in forelimb motor control.  Brain-injured animals also demonstrated 
hypoactivity in the forelimb region of the motor cortex at 3 days post-injury that later 
evolved into a hyperactivity at 21 days post-injury.  Acute treatment with minocycline 
reduced the NOR impairment, reversed the deficit in forelimb motor function, and 
completely rescued the alterations in neuronal activity in the forelimb region of the motor 
cortex at both 3 days and 4 weeks post-injury.  This treatment, however, did not have any 
effect on seizure susceptibility. Similarly, acute clodronate administration to the impact 
site did not affect the forelimb motor control deficit or the hyperactivity at 4 weeks post-
injury. 
 In our animals, we observed a mild increase in anxiety-like behavior as evidenced 
by an increase in the time spent in the closed arms of the EPM.  The mild, but 
insignificant, decrease observed in the closed arm entries may indicate that our animals 
were spending more time in the closed arms simply due to a decrease in overall 
locomotion.  This, however, is not true as brain-injured and sham-injured animals 
performed similarly in measures of basic locomotion in the open field activity monitoring 
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chamber.  Our results are in line with the previous observation that brain injury in young 
rats (PND7 & PND17) resulted in increased anxiety-like behavior in the open field or 
elevated zero maze (Sonmez et al., 2007, Ajao et al., 2012).  Groups using older animals 
(PND21-PND30), however, observed a decrease in anxiety-like behavior (Pullela et al., 
2006; Mychasiuk et al., 2014) that may point to an age-at-injury effect indicating that 
impact to a younger brain may result in a different manifestation of anxiety-like 
behaviors.  There is also evidence in both humans and animals that injury to the 
developing brain may have profound effects on social behavior and result in a form of 
social anxiety (Yeates et al., 2004; Max et al., 2011; Semple et al. 2012).  Semple et al. 
(2012) demonstrated an increase in social anxiety behavior in an animal model using 
PND21 mice that had previously shown a decrease in general anxiety behavior.  Studies 
such as this indicate that assessment of social anxiety after injury may yield very different 
results from the assessment of general anxiety (or novel environment anxiety as the case 
may be for tests utilizing open fields and elevated mazes) and this may be a worthwhile 
avenue of investigation in our injury model.       
 We have previously shown that our animals (injured on PND11) demonstrate 
cognitive impairment in the form of spatial learning and memory deficits in the Morris 
water maze at 4 weeks post-injury (Raghupathi & Huh, 2007). Interestingly, when the 
same injury was performed on slightly older rat pups (PND17), these animals did not 
demonstrate any deficit in this same spatial learning and memory task at 4 weeks.  
Anatomical structures that have implications for this task include the retrosplenial cortex, 
the subiculum of the hippocampus, and the laterodorsal thalamus (Vann et al., 2009; 
O’Mara et al., 2009; van Groen et al., 2002)- all of which demonstrate some degree of 
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cellular pathology (neurodegeneration and microglial/macrophage reactivity) in our 
injury model (Chapter 3, Hanlon et al., 2016b). Working memory tasks that involve long 
intervals between training and assessment have been found to involve hippocampal 
connections, but short-term working memory, especially object recognition based 
memory, involves the prefrontal cortex and the perirhinal cortex (Barker et al., 2007).  
While these regions did not demonstrate any cellular pathology after our CCI injury, 
other injury models using young animals have demonstrated novel object recognition 
memory deficits (Scafidi et al., 2010; Schober et al., 2012).  The fact that our injury 
produced deficits in this assessment illustrates the diffuse nature of our impact-based 
model as it is possible that there are alterations in activity in the circuitry responsible for 
novel object recognition.  
 The forelimb deficit that was observed in the straight path swim task may be 
directly related to the alteration in neuronal activity in the forelimb region of the motor 
cortex.  This task is dependent on the animal’s ability to exert inhibitory control over 
excitatory processes that contribute to forelimb locomotion as rats typically swim in a 
straight path using only their hindlimbs for propulsion. Stoltz et al. (1999) showed that a 
lesion in this region of the motor cortex resulted in a sustained deficit in forelimb 
inhibitory motor control.  Adult rats that underwent lesion injury to the forelimb region of 
the motor cortex exhibited increased use of the forelimb contralateral to the lesion in the 
straight-path swim task out to 8 weeks post-lesion.  Our animals also showed increased 
utilization of the forelimb contralateral to the injury that coincided with increased EFP 
signal amplitudes and decreased signal latencies in the forelimb region of the motor 
cortex.  This hyperactivity may be indicative of a loss of inhibitory control in this region 
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thus resulting in the observed behavioral alteration. This evidence of hyperactivity within 
the brain may also contribute to the observed increase in seizure susceptibility at 4 weeks 
post-injury.  With these results, investigation into the integrity of the inhibitory signaling 
in the brain may provide new mechanistic insight into the observed alterations.  
     We have demonstrated that systemic minocycline administration can reduce 
injury-induced microglial/macrophage reactivity at 3 days post-injury within the impact 
site, but does not affect spatial learning and memory impairment (Chapter 4, Hanlon et 
al., 2016b).   It is unclear, however, whether minocycline treatment can alter 
microglial/macrophage function in regions without cellular pathology thereby altering 
functional outcomes as well.  In this study, treating brain-injured animals with 
minocycline for only the first 3 days post-injury resulted in functional recovery at 4 
weeks post-injury.  This treatment reduced the NOR deficit, reversed the deficit in 
forelimb inhibitory motor control, and also reversed both the acute and chronic 
alterations in neuronal activity in the forelimb region of the motor cortex.  Minocycline 
has previously been effective in reversing novel object recognition deficits in the chronic 
post-injury period following brain-injury in adult mice (Siopi et al., 2012).  Our similar 
results indicate that minocycline may have effects on the circuitry behind NOR memory.  
The fact that the reversal of the injury-induced hyperactivity in the forelimb 
region of the motor cortex also coincided with a complete rescue of the deficit in 
forelimb inhibitory motor control supports the hypothesis that the behavior is directly 
related to the alteration in activity in this region.  Despite a reduction in this 
hyperactivity, however, minocycline treatment did not affect seizure susceptibility 
indicating that the hyperactivity in the forelimb region of the motor cortex and the 
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increased vulnerability to seizure may be unrelated.  Minocycline administration, 
however, may have direct effects on neuronal activity as it has been shown that one week 
of daily minocycline treatment decreased hyperactivity in dorsal root neurons in a model 
of burn-induced pain 4 weeks after the burn injury (Chang & Waxman, 2010). 
Additionally, when minocycline is directly applied to hippocampal neurons, the treatment 
can decrease glutamate-induced hyperactivity and intracellular calcium increases 
(Gonzalez et al., 2007).   
Together with our data, this indicates that minocycline may have effects that are 
unrelated to its ability to alter the microglial/macrophage activation state. This is further 
supported by the fact that clodronate-mediated microglial/macrophage depletion within 
the impact site did not alter the neuronal hyperactivity at 4 weeks or the deficit in 
forelimb motor control. If the minocycline-mediated effects were related to the decrease 
in microglial/macrophage reactivity in the impact site, the results of the clodronate study 
would have mirrored the results of the minocycline study.  It is also possible that 
microglia/macrophages in the regions anterior to the impact site that are implicated in 
these behaviors (PFC, forelimb motor cortex) are still releasing mediators that could 
affect neuronal activity.  For example, high levels of the pro-inflammatory mediator, IL-
1beta, have been shown to decrease the amplitude of extracellular signals in hippocampal 
slices (Bellinger et al., 1993). As the minocycline treatment is systemic (instead of local 
such as the clodronate administration), it is possible that the drug is having an effect on 
soluble mediators in this region.  Determining the concentrations of inflammatory 
mediators in these frontal regions may reveal an additional mechanism behind 
minocycline’s beneficial effects.       
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5.6 FIGURE LEGENDS 
 
Figure 5.1 Experimental timelines. (A) Schematic representing the order of the 
behavioral assessments that occurred in the 4
th 
week post-injury (days 20-28) of the 
characterization study. (B) Schematic representing the treatment paradigm and the 
functional outcomes for the minocycline study. (C) Schematic representing the treatment 
paradigm and functional outcomes for the clodronate study.   
 
Figure 5.2 Assessment of anxiety behavior using the elevated plus maze (EPM). (A) 
Diagram of the EPM apparatus. (B) Quantified closed arm time. (C) Number of entries 
into the closed arms. (D) Total time spent in the open arms (includes 2-paw and 4-paw 
entires). (E) Total time spent in the open arm with a complete 4-paw entry. (F) Number 
of entries into the open arm with all 4 paws. (G) Number of times animals looked over 
the edge of the open arms. (H) Number of entries into the open arm with only 2 paws. 
*p≤0.05 compared to sham-injured group.   Error bars represent the standard error of the 
mean.   
 
Figure 5.3. Assessment of short-term working memory using novel object 
recognition (NOR) (A) Schematic representing the habituation to the NOR chamber in 
which the animals were left to explore the empty chamber for two 10-minute sessions in 
the 2 days prior to testing. (B) Schematic representing the pre-test trial in which animals 
were left to explore two identical objects for a 5-minute period. (C) Schematic 
representing the test trial in which one of the original objects was replaced with a novel 
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object and animals were left to explore the objects for a 5-minute period. (D) 
Quantification of exploratory behavior during the pre-test trial.  (E) Quantification of 
exploratory behavior during the test trial.  Quantitative data (D,E) presented as the 
proportion of time spent with the objects over the total exploratory time.  *p≤0.05 
compared to sham-injured animals. Error bars represent the standard error of the mean. 
 
Figure 5.4. Assessment of flurothyl-induced seizure susceptibility. (A) Schematic of 
the seizure induction chamber. (B) Quantification of the latency to the first myoclonic 
jerk. (C) Quantification of the length of seizure. Quantitative data (B,C) presented as 
time in seconds. *p≤0.05 compared to sham-injured animals. Error bars represent the 
standard error of the mean. 
 
Figure 5.5. Assessment of open field locomotion. (A) Quantification of the number of 
beam breaks that qualified for basic ambulatory locomotion. (B) Quantification of the 
beam breaks that did not meet criterion for ambulatory or rearing motion and were thus 
characterized as fine locomotion. (C) Vertical beam breaks that qualified as rearing 
behavior. Data presented as number of beam breaks. *p≤0.05 compared to sham-injured 
animals. Error bars represent the standard error of the mean. 
 
Figure 5.6. Assessment of forelimb motor function using the straight-path swim 
task. (A) Schematic of the swim test aquarium and experimental set-up. (B) Still image 
depicting the swimming form of a sham-injured animal. (C) Still image depicting the 
swimming form of a brain-injured animal. Note the use of the forelimb (red circle). (D) 
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Quantification of right (contralateral to impact) and left (ipsilateral to impact) forelimb 
use. (E) Quantification of right (contralateral to impact) and left (ipsilateral to impact) 
hindlimb use. Quantitative data (D,E) presented as the average number of strokes. 
*p≤0.05 compared to sham-injured animals. Error bars represent the standard error of the 
mean. 
  
Figure 5.7. Assessment of neuronal activity in the forelimb region of the motor 
cortex. (A) Diagram representing electrode placement and recording location relative to 
the impact site. (B) Representative evoked field potentials (EFPs) from sham-injured and 
brain-injured animals at 3 days post-injury. (C) Representative EFPs from sham-injured 
and brain-injured animals at 21 days post-injury. (D) Quantification of the signal 
amplitude (mV) for sham-injured and brain-injured animals at 3, 7 and 21 days post-
injury. (E) Quantification of the signal latency (s) for sham-injured and brain-injured 
animals at 3, 7, and 21 days post-injury. (F) Duration/signal width (s) for sham-injured 
and brain-injured animals at 3, 7, and 21 days post-injury.  Quantitative data (D,E,F) 
presented at 800 μA stimulus intensity. *p≤0.05 compared to corresponding sham-injured 
group. Error bars represent the standard error of the mean. 
 
Figure 5.8 Assessment of working memory following acute minocycline treatment. 
(A) Percent time spent with the identical objects in the pre-test. (B) Percent time spent 
with the novel and original objects in the test. *p≤0.05 compared to corresponding sham-
injured group. #p≤0.05 compared to the brain-injured vehicle group. Error bars represent 
the standard error of the mean. 
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Figure 5.9 Assessment of seizure susceptibility following acute minocycline 
treatment. (A) Latency to the first myoclonic jerk measured in seconds. (B) Length of 
the seizure measured in seconds. *p≤0.05 compared to corresponding sham-injured 
group. Error bars represent the standard error of the mean. 
 
Figure 5.10 Assessment of open field locomotion after acute minocycline treatment. 
(A) Number of basic movement beam breaks. (B) Number of fine movement beam 
breaks. (C) Number of rearing beam breaks. *p≤0.05 compared to corresponding sham-
injured group. #p≤0.05 compared to the brain-injured vehicle group. Error bars represent 
the standard error of the mean. 
 
Figure 5.11 Assessment of forelimb use after acute minocycline treatment. Number 
of strokes by the forelimbs contralateral (right) or ipsilateral (left) to the injury. *p≤0.05 
compared to corresponding sham-injured group. #p≤0.05 compared to the brain-injured 
vehicle group. Error bars represent the standard error of the mean. 
 
Figure 5.12 Assessment of evoked field potentials in the forelimb region of the motor 
cortex after acute minocycline treatment. (A) Representative traces from sham-injured, 
brain-injured vehicle, and brain-injured minocycline animals at 3 days post-injury. (B) 
Representative traces from sham-injured, brain-injured vehicle, and brain-injured 
minocycline animals at 4 weeks post-injury. (C) Quantification of signal amplitude for 
sham-injured, brain-injured vehicle, and brain-injured minocycline animals at 3 days and 
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4 weeks post-injury. (D) Quantification of signal latency for sham-injured, brain-injured 
vehicle, and brain-injured minocycline animals at 3 days and 4 weeks post-injury. (E) 
Quantification of the duration/width of the signal from sham-injured, brain-injured 
vehicle, and brain-injured minocycline animals at 3 days and 4 weeks post-injury. 
*p≤0.05 compared to corresponding sham-injured group. #p≤0.05 compared to the brain-
injured vehicle group. Error bars represent the standard error of the mean. 
 
Figure 5.13 Assessment of forelimb use following acute microglial/macrophage 
depletion. Number of strokes by the forelimbs contralateral (right) or ipsilateral (left) to 
the injury. *p≤0.05 compared to corresponding sham-injured group. #p≤0.05 compared to 
the brain-injured empty-lip group. Error bars represent the standard error of the mean. 
 
Figure 5.14 Assessment of evoked field potential in the forelimb region of the motor 
cortex following acute microglial/macrophage depletion. (A) Representative traces 
from sham-injured empty-lip, brain-injured empty-lip, sham-injured clod-lip and brain-
injured clod-lip animals at 4 weeks post-injury. (B) Quantification of signal amplitude for 
sham-injured empty-lip, brain-injured empty-lip, sham-injured clod-lip and brain-injured 
clod-lip animals at 4 weeks post-injury. (C) Quantification of signal latency for sham-
injured empty-lip, brain-injured empty-lip, sham-injured clod-lip and brain-injured clod-
lip animals at 4 weeks post-injury. (D) Quantification of the duration/width of the signal 
from sham-injured empty-lip, brain-injured empty-lip, sham-injured clod-lip and brain-
injured clod-lip animals at 4 weeks post-injury. *p≤0.05 compared to corresponding 
sham-injured group. Error bars represent the standard error of the mean. 
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  5.7 TABLES and FIGURES 
 
Table 5.1 Listing of characterization animals for Part A 
*The same animals were used for EPM, NOR, Seizure, Activity Monitoring, and Swim Test  
 
Outcome Experiment Time Point 
(days) 
Group N 
Elevated Plus Maze Characterization 24 Sham 11 
Injured 12 
Novel Object 
Recognition 
Characterization 27 Sham 11 
Injured 12 
Seizure Characterization 28 Sham 11 
Injured 12 
Activity Monitoring Characterization 20 Sham 11 
Injured 12 
Swim Test Characterization 22 Sham 11 
Injured 12 
+1mm E-phys Characterization 3 Sham 6 
Injured 6 
7 Sham 6 
Injured 6 
21 Sham 6 
Injured 6 
Total* Characterization  Sham 29 
Injured 30 
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Table 5.2 Listing of minocycline and clodronate study animals for Part B 
 
*Overlap in some behavioral animals 
 
**Overlap in some behavioral and E-phys animals  
 
Outcome Experiment Time Point 
(days) 
Group N 
Novel Object 
Recognition 
Minocycline 27 Sham 11 
Injured Vehicle 12 
Injured Minocycline 12 
Activity 
Monitoring 
Minocycline 20 Sham 15 
Injured Vehicle 16 
Injured Minocycline 17 
Seizure Minocycline 28 Sham 3 
Injured Vehicle 4 
Injured Minocycline 4 
Swim Test Minocycline 22 Sham 7 
Injured Vehicle 8 
Injured Minocycline 9 
+1 mm E-phys Minocycline 3 Sham 7 
Injured Vehicle 6 
Injured Minocycline 6 
21-28 (4 
weeks) 
Sham 4 
Injured Vehicle 4 
Injured Minocycline 8 
Total* Minocycline  Sham 22 
Injured Vehicle 22 
Injured Minocycline 26 
Swim Test Clodronate 24 Sham Empty-Lip 9 
Injured Empty-Lip 8 
Sham Clod-Lip 9 
Injured Clod-Lip 9 
+1mm E-phys Clodronate 25-30 (4 
weeks) 
Sham Empty-Lip 8 
Injured Empty-Lip 8 
Sham Clod-Lip 9 
Injured Clod-Lip 8 
Total** Clodronate  Sham Empty-Lip 9 
Injured Empty-Lip 8 
Sham Clod-Lip 9 
Injured Clod-Lip 9 
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Figure 5.1 Experimental Timelines 
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Figure 5.2 Assessment of anxiety behavior using the elevated plus maze (EPM). 
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Figure 5.3 Assessment of short-term working memory using novel object 
recognition (NOR)  
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Figure 5.4 Assessment of flurothyl-induced seizure susceptibility 
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Figure 5.5 Assessment of open field locomotion 
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Figure 5.6 Assessment of forelimb motor function using the straight-path swim task  
 
 
 
 
 
 
 
 
 
 
 
 
 
231 
 
Figure 5.7 Assessment of neuronal activity in the forelimb region of the motor 
cortex 
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Figure 5.8 Assessment of working memory following acute minocycline treatment 
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Figure 5.9 Assessment of seizure susceptibility following acute minocycline 
treatment 
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Figure 5.10 Assessment of open field locomotion after acute minocycline treatment 
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Figure 5.11 Assessment of forelimb use after acute minocycline treatment 
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5.12 Assessment of evoked field potentials in the forelimb region of the motor cortex 
after acute minocycline treatment 
 
 
 
237 
 
5.13 Assessment of forelimb use following acute microglial/macrophage depletion 
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Fig. 5.14 Assessment of evoked field potential in the forelimb region of the motor 
cortex following acute microglial/macrophage depletion 
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CHAPTER 6: GENERAL DISCUSSION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
240 
 
6.1 SIGNIFIGANCE OF FINDINGS 
 
 The current set of studies is the first to take a multi-faceted approach in 
investigating microglial/macrophage reactivity following impact-based trauma in the 
immature brain.  Through the use of clodronate-mediated microglial/macrophage 
depletion and minocycline-mediated reduction in microglial/macrophage activation, these 
experiments emphasize the crucial role that microglia/macrophages play in the acute 
post-injury period.  Despite the fact that these interventions are very different in their 
mechanisms of action, treatment resulted in similar exacerbations of injury-induced 
neuropathology.  These results challenge the dogma that acute microglial/macrophage 
activation following traumatic brain injury perpetuates neuronal damage (Loane, 2010).  
They also suggest that the microglial/macrophage response following injury to the 
immature brain is not only different from the response following injury to the adult brain, 
but that it is necessary to contain the spread of neuropathology. With these results, how 
should a physician treat a brain-injured infant? This project indicates that acute 
pharmacologic intervention beyond vital stabilization may not be appropriate for 
treatment of traumatic brain injury in the infant.   
This project also emphasizes the complexities of injuring a developing brain.  
Brain development in the rat continues through the first 7 weeks of life with full adult 
maturation evident at PND60 (Semple et al., 2013).  Injuring the animal at postnatal day 
11 can impact not only the processes happening around that time, but everything that 
occurs after the time of injury.  On postnatal day 11, the rat pup is equivalent to a 
newborn infant in terms of scaled brain weight and developmental benchmarks (Clancy et 
al., 2007; Semple et al., 2013).  Right around this time there is immense brain growth, 
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gliogenesis, increases in axonal and dendritic densities, maturation of the immune 
system, and an increase in immature oligodendrocytes in the white matter (Semple et al., 
2013).  The diagram below adapted from Semple et al., 2013 identifies processes that are 
altered by insult to the developing brain thus leading to functional impairments.  
 
These processes include cell proliferation, myelination, immune system maturation, 
blood brain barrier (BBB) formation, and synapse generation and elimination. All of 
these processes have implications for this project.  Disruption of myelination may factor 
into the alterations we observed in compound action potential electrophysiology in 
addition to the observed increase in white matter damage that was unaffected by the 
treatments.  The concurrent development of the BBB and maturation of the immune 
system around the time of injury may play a role in the differential effects observed in 
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targeting microglial/macrophage activation following injury to the adult and developing 
brain (Chapter 1.4).  Affecting the developmental processes of cell proliferation, synapse 
generation, and synapse elimination with an injury may have profound effects on the 
formation of proper circuitry and may therefore result in alterations in neuronal activity.  
More specifically during this time, the GABAergic system in the cortex is still maturing 
and only approximately 50% of mature GABAergic synapses have formed by 11 days 
after birth.  Importantly, at 11 days old, the alterations that allow for GABA to switch 
from acting as an excitatory neurotransmitter to an inhibitory neurotransmitter are still 
underway (Le Magueresse and Monyer, 2013).  This interplay with developmental 
processes has significant implications for the electrophysiological results observed in this 
set of studies. We observed a developmental decrease in the amplitude of signal from 
sham-injured animals that may correspond with the maturation of the GABAergic system 
and a disruption in this maturation may explain the alterations in cortical activity that 
were observed in our studies.  It is, therefore, important to consider any effects on 
developmental processes that may contribute to the post-injury pathology when 
interpreting experimental results.  Further research into the interplay between 
development and injury in this model of TBI in the neonate rat is necessary.    
In this thesis, minocycline was used as a tool to reduce microglial/macrophage 
activation, but this FDA-approved antibiotic has real potential for being used as a post-
injury therapeutic intervention (Potts et al., 2006, Plane et al., 2010).  The results of this 
study suggest that minocycline may not be safe to use in the acute post-injury period in 
brain-injured children.  Minocycline administration did not ameliorate white matter 
damage, resulted in prolonged exacerbation of injury-induced grey matter pathology, and 
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caused a deficit in neuronal activity within the impact site.  This treatment did, however, 
ameliorate working memory deficits, rescue deficits in forelimb motor control, and 
reverse changes in neuronal activity in the forelimb region of the motor cortex.  These 
conflicting results emphasize the need for further investigation into this drug and its 
potential off-target effects in the developing brain.  
 These studies also lend support for the idea that microglial/macrophage reactivity 
is not associated with axonal pathology in the injured or diseased brain (Bennett and 
Brody, 2014; de Monasterio-Schrader et al., 2013, Hanlon et al., 2016a).  In the grey 
matter, acute microglial/macrophage manipulation resulted in a potential rebound effect 
in which activated microglia/macrophages were increased in chronic post-injury period 
and this was associated with an increase in neurodegeneration.  While clodronate-
mediated microglial/macrophage depletion was associated with increased 
neurodegeneration, it did not coincide with an increase in microglial/macrophage 
reactivity.  Conversely, minocycline treatment resulted in an increase in 
microglial/macrophage reactivity in the chronic post-injury period that was not associated 
with an increase in axonal degeneration.  Additionally, neither intervention affected APP 
accumulation in the acute post-injury period and minocycline had no effect on the 
transport of Fluoro-gold two weeks following the injury.  Also, microglial/macrophage 
depletion in the white matter had no effect on axonal conductance as measured by 
compound action potential electrophysiology and minoncycline treatment had no effect 
on atrophy in the white matter.  Taken together, these results may indicate that function 
of activated microglia/macrophages in the white matter may be very different from the 
function of activated microglia/macrophages in the grey matter and, therefore, may 
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respond to treatment differently.  More specific investigation into white matter pathology, 
such as myelination and oligodendrocyte damage, may be necessary to accurately 
understand the interactions between microglia and white matter pathology following 
injury.    
 This thesis also expands our knowledge of neuronal activity following injury to 
the immature brain.  A large body of evidence from the undercut model of brain injury in 
the PND21 rat implicates a role for excitatory/inhibitory imbalance in the brain following 
injury (Prince, 2009, more detail in Chapter 5.2).  Modulation of post-injury excitation 
using a positive modulator of the GABAA receptor (Diazepam) rescued injury-induced 
spatial learning and memory deficits while blocking this receptor exacerbated deficits in 
adult rats (O’Dell et al., 2000).  Also, in a model of TBI in the adult mouse, hypoactivity 
was evident in the first day post-injury and hyperactivity was observed at 2 weeks post-
injury (Ping and Jin, 2015).  The work in my dissertation demonstrates a similar 
hypoactivity-to-hyperactivity phenotypic switch suggesting that closed head injury to the 
PND11 rat may have an effect on the inhibitory/excitatory balance required for proper 
maintenance of neuronal circuitry.  Evoked field potential recording, however, may not 
be sensitive enough to make accurate statements regarding the effect of injury on the 
excitatory/inhibitory balance in the cortex and whole-cell patch clamp recording in the 
cortex may be necessary.  These studies open the door for further investigation into this 
phenomenon and its implications for post-injury functional deficits. 
 Finally, characterization of the microglial/macrophage response and assessment 
of functional impairments in the chronic post-injury period greatly emphasized the 
relevance of this PND11 injury as a preclinical model of pediatric TBI.  Previously, the 
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only functional deficit reported in our animals was a prolonged spatial learning and 
memory deficit (Raghupathi and Huh, 2007).  Demonstrating the working memory 
impairments, increases in anxiety, vulnerability to seizure activity, and locomotor 
impairment in addition to prolonged microglial/macrophage responses and alterations in 
neuronal activity not only lends support for the relevance of this model but also provides 
new avenues of investigation into the mechanisms behind injury-induced functional 
impairment.   
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6.2 FUTURE DIRECTIONS  
 
This thesis provides support for the notion that the microglial/macrophage 
response following injury to the developing brain is distinct from the response following 
injury to the adult brain.  In the developing brain, eliminating microglia/macrophages or 
reducing the microglial/macrophage activation state resulted in an exacerbation of 
pathology at the doses used in this study.  This is in contrast to what has been reported in 
the adult brain and has vast implications for post-injury therapeutics based on the age-
dependent efficacy of the drug.  From characterization of the microglial/macrophage 
response, we now know that the microglial/macrophage reactivity is sustained out to 4 
weeks after injury.  It raises the question as to whether delayed treatment has any effect 
on injury-induced pathology.  In a preliminary study, we administered our same 
minocycline treatment paradigm (Chapter 4; 45 mg/kg every 12 hours for 3 days) 
beginning on day 12 after injury and euthanized the animals for histology on post-injury 
day 15 to assess microglial/macrophage reactivity and neurodegeneration.  With very few 
animals per group (N = 3 animals/group), we observed a decrease in 
microglial/macrophage reactivity and a decrease in neurodegeneration in the cortex of 
brain-injured animals treated with the delayed minocycline paradigm (Fig. 6.2.1).  
Quantification of ED-1-labeled activated microglia/macrophages in the cortex (Fig. 6.2.1 
A,B) revealed a significant effect of status for both amoeboid- (F2,6=82.52, p<0.001) and 
rod-shaped cells (F2,6=9.04, p<0.05, Fig. 6.2.1 E); and post-hoc analysis revealed that 
both brain-injured groups had significantly more amoeboid microglia/macrophages 
compared to sham-injured animals (p<0.05) and that minocycline-treated brain-injured 
animals had significantly fewer amoeboid microglia/macrophages compared to brain-
247 
 
injured animals that received the vehicle (p<0.001).  Brain-injured animals that received 
the vehicle also had more rod-shaped ED-1(+) microglia/macrophages compared to both 
sham-injured and brain-injured minocycline-treated animals (p<0.05).  Sham-injured 
animals and brain-injured animals treated with  minocycline did not differ in the number 
of rod-shaped microglia/macrophages in the cortex (p=0.49).  Similar decreases in ED-1 
labeling were also observed in the thalamus and subiculum, but not in the white matter.  
FJB(+) profiles were also decreased in the cortex following delayed minocycline 
treatment (Fig. 6.2.1 C,D), but this result failed to reach significance potentially due to a 
small sample size (t(4)=-2.05, p=0.11, Fig. 6.2.1 F).  Despite no difference in ED-1 
labeling between brain-injured minocycline-treated animals and those that received the 
vehicle in the white matter, there was a mild reduction in FJB(+) profiles in the white 
matter (t(4)=-2.97, p=0.04).  Additionally, there was a significant reduction of FJB(+) 
profiles in the thalamus and the reduction in the subiculum was trending on significant.  
More animals are needed to complete this study, but these preliminary results indicate 
that delayed targeting of the microglial/macrophage response may be more effective in 
treating injury-induced neuropathology.  Additionally, animals that receive this paradigm 
will have to be tested for injury-induced behavioral deficits to see if the delayed treatment 
can also ameliorate long-term functional deficits.  
The results stated in this thesis project raise questions about the activation state of 
microglia/macrophages and the mediators that these cells release.  While previous 
attempts at ELISA-mediated assessment of pro- and anti-inflammatory mediators have 
been unsuccessful in our lab, we recently conducted a set of experiments to evaluate the 
mRNA expression of different mediators in the cortex of sham- and brain-injured 
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animals. In light of the interesting electrophysiological results observed in the forelimb 
region of the motor cortex and minocycline’s effects on this measure (Chapter 5), I 
collected tissue from this region and the -3mm cortical region for QPCR evaluation at 3 
days post-injury (Fig. 6.2.2).  With small sample sizes (N=3/group), there appeared to be 
an injury-induced increase in cytokine expression in the +1mm section anterior to the 
impact site where we did not observe cellular microglial/macrophage activation (Fig. 
6.2.2 A-C).  Brain-injured animals demonstrate approximately a 75% increase in TNFα 
mRNA expression (Fig. 6.2.2 A), a 300% increase in IL-1β mRNA expression (Fig. 6.2.2 
B), and a 66% increase in IL-10 mRNA expression (Fig. 6.2.2 C) compared to sham-
injured animals.  Interestingly, in the -3mm section where we observed dense cellular 
pathology, there did not seem to be an injury-induced increase in TNFα mRNA 
expression (Fig. 6.2.2 D), but there was a 475% increase in IL-1β mRNA expression 
(Fig. 6.2.2 E) and an almost 300% increase in IL-10 mRNA expression (Fig. 6.2.2F) 
compared to sham-injured animals.  In the +1mm section, minocycline administration 
seemed to decrease mRNA expression of both IL-1β and IL-10 without affecting TNFα 
expression levels (Fig. 6.2.2 A-C).  The modulation of IL-1β by minocycline may explain 
the ability of minocycline to reverse injury-induced hypoactivity in this region at this 
time point (Chapter 5) as it has been demonstrated that exposure to high levels of IL-1β 
can decrease extracellular field potentials (Ross et al., 2003, Fig. 6.2.2 B).  Minocycline 
treatment also decreased IL-1β and IL-10 mRNA expression in the impact site (-3mm) 
indicating that the minocycline-induced decrease in microglial/macrophage activation 
observed at 3 days was associated with a decrease in both pro- and anti-inflammatory 
cytokines (Fig. 6.2.2 E,F).  It has been shown that TNFα can modulate α-amino-3-
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hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) and gamma-aminobutyric acid 
(GABA) receptor membrane trafficking to affect both excitatory and inhibitory 
neurotransmission (Stellwagen et al., 2005).  Additionally, IL-1β has been shown to 
affect neuronal activity through the modulation of NMDA-mediated currents (Yang et al., 
2005).  While our extracellular field potential data indicated that there were injury-
induced alterations in neuronal activity, it is unclear what is happening at the single cell 
level and further investigation is needed to tie these changes in population activity to the 
observed changes in cytokine mRNA expression.  It is also unclear how these 
manipulations factor into the observed prolonged neuropathology and further QPCR 
studies at chronic time points are needed.    
 The results from these studies indicate a role for peripheral cell infiltration 
following injury. The markers used (Iba1 and ED-1) have been shown to label both 
endogenous microglia and infiltrating peripheral macrophages that can enter the brain 
following injury (Jeong et al., 2013). Separating infiltrating cells from resident microglia 
would allow for more specific characterization and targeting of the endogenous response.  
Infiltration also becomes very relevant in experiments dealing with 
microglial/macrophage depletion.  There is some evidence that speaks to repopulation 
through peripheral cells in the absence of microglia in the aging brain (Varvel et al., 
2012), but it is possible that peripheral infiltration in the developing brain is different, 
especially in the context of injury.  In comparing the microglia/macrophage response 
following a lesion to the visual cortex, peripheral macrophages were the predominant 
responder cell in the lesioned neonatal cortex whereas microglia were the main responder 
following lesion to the adult cortex (Milligan et al., 1991).  After stroke in the neonate 
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rat, peripheral infiltration was assessed and it was determined that the cells responding 
around the infarct were endogenous microglia despite high increases in monocyte 
chemoattractant protein-1 (MCP-1) (Denker et al., 2007).  One way to separate the 
endogenous microglia from peripheral macrophages would be to use flow cytometry to 
separate cells based on specific markers.  The most common way of doing this is to use a 
non-specific microglia/macrophage marker such as Iba1 to distinguish 
microglia/macrophages from neutrophils and then to use CD45 expression levels to 
differentiate between peripheral macrophages (CD45 high) and endogenous microglia 
(CD45 low) (Jeong et al., 2013). A working flow cytometry protocol would also answer 
the question of repopulation following clodronate-mediated microglial/macrophage 
depletion.  In the absence of a working protocol, however, we may be able to answer 
these questions by using clodronate to deplete peripheral macrophages prior to injury and 
prior to the depletion of endogenous microglia.        
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Fig. 6.2.1 Effect of delayed minocycline treatment in the cortex. Representative 
photomicrographs of ED-1(+) microglia (A,B) and FJB(+) profiles (C,D) in the cortex 
of brain-injured animals that received the vehicle (A,C) and those that received 
minocycline (B,D).  Quantification of amoeboid and rod microglia (E) and FJB(+) 
profiles (F) in the cortex at 15 days post-injury.  Error bars represent the standard 
error of the mean. *p≤0.05 compared to the sham-injured group, #p≤0.05 compared to 
the brain-injured vehicle group.   
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Fig. 6.2.2 Effect of acute minocycline administration on mRNA expression of pro- 
and anti-inflammatory cytokines in specific cortical regions.  Quantification of 
cytokines at +1mm (A-C) and -3mm (D-F).  Error bars represent the standard error of 
the mean.    
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APPENDIX 1: 
 
Differential effects of minocycline on microglial activation and neurodegeneration 
following closed head injury in the neonate rat 
 
Hanlon L.A., Raghupathi R., Huh J.W. (2016) 
Experimental Neurology 290:1-14. 
 
The following is work that, in conjunction with a portion of the data from chapter 4, was 
published by Experimental Neurology in 2016 (Print in 2017).  
 
This work explores the effect of a prolonged minocycline dosing paradigm (9 days) on 
sustained microglial/macrophage activation, neurodegeneration, axonal 
degeneration, and spatial learning and memory deficits.  
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A1.1 ABSTRACT 
 
Microglial/macrophage activation can be a chronic phenomenon that may require 
prolonged treatment.  The antibiotic minocycline has been effective in decreasing 
microglial/macrophage activation and ameliorating neuronal damage, but some of these 
studies indicate that the effects of minocycline are transient.  The half-life of the drug in 
rodents (2-3 hours) is much shorter than the half-life in humans (Up to 16 hours).   To 
test whether extended dosing of minocycline may be necessary to reduce ongoing 
pathologic alterations, a group of animals received minocycline for 9 days. Immediately 
following termination of treatment, microglial/macrophage reactivity and 
neurodegeneration in all regions examined were exacerbated in minocycline-treated 
brain-injured animals compared to brain-injured animals that received vehicle (p<0.001), 
an effect that was only sustained in the cortex and hippocampus up to 15 days post-injury 
(p<0.001). Whereas injury-induced spatial learning deficits remained unaffected by 
minocycline treatment, memory deficits appeared to be significantly worse (p<0.05).  
These results indicate that supressing the microglial/macrophage response following 
injury to the developing brain may be detrimental to long-term pathological alterations 
and cogntive function.   
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A1.2 INTRODUCTION 
 
The acute response to injury in the developing brain includes a robust 
neuroinflammatory cascade evident by the presence of pro- and anti-inflammatory 
mediators in the cerebrospinal fluid of brain-injured children (Amick et al., 2001, 
Buttram et al., 2007, Berger et al., 2009).  Additionally, increased levels of quinolinic 
acid (a marker of microglial/macrophage activation) were also discovered in the CSF of 
brain-injured children indicating a role for microglia/macrophages in perpetuating this 
immune response (Berger et al., 2004).  Work in pre-clinical animal models of pediatric 
TBI suggest that microglial/macrophage activation is a sustained phenomenon that lasts 
well into the chronic post-injury period and may be associated with long-term functional 
impairment.  Microglial activation was evident out to 3 weeks post-injury in the cortex 
and subcortical white matter of brain-injured neonatal rabbits and these animals also 
demonstrated cognitive impairments in novel object recognition memory (Zhang et al., 
2015).  Minocycline is an antibiotic that has anti-inflammatory properties and has been 
shown to decrease microglial/macrophage activation (Garrido-Mesa et al., 2013).  While 
minocycline treatment has resulted in lasting neuroprotective and beneficial effects 
following brain injury (Homsi et al., 2010, Siopi et al., 2012), there is also some evidence 
that suggests that the effects of minocycline are transient (Bye et al., 2007, Chhor et al., 
2016, Hanlon et al., 2016).  Minocycline treatment  reduced microglial activation, cell 
death, and injury severity at 1 day post-injury in brain-injured neonatal mice, but this 
effect was lost by 5 days post-injury (Chhor et al., 2016).  In a model of repetitive brain 
injury in the neonatal rat, minocycline administration only decreased 
microglial/macrophage activation in the white matter at 3 days post-injury- an effect that 
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was not replicated in other brain regions, had no effect on injury-induced degeneration, 
and was not sustained out to 7 days (Hanlon et al., 2016).  We’ve also demonstrated that 
minocycline administration following a single injury to the immature brain only 
decreased microglial/macrophage activation the day after ending the treatment (3 days 
post-injury) and that this had no effect on spatial learning and memory impairment (See 
Chapter 4).  With these results and the knowledge that minocycline has an extremely 
short half-life in rodents (Andes and Craig, 2002), we hypothesized that an extended 
minocycline dosing paradigm may be necessary to produce prolonged neuroprotection 
and ameliorate cognitive impairment after injury to the developing brain.  
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A1.3 MATERIALS AND METHODS 
 
A1.3.1 Brain Injuries and Minocycline Administration 
 
Brain injuries were conducted as described in Chapter 3.  Immediately after 
injury, animals were randomly assigned to receive intraperitoneal injections of either 
minocycline (45mg/Kg) or PBS vehicle (0.2mL/Kg); following a second injection of 
minocycline or vehicle 12 hours later, animals received once daily intraperitoneal 
injections of minocycline or vehicle (45mg/Kg/injection or 0.2mL/Kg/injection) for 9 
days for a total of 11 injections. Sham-injured animals were also randomly assigned to 
receive either vehicle or minocycline. Similar extended dosing paradigms have been 
successful in reducing microglial activation in the chronic post-injury period following 
HI in neonate rats (Carty et al., 2008, Wixey et al., 2011), diffuse TBI in the adult mouse 
(Ng et al., 2012) and contusive TBI in the adult rat (Lam et al., 2013).  
 
A1.3.2 Histology, Immunohistochemistry, and Quantification 
 
 Tissue processing and immunohistochemistry were conducted according to the 
procedures outlined in Chapter 3.3.4 with the exception that activated 
microglia/macrophages were only evaluated using Iba1 and not CD68/ED-1.  
Additionally, astrocytic reactivity (GFAP) and axonal injury (APP) were not evaluated in 
this study.  Quantification was conducted as previously described (Chapter 3.3.4).  
Briefly, total and activated Iba1(+) microglia/macrophages were counted in 20x HPF 
images in the cortex, subiculum, and thalamus.  Quantification of Iba1 immunoreactivity 
in the white matter was conducted by a thresholded area analysis as previously described 
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(Hanlon et al., 2016).  FJB(+) profiles were counted in 20x HPF images in the cortex, 
white matter, subiculum, and thalamus. Areas of the cortex and white matter were 
measured using manual tracing of 1x (cortex) or 4x (white matter) images in the program 
Image J.   
 
A1.3.3 Spatial learning and Memory  
 
 Animals were assessed using a Morris water maze spatial learning paradigm on 
post-injury days 10-13 and subjected to 2 probe retention trials and a visible platform trial 
to assess potential vision deficits on post-injury day 14.  See Chapter 3.3.8 for full 
procedure.  
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A1.4 RESULTS 
 
A1.4.1 Effect of minocycline in the cortex and white matter tracts 
 
At 10 and 15 days post-injury, brain-injured animals demonstrated evidence of 
microglial/macrophage activation and FJB reactivity in the same areas of the cortex and 
white matter tracts (Fig. A1.1) as those observed at 3 and 7 days post-injury. In sham-
injured animals, resting Iba1 (+) microglia/macrophages with elongated cell bodies and 
long processes predominated (Fig. A1.1A inset), whereas Iba1(+) microglia/macrophages 
in brain-injured animals, were amoeboid in appearance (Fig. A1.1B inset). The effects of 
extending minocycline administration to 9 days following brain injury (study 2) on 
microglial/macrophage reactivity and neurodegeneration were different from the effects 
of the short duration treatment paradigm used in study 1. In the cortex, a 3-way ANOVA 
revealed an interaction effect only between group and time (F2,23=32.13, p<0.001; Fig. 
A1.1A), and not between group, time and sex (F2,23=0.05, p=0.96); post-hoc analysis 
indicated that at 10 days post-injury, minocycline-treated, brain-injured animals had 
significantly fewer microglia/macrophages compared to vehicle-treated brain-injured 
animals (p<0.01; Fig. A1.1A). In contrast, at the 15-day time point, the number of 
Iba1(+) cells in the minocycline group was significantly greater than that in the vehicle 
group (p<0.001; Fig. A1.1A). Analysis of the proportion of activated 
microglia/macrophages also demonstrated an interaction effect between group and time 
(F2,23=10.11, p<0.001) with minocycline-treated, brain-injured animals exhibiting a 
significantly greater proportion compared to their counterparts that received vehicle at 
both 10 (p<0.001; Fig. A1.1B) and 15 days (p<0.001, Fig. A1.1B). Again, sex of the 
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animal had no interaction effect with group or time (F2,23=0.15, p=0.87).   Minocycline-
treated, brain-injured animals contained significantly more FJB(+) profiles compared to 
brain-injured animals that received vehicle (F1,15=76.78, p<0.001; Fig. A1.1C). There 
was an interaction effect between group, sex and time (F1,15=10.29, p<0.01) that indicated 
that at 10 days post-injury, male minocycline-treated, brain-injured animals had 
significantly more FJB(+) profiles in the cortex compared to male brain-injured animals 
that received the vehicle (p<0.001; Fig. A1.1C). FJB reactivity was greater in the cortex 
of brain-injured females that received the vehicle compared to their male counterparts at 
10 days (p<0.01), but female brain-injured minocycline-treated animals had significantly 
fewer FJB(+) profiles in the cortex compared to their male counterparts at 10 days 
(p<0.05).  Female brain-injured animals demonstrated similar FJB reactivity irrespective 
of treatment at 10 days post-injury (p=0.24).  At 15 days, however, both male and female 
brain-injured minocycline-treated animals had significantly more FJB(+) profiles than 
their brain-injured counterparts that received the vehicle (p<0.05).  
In the white matter tracts below the site of impact, area analysis of Iba1 labeling 
revealed an interaction effect between group and time (F2,23=71.6, p<0.001) with a post-
hoc analysis indicating that minocycline-treated, brain-injured animals had significantly 
greater labeled area at 10 days post-injury (p<0.001), but not at 15 days (p=0.30), than 
brain-injured animals that received vehicle (Fig. A1.1D). There was an interaction effect 
between sex and condition that indicated that male brain-injured animals that received the 
vehicle had significantly decreased labeled white matter area compared to female brain-
injured animals that received the vehicle (p<0.001) while brain-injured minocycline-
treated males had significantly increased labeled white matter area compared to brain-
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injured minocycline-treated females (p<0.01). Furthermore, both brain-injured 
minocycline-treated males and females demonstrated increased white matter area 
compared to their counterparts that received the vehicle (males, p<0.001; females, 
p<0.01). Minocycline-treated, brain-injured animals had significantly more FJB+ profiles 
at 10 days (p<0.001), but not at 15 days (p=0.91) post-injury, than their counterparts that 
received vehicle (Fig. A1.1E) and this was not affected by the sex of the animals.   
Compared to sham-injured animals (Fig. A1.1F), brain-injured animals exhibited 
a substantially enlarged lateral ventricle in the hemisphere ipsilateral to the impact site at 
10 (Fig. A1.1G and A1.1H) and 15 days post-injury (not shown). Moreover, both the 
cortex and the underlying white matter tracts were visibly thinner in the brain-injured 
animals. Quantitative analysis of the area of the cortex revealed an interaction effect 
between group and time post-injury (F2,22=4.70, p<0.05; Fig. A1.1I); post-hoc analysis 
indicated that at 10 days post-injury both brain-injured groups exhibited smaller cortical 
areas compared to the sham-injured group (p<0.01). Importantly, the area of the cortex in 
the brain-injured group that was treated with minocycline was significantly less than that 
in brain-injured animals that received vehicle (p<0.001; Fig. A1.1I). At 15 days post-
injury, the cortical areas in both brain-injured groups were significantly less than in 
sham-injured animals (p<0.001; Fig. A1.1I) but the minocycline-treated group was not 
different from the group that received vehicle (p=0.31). An interaction effect between 
group, sex, and time was observed (F2,22=3.42, p=0.05) that indicated that sham-injured 
males had significantly increased cortical area compared to sham-injured females 
(p<0.05) at 15 days post-injury. In sham-injured animals and in the hemisphere 
contralateral to the impact site in brain-injured animals, robust myelin labeling in the 
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corpus callosum and lateral white matter was observed (Figures A1.1F-H). In brain-
injured animals the white matter atrophy that was observed at both 3 and 7 days post-
injury (vide supra) persisted to the 10 and 15 day time points. Quantitative analyses 
revealed an interaction effect between group and time (F2,23=57.23, p<0.001; Fig. A1.1J) 
and the post-hoc analysis indicated that brain-injured animals exhibited a significantly 
smaller area compared to sham-injured animals at both 10 and 15 days post-injury 
(p<0.001); importantly, minocycline-treated brain-injured animals had significantly 
smaller white matter areas than the brain-injured animals that received the vehicle at 10 
days post-injury (p<0.05), but not at 15 days post-injury (p=0.93; Fig. A1.1J).  An 
interaction effect between group, sex and time (F2,23=5.19, p<0.05) indicated that sham-
injured males had significantly greater white matter areas than sham-injured females 
(p<0.001) at 15 days post-injury.  
 
A1.4.2 Effect of minocycline in the hippocampus and thalamus 
 
 At 10 and 15 days post-injury, brain-injured animals demonstrated increased 
numbers of microglia/macrophages and FJB reactivity in the hippocampus and thalamus 
compared to their sham-injured counterparts (Fig. A1.2). In the hippocampus, these 
alterations continued to be restricted to the dorsal aspect of the subiculum wherein a 3-
way ANOVA revealed an interaction effect between group and time (F2,23=23.01, 
p<0.001; Fig. A1.2A), but no effect of sex (F2,23=0.01, p=0.99); post-hoc analysis 
indicated that at 10 days post-injury, minocycline-treated, brain-injured animals had 
significantly fewer microglia/macrophages compared to their counterparts that received 
vehicle (p=0.05; Fig. A1.2A).  At 15 days post-injury, however, minocycline-treated 
308 
 
brain-injured animals had significantly more microglia/macrophages than brain-injured 
animals that received vehicle (p<0.001).  The proportion of activated 
microglia/macrophages in the subiculum also demonstrated an interaction effect between 
group and time (F2,23=3.93, p<0.05; Fig. A1.2B) with no effect of sex (F2,23=2.59, 
p=0.10).  There was, however, an increase in the proportion of activated 
microglia/macrophages in minocycline-treated, brain-injured animals compared to those 
that received vehicle animals at both times post-injury (p<0.001; Fig. A1.2B). 
Minocycline-treated animals also contained greater numbers of FJB(+) profiles at both 
time points post-injury compared to brain-injured animals that received vehicle 
(F1,15=18.15, p<0.001; Fig. A1.2C). Similarly, there was no effect of sex with regards to 
FJB in the subiculum (F1,15=0.57, p=0.46). 
In the thalamus, the regional distribution of activated microglia/macrophages and 
FJB reactive profiles at 10 and 15 days post-injury was similar to that observed at 3 and 7 
days post-injury (not shown). Analysis of the number of microglia/macrophages revealed 
an interaction effect between group and time (F2,23=16.26, p<0.001; Fig. A1.2D) with the 
post-hoc test indicating that brain-injured animals had significantly more 
microglia/macrophages compared to sham-injured animals at 10 days post-injury 
(p<0.001), but not at 15 days post-injury (vehicle group, p=0.48; minocycline group, 
p=0.59).  Sex did not influence the interaction between group and time (F2,23=1.05, 
p=0.37). When the population of activated microglia/macrophages was analyzed, an 
interaction effect between group and time (F2,23=53.46, p<0.001; Fig. A1.2E) was 
observed with a subsequent post-hoc analysis revealing that at 10 days post-injury, 
minocycline-treated, brain-injured animals had a higher percentage of activated cells 
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compared to brain-injured animals that received vehicle (p<0.001), and that this effect 
was lost at 15 days post-injury (p=0.39); there was no effect of sex (F2,23=2.50, p=0.10).  
Minocycline-treated, brain-injured animals exhibited significantly more FJB+ profiles in 
the thalamus at 10 days post-injury (p<0.001), but not at 15 days post-injury (p=0.88), 
compared to brain-injured animals that received vehicle (Fig. A1.2F) and this was 
unaffected by sex (F1,15=0.79, p=0.39).    
 
A1.4.3 Effect of minocycline on spatial learning and memory 
 
 As observed in study 1, brain-injured animals in study 2 were also 
impaired in their ability to learn and remember the location of the submerged platform 
(Fig. A1.3). Analysis of spatial learning patterns illustrated in Figure A1.3A revealed 
main effects of group (F2,105=9.16, p<0.001) and training day (F3,105=44.72, p<0.001), but 
no interaction (F6,105=1.41, p=0.22; Fig. A1.3A). Post-hoc analysis demonstrated that 
brain-injured animals took significantly longer to locate the hidden platform compared to 
sham-injured animals (p<0.01), and that there was no difference in latencies between the 
two brain-injured groups (p=0.65) indicating that prolonged minocycline treatment had 
no effect on injury-induced spatial learning deficits; there was no influence of sex of the 
animal on these observations (F6,105=0.62, p=0.71).  A 2-way ANOVA for the time spent 
in the platform zones revealed a main effect of group (F2,35=7.33, p<0.01) and an 
interaction effect between group and sex (F2,35=3.31, p<0.05). Post-hoc analysis indicated 
that sham-injured animals spent more time in the platform zones than brain-injured 
animals treated with minocycline (p<0.01), but not with vehicle (p=0.18); however, 
brain-injured minocycline-treated animals spent significantly less time in the platform 
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zone than their counterparts that received vehicle (p<0.05). Male sham-injured animals 
spent more time in the platform zone than their minocycline-treated, brain-injured 
counterparts (p=0.10), but this was not different from either brain-injured counterparts 
that received vehicle (p=0.10) or female sham-injured animals (p>0.05). Similarly, 
analysis of the time spent in the peripheral zone revealed a main effect of group 
(F2,35=6.24, p<0.01) and an interaction effect between group and sex (F2,35=4.15, p<0.05). 
Post-hoc analyses indicated that sham-injured animals spent significantly less time in the 
peripheral zone compared to brain-injured animals treated with minocycline (p<0.01), but 
not brain-injured animals that received vehicle (p=0.15; Fig. A1.3B); importantly, 
minocycline-treated brain-injured animals spent more time in the peripheral zones 
compared to their counterparts that received the vehicle (p=0.05).  Male sham-injured 
animals spent less time in the peripheral zone compared to males from both brain-injured 
groups (vehicle, p<0.05; minocycline, p<0.01) and female sham-injured animals 
(p<0.05). There was no group or sex effect in the visible platform trial, indicating that 
observed spatial learning deficits in brain-injured animals were not due to a problem in 
visual function (F2,35=0.08 ,p=0.92; Fig. A1.3B). Additionally, deficits in learning and 
retention were not due to deficits in motor function as indicated by a lack of differences 
between groups or sexes in swim speed (sham-injured: 26 ± 0.43 cm/s; brain-injured 
vehicle: 24 ± 0.81 cm/s; brain-injured minocycline: 24 ± 0.82 cm/s; F2,35=1.52, p=0.23).    
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A1.5 DISCUSSION 
 
Because sustained benefits with the short-term administration of minocycline 
were not observed (Chapter 4), the dosing was extended into the second week post-injury 
and terminated immediately prior to behavioral analyses. Dosing minocycline for 6 days 
decreased microglial/macrophage activation while simultaneously reducing the extent of 
HI-induced oligodendrocyte cell death and myelin loss (Carty et al., 2008, Wixey et al., 
2011) and neurodegeneration (Leonardo et al., 2008).  In contrast, a 7- or 14-day dosing 
paradigm that was effective in decreasing the number of activated microglia/macrophages 
did not affect brain trauma-induced neurogenesis at 2 or 6 weeks post-injury (Ng et al., 
2012). In a model of adult TBI, daily administration of minocycline for 7, 12 or 16 days 
reduced microglial/macrophage activation and reversed spatial learning and memory 
deficits at 8 weeks post-injury but did not attenuate lesion volume (Lam et al., 2013). In 
the current study, extended minocycline administration resulted in an increase in the 
number of activated microglia/macrophages in the multiple brain regions which was 
accompanied by an increase in the number of FJB(+) profiles. This observation is 
consistent with that in a mouse model of visual cortex ablation in which minocycline 
administration to injured metallothionein-deficient immature brain increased the number 
of activated microglia/macrophages while simultaneously increasing the extent of 
neuronal loss which was associated with a minocycline-induced upregulation of pro-
apoptotic genes (Potter et al., 2009). Moreover, the modest exacerbation of spatial 
memory deficits observed in the minocycline-treated animals may be related to increased 
neurodegeneration in the subiculum of the hippocampus, an area that has been implicated 
in spatial learning and memory function (O'Mara, 2005, O'Mara et al., 2009). In addition, 
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the increased numbers of activated microglia/macrophages may have led to pathologic 
increases in pro-inflammatory cytokines such as IL-1β which can inhibit both long-term 
potentiation and worsen acquisition and retention of a spatial memory task (Ross et al., 
2003, Trofimov et al., 2012).         
A major limitation to the current set of experiments, and in all of our work with 
minocycline, is that we’ve only used one dose- 45mg/kg.  This dose has shown efficacy 
in several models of brain injury (Buller et al., 2009, Hanlon et al., 2016), but it is 
possible that it is not an appropriate dose for extended use.  Neonatal mice that received a 
lower daily dose (22.5 mg/kg) of minocycline for 6 days showed improvement in white 
matter pathology following hypoxia-ischemia (Carty et al., 2008), raising the possibility 
the 45 mg/kg dose for 9 days may be too high.  Irrespective of potential dosing 
confounds, the results of the present study suggest that the use of minocycline and 
suppression of the acute microglial/macrophage response following injury to the 
immature brain may not be viable therapeutic strategies.  
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A1.6 FIGURE LEGENDS 
 
Figure A1.1 Effect of extended minocycline administration in the cortex and 
subcortical white matter tracts. 
Graphs illustrate counts of Iba1(+) cells (A), the proportion of activated Iba1(+) 
cells (B), and counts of FJB(+) profiles (C) in the cortex, area of Iba1 immunoreactivity 
(D), and the number of FJB(+) profiles (E) in the subcortical white matter. Inset images 
in panels A and B are representative of Iba1 (+) cells from sham-injured and brain-
injured animals, respectively.  Representative photomicrographs of Nissl-myelin stained 
sections from sham-injured (F), brain-injured injected with vehicle (G), and brain-
injured, minocycline-treated animals (H) at 10 days post-injury. Graphs illustrate the area 
of the cortex (I) and the underlying white matter (J). The sex of the animals affected the 
values for FJB profile counts (C) but did not affect the quantification in other outcomes 
and areas. *, p ≤ 0.05 compared to sham-injured values; #, p ≤ 0.05 compared to brain-
injured animals receiving vehicle; @, p ≤ 0.05 compared to corresponding males. HPF, 
high power field. Scale bar for insets in panels A and B in panel A=10µm; scale bar for 
panels F-H in panel H=500µm. 
 
Figure A1.2 Effect of extended minocycline administration in the hippocampus and 
thalamus.  
  Graphs illustrate counts of Iba1(+) (A, D), the proportion of activated Iba1(+) 
cells (B,E), and counts of FJB(+) profiles (C,F) in the hippocampus (A-C) and the 
thalamus (D-F). Sex had no influence on outcomes so values for male and female rats 
314 
 
were combined for graphical representation. *, p ≤ 0.05 compared to sham-injured 
values; #,p ≤ 0.05 compared to brain-injured animals injected with vehicle. HPF, high 
power field. 
 
Figure A1.3 Effect of extended minocycline administration on injury-induced spatial 
learning and memory deficits. 
(A) Latency to the platform on each day represents the average of 4 trials.  
(B) Average times spent in the area surrounding the platform location and the periphery 
of the maze during the spatial retention (probe) trial. Also included is the time to the 
visible platform. Sex had no effect on spatial learning and memory outcomes so values 
for male and female rats were combined for graphical representation. *, p ≤ 0.05 
compared to sham-injured animals; #, p ≤ 0.05 compared to brain-injured animals 
injected with vehicle. 
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A1.7 FIGURES 
 
Figure A1.1 Effect of extended minocycline administration in the cortex and 
subcortical white matter tracts. 
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Figure A1.2 Effect of extended minocycline administration in the hippocampus and 
thalamus.  
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Figure A1.3 Effect of extended minocycline administration on injury-induced spatial 
learning and memory deficits. 
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APPENDIX 2: 
 
Minocycline transiently reduces microglia/macrophage activation but exacerbates 
cognitive deficits following repetitive traumatic brain injury in the neonate rat 
Hanlon, L.A., Huh, J.W., and Raghupathi, R. (2016) 
Journal of neuropathology and experimental neurology 75:214-226. 
 
 The following work was conducted as my original rotation project in the 
Raghupathi lab and describes microglial/macrophage activaiton and the effects of 
minocycline in a neonatal rat model of repetitive traumatic brain injury. This was 
published in 2016 in the Journal of Neuropathology and Experimental Neurology.  
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A2.1 ABSTRACT 
 
 Elevated microglial/macrophage-associated biomarkers in the cerebrospinal fluid 
of infant victims of abusive head trauma (AHT) suggest that these cells play a role in the 
pathophysiology of the injury.  In this model of AHT in the 11-day-old rat, three impacts 
(24 hours apart) resulted in microglial/macrophage reactivity, traumatic axonal injury, 
neuronal degeneration, cortical and white matter atrophy, and spatial learning and 
memory deficits.  In models of neonatal hypoxic ischemia, the antibiotic minocycline has 
been effective in decreasing injury-induced microglial/macrophage activation while 
simultaneously attenuating cellular and functional deficits, but the potential for this 
compound to rescue deficits after impact-based trauma to the immature brain remains 
unexplored.  Acute minocycline administration in this model of AHT decreased 
microglial/macrophage reactivity in the corpus callosum of brain-injured animals at 3 
days post-injury, but this effect was lost by 7 days post-injury.  Additionally, minocycline 
treatment had no effect on traumatic axonal injury, neurodegeneration, tissue atrophy, or 
spatial learning deficits.  Interestingly, minocycline-treated animals demonstrated 
exacerbated injury-induced spatial memory deficits.  Our results contradict previous 
findings in other models of brain injury and suggest that minocycline is ineffective in 
reducing microglial/macrophage activation and ameliorating injury-induced deficits 
following repetitive neonatal traumatic brain injury.    
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A2.2 INTRODUCTION 
 
 Inflicted injury or abuse is one of the leading causes of traumatic brain 
injury (TBI) in infants under 1 year of age (Bishop, 2006).  The annual incidence for 
abusive head trauma (AHT) in this age group is estimated to be in the range of 20-30 
cases per every 100,000 patients (SE Parks, 2012) and survivors of early childhood TBI 
often develop cognitive and behavioral deficits well into adulthood (Bonnier et al., 1995, 
Duhaime et al., 1996, Barlow et al., 2005, Ewing-Cobbs et al., 2006). Whereas subdural 
hemorrhages are particularly indicative of AHT (Reece and Sege, 2000, Myhre et al., 
2007, Matschke et al., 2009), subarachnoid hemorrhage, epidural hematomas, edema, and 
contusions are also prevalent in injured infant brains (Dias et al., 1998). Importantly, the 
presence of chronic subdural hematomas, cerebral atrophy, and ex vacuo 
ventriculomegaly suggests that these children are incurring multiple TBIs as a result of 
repeated instances of abuse (Dias et al., 1998, Jenny et al., 1999, Ewing-Cobbs et al., 
2000). 
The initial models of abusive head trauma utilized unrestrained shaking or rapid 
rotations of the head (Smith et al., 1998, Bonnier et al., 2002, Raghupathi et al., 2004, 
Friess et al., 2009, Finnie et al., 2012).  Repetitive shaking in lambs and neonate rodents 
resulted in axonal injury, glial reactivity, retinal tearing, and hemorrhage (Smith et al., 
1998, Bonnier et al., 2002, Finnie et al., 2012).  In piglets, two rotational injuries 
exacerbated traumatic axonal injury and resulted in cognitive deficits (Raghupathi et al., 
2004, Friess et al., 2009).  With the recognition of impact as an important component of 
AHT (Christian et al., 2009), impact-based models of pediatric have been developed.  In 
11-day-old rat pups, 2 impacts to the intact skull exacerbated traumatic axonal injury, and 
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astrogliosis compared to a single impact, whereas 3 impacts accelerated traumatic axonal 
injury and resulted in ex vacuo ventriculomegaly (Huh et al., 2007).In the juvenile rat 
(35-days-old), two impacts exacerbated axonal injury, astrocytic reactivity, and cognitive 
deficits (Prins et al., 2010).  Collectively, these data underscore the importance of the 
utility of multiple animal models of AHT.  
  A number of studies have evaluated biomarkers in the cerebrospinal fluid of 
infants and children subjected to inflicted or accidental TBI (Papa et al., 2013). 
Compared to accidental TBI, victims of AHT have increased levels of 
macrophage/microglial-associated proteins and neurochemicals such as interleukins-4 
and -12 and quinolinic acid (Amick et al., 2001, Berger et al., 2004).  Few studies have 
evaluated microglia/macrophage activation in pediatric TBI models. In a neonatal mouse 
model of TBI, microglial reactivity was present in the same areas as degenerating 
neurons (Tong et al., 2002).  In contrast, the microglial/macrophage response has been 
extensively documented following hypoxic-ischemic brain injury in the neonate rat 
(McRae et al., 1995, Ivacko et al., 1996, Cowell et al., 2002); importantly, the 
microglial/macrophage response in 9-day-old animals was increased compared to animals 
that were injured on post-natal day 30 (Ferrazzano et al., 2013).  The neuroinflammatory 
cascade and microglial reactivity have, therefore, been identified as targets for 
therapeutic action in both adult and pediatric TBI (Potts et al., 2006, Loane and Byrnes, 
2010).During development, microglia play a crucial role in removing apoptotic cells and 
dysfunctional synapses so it is not uncommon to observe activated microglia/macrophage 
profiles in an uninjured neonate animal (Paolicelli et al., 2011, Pont-Lezica et al., 2011). 
Limiting microglial/macrophage activation in a developing injured brain needs to be 
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carefully evaluated because it may negatively impact the normal developmental functions 
of microglia.  
Minocycline is a broad-spectrum tetracycline antibiotic that is effective in 
reducing brain damage in multiple models of brain injury across the age spectrum (Elewa 
et al., 2006, Plane et al., 2010).  It reduces microglial activation and proliferation thereby 
attenuating injury-induced deficits in adult models of TBI (Sanchez Mejia et al., 2001, 
Homsi et al., 2010, Kovesdi et al., 2012).  In rat models of neonatal hypoxic-ischemia 
(HI), minocycline also decreased microglial activation and subsequently rescued injury-
induced tissue atrophy, myelination deficits, oligodendrocyte cell death, and locomotor 
activity deficits (Arvin et al., 2002, Cai et al., 2006, Fan et al., 2006).  However, the 
efficacy of minocycline in neonate brain injury may be limited. Thus, minocycline 
administration was not effective in rescuing injury-induced cell death in brains that were 
more severely injured (Cai et al., 2006).  In a model of focal cerebral ischemia in the 
neonatal rat brain, minocycline was only able to decrease injury volume 24 hours after 
the insult, but had no effect 7 days after injury, indicative of the transient nature of the 
neuroprotection (Fox et al., 2005).  In a mouse model of neonatal hypoxic-ischemia, 
minocycline exacerbated injury-induced tissue damage (Tsuji et al., 2004).  It must be 
noted that most of these studies used a single dose and therefore the limited efficacy may 
be attributed to an incorrect dose/dosing paradigm. To date, there have been no studies 
specifically evaluating the efficacy of minocycline in a model of pediatric TBI. The 
present study sought to test the hypothesis that minocycline administration following 
repetitive TBI in the neonate rat will ameliorate post-traumatic cellular pathology and 
spatial learning deficits by reducing microglial/macrophage reactivity.  
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A2.3 MATERIALS AND METHODS 
 
A2.3.1 Brain Injuries and Drug Administration 
 
Eleven-day-old male and female Sprague-Dawley rat pups (Charles River, 
Wilmington MA) were injured (N=43) using an electrically-driven impact device (eCCI, 
Custom Design and Fabrication, Richmond VA) as previously described (Huh et al., 
2007).  Injuries (3 impacts spaced 24 hours apart) were conducted using a metal tip 
impactor centered over the exposed midline suture at a depth of 2mm and a velocity of 5 
m/s. As an analgesic, carprofen (0.1mg/kg, Rimadyl™, Pfizer Animal Health, New York 
NY) was administered subcutaneously after each impact.  Immediately following the 
third impact, animals received a 45mg/kg dose of minocycline hydrochloride (N=22, 
Sigma, St. Louis MO) or phosphate buffered saline (N=21, PBS, 0.2ml/kg) vehicle via an 
intraperitoneal (i.p.) injection.  Animals subsequently received injections every 12 hours 
for 3 days for a total of 6 injections (45 mg/kg/injection or 0.2 ml/kg/injection).  This 
dose was based on the efficacy in models of hypoxic ischemia and stroke in neonate 
animals (Arvin et al., 2002, Fox et al., 2005, Cai et al., 2006, Fan et al., 2006).  The 
dosing paradigm reflected the short half-life of minocycline in rodents (2-3 hours) (Andes 
and Craig, 2002) and has been successful in reducing brain damage following trauma 
and/or stroke (Sanchez Mejia et al., 2001, Bye et al., 2007, Plane et al., 2010, Xue et al., 
2010).  Sham-injured animals (N=26) received incisions under anesthesia on all 3 days, 
followed by subcutaneous injections of Rimadyl™.  Sham-inujured animals also 
receivedeither vehicle (N=12) or minocycline (N=14) injections.  
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A2.3.2 Tissue Collection and Preparation for Immunohistochemistry and Histology 
 
 At 3, 7, and 21 days after the third injury, separate groups of brain-injured (3 
days: 5 vehicle, 5 minocycline; 7 days: 5 vehicle, 6 minocycline; 21 days: 11 vehicle, 11 
minocycline) and sham-injured animals (3 days: 3 vehicle, 4 minocycline; 7 days: 3 
vehicle, 4 minocycline; 21 days: 6 vehicle, 6 minocycline) were euthanized and the 
brains were processed for histology (Huh et al., 2007). Twelve sets of coronal sections 
(45μm thick, 12-14 sections per set) were collected for each animal.  Adjacent sets of 
sections were mounted on gelatin-coated slides and stained for Fluoro-Jade B (FJB) (Huh 
et al., 2008) or Nissl-myelin (2% Cresyl Violet and 0.2% Cyanine R).  Additional 
separate sets of sections were evaluated for microglia/macrophages using antibodies for 
anti-ionized calcium-binding adaptor molecule 1 (Iba1, Wako, Richmond, VA, 1:20,000) 
and CD68 (Clone ED1, AbD Serotech, Raleigh, NC, 1:500), and traumatic axonal injury 
using a polyclonal antibody to the C-terminal end of amyloid precursor protein (APP, 
Zymed, San Francisco, CA, 1:2,000).  For anti-APP immunohistochemistry, antigen 
retrieval was executed by incubation with 10mM sodium citrate (pH 6.5) in a 60ºC water 
bath for 20 minutes.  Primary antibody binding was detected using biotinylated donkey 
anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA, 1:1000 for APP and 1:500 
for Iba1) or biotinylated donkey anti-mouse IgG (Jackson ImmunoResearch, West Grove, 
PA, 1:500).  Antibody binding was visualized using the ABC Elite System with 
diaminobenzidine (Vector Laboratories, Burlingame, CA).   
 All quantifications were performed in 3 non-adjacent sections between 2 and 5 
mm posterior to bregma.  Quantification of pathology in the cortex and corpus callosum 
included the area between the cingula and extended to approximately 2mm on either side 
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of the cingula.  Analysis in the thalamus was limited to the regions of staining 
(dorsolateral thalamus and lateral geniculate nucleus). FJB(+) profiles were manually 
counted in the cortex (18 high-powered fields, HPF) and thalamus (12 HPF) of brain-
injured animals and presented as an average number of profiles per HPF.  Analysis of 
APP-labeled sections was conducted using the grid analysis as previously described 
(DiLeonardi et al., 2009).  Measurements of the areas of the corpus callosum and cortex 
were taken from Nissl-myelin stained sections as previously described (Creed et al., 
2011).  Because of the density of Iba1 and ED1 labeling, clear cellular bodies could not 
be distinguished in order to conduct reliable cell counting.  For this reason, we used a 
thresholding approach from digitized images as described by Donnelly et al. (Donnelly et 
al., 2009) and the labeled area was divided by the corresponding total area measured in 
the Nissl-myelin stained sections.  For the thalamus, the labeled area was divided by the 
total area of the analyzed image (10x).  The hippocampus was analyzed between 2 and 
5mm posterior to bregma. 
 
A2.3.3 Spatial Learning and Memory Assessment 
 
 Spatial learning was assessed on days 7-10 after the third injury (N=12 sham-
injured, 11 brain-injured vehicle, 11 brain-injured minocycline) as previously described 
(Huh et al., 2008); the inter-trial interval was 15 minutes for each rat.  On day 11 post-
injury, animals were tested for retention of the location of the platform (spatial memory) 
in 2 probe trials of 60 sec duration each and the times spent in the zone closest to the 
former location of the platform and the periphery of the pool was measured.  Following 
the probe trials, animals were subjected to a visible platform trial in which the top inch of 
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the platform was exposed and a flag was adhered to the top of the platform.  These data 
were analyzed in terms of latency to the platform in order to detect if the animals had any 
type of visual deficits. Visual deficits have been observed following focal and diffuse 
trauma to the neonate animal (Huh and Raghupathi, 2007, Raghupathi and Huh, 2007). 
 
A2.3.4 Statistical Analysis 
 
 All data are presented as mean ± standard deviation. Vehicle-treated sham-injured 
animals and minocycline-treated sham-injured animals showed no differences on any 
analyses and were therefore combined into one group.  All statistics were performed 
using Statistica 7 (StatSoft, Tulsa OK). Areas of corpus callosum and cortex, and the 
percent area of Iba1 or ED1 labeling were evaluated using a factorial analysis of variance 
(ANOVA) with injury status (sham-injured, brain injured vehicle-treated, and brain 
injured minocycline-treated) and time after injury (3 days, 7 days, and 21 days) used for 
between-subject comparison.  Analysis of APP and FJB labeling were compared using 
independent samples t-tests.  For analyses of the spatial learning, a repeated measures 
ANOVA was used to compare the latencies to the platform over 4 learning days between 
the 3 injury groups.  A one-way ANOVA was used to compare the times spent in the 
platform and peripheral zones during the probe trials and the latencies in the visible 
platform trial.  Animals that did not find the visible platform were excluded from all 
statistical analyses of spatial learning, probe, and visible platform data (1/12 sham-
injured, 4/11 brain-injured vehicle, 4/11 brain-injured minocycline). When appropriate, 
post-hoc analyses were performed using the Newman-Keuls test and a value of p ≤ 0.05 
was considered significant for all analyses.          
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A2.4 RESULTS 
  
A2.4.1 Minocycline does not affect the extent of Iba1 immunoreactivity  
 
Microglia/macrophages in the corpus callosum of sham-injured animals appeared 
flat with elongated cell bodies and long processes indicative of a resting phenotype (Fig. 
A2.1A).  Repetitive TBI resulted in activation of microglia/macrophages as evident by an 
increase in the extent of Iba1 immunoreactivity and an enlargement of the cell bodies 
(Fig. A2.1B,C).  Increased Iba1 labeling was observed between 0.8 and 6 mm posterior to 
bregma, extended 2 mm lateral to each cingulum, and was present throughout the 
thickness of the corpus callosum.  Quantification of the area of staining revealed an 
injury effect [F2,42=34.66, p<0.001], a time effect [F2,42=24.63, p<0.001], and an 
interaction effect between time and injury [F4,42=5.36, p<0.01].  Post hoc analysis 
revealed that brain-injured animals had significantly increased areas of staining compared 
to the corresponding sham-injured groups at both 3 and 7 days, but not at 21 days (Fig. 
A2.1J; p<0.001).  Additionally, brain-injured vehicle-treated animals demonstrated 
decreased areas of staining at 7 (p<0.001) and 21 days (p<0.001) compared to 3 days 
post-injury, indicating that microglial/macrophage activation in the white matter 
decreases over time.  There was no effect of minocycline treatment at any time post-
injury.  
Microglia/macrophages in the cortex of sham-injured animals appeared rounded, 
but still resembled the resting phenotype with clearly visible processes (Fig. A2.1D).  In 
brain-injured animals, regardless of treatment, there was a characteristic pattern of dense 
immunoreactivity (Fig. A2.1E,F) that extended from the cingulum toward the midline 
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encompassing the agranular retrosplenial cortex, parts of the frontal cortex (rostral), and 
parts of the medial occipital cortex (caudal); increased immunoreactivity in the cortex 
was observed between 2 and 6 mm posterior to bregma.  Although quantification of the 
area of labeling revealed an effect of injury [F2,42=4.25, p=0.02], post hoc analysis did not 
reveal any significant differences between sham- and brain-injured groups (Fig. A2.1K). 
However, an overall effect of time post-injury was observed [F2,42=21.21, p<0.001] and 
the post hoc analysis revealed that the area of labeling was significantly greater at 3 days 
compared to 7 (p<0.001) and 21 days post-injury (p<0.001), and at 7 days compared to 
21 days following injury (p<0.05). Minocycline treatment had no effect on Iba1 labeling 
in the cortex at any time post-injury.     
Similar to the cortex, microglia/macrophages in the thalamus of sham-injured 
animals predominantly exhibited a resting phenotype (Fig. A2.1G). Iba1 
immunoreactivity was increased in both brain-injured groups compared to the sham-
injured group (Fig. A2.1H,I). Microglial/macrophage reactivity was restricted to lateral 
aspects including the laterodorsal nucleus (rostral) and parts of the lateral geniculate 
nucleus (caudal) and was only observed up to 7 days post-injury.  Quantification revealed 
an effect of injury [F2,29=29.70, p<0.001] and time [F1,29=35.25, p<0.001, Fig. A2.1L].  
Post hoc analysis of the injury effect revealed that both groups of brain-injured animals 
showed significantly greater areas of thalamic Iba1 labeling when compared to sham-
injured animals (Fig. A2.1L; p<0.001).  Minocycline treatment did not affect this injury-
induced increase in Iba1 labeling in the thalamus.  No increase in Iba1 staining was 
observed in the hippocampus of brain-injured animals (data not shown).    
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A2.4.2 Treatment with minocycline decreases ED1 labeling in the corpus callosum. 
  
ED1 labeling was minimally observed in the corpus callosum of sham-injured 
animals (Fig. A2.2A), but was much more extensive in the brain-injured animals (Fig. 
A2.2B,C).  ED1-positive cells took on a rounded amoeboid morphology with very few, if 
any, visible processes.  The topography and pattern of ED1 immunoreactivity in this 
region was similar to the pattern previously described for Iba1 staining in the corpus 
callosum.  Quantification of the area of staining (Fig. A2.2G) revealed an injury effect 
[F2,35=24.85, p<0.001], a time effect [F2,35=17.73, p<0.001], and an interaction effect 
[F4,35 =4.98, p<0.01].  Post hoc analysis of the injury effect revealed that the ED1 
immunoreactivity was significantly increased in both brain-injured groups compared to 
the sham-injured group (p<0.001).  Post hoc analysis of the time effect revealed that 
injured animals had significantly larger areas of staining at both 3 (vehicle, p<0.001; 
minocycline, p<0.001) and 7 days (vehicle, p<0.05; minocycline, p<0.01) post-injury, but 
this effect was lost at 21 days. Interestingly, a treatment effect was observed at 3 days 
post-injury with minocycline-treated brain-injured animals exhibiting a mild decrease in 
the area of ED1 labeling compared to vehicle-treated brain-injured animals (p=0.05).   
 In sham-injured animals, ED1 staining was present in the cortex around what 
appeared to be blood vessels (Fig. A2.2D). In brain-injured animals, ED1-labeled cells 
were rounded and had very few visible processes (Fig. A2.2E,F).  Quantitative analysis 
of the area of immunoreactivity (Fig. A2.2H) revealed an injury effect [F2,35=8.57, 
p<0.001], a time effect [F2,35=16.44, p<0.001], and an interaction effect between injury 
and time [F4,35=2.76, p<0.05].  Post hoc analysis of the injury effect indicated that brain-
injured animals, irrespective of treatment, possessed significantly larger areas of staining 
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compared to sham-injured animals (p<0.01).  Post hoc analysis of the time effect revealed 
that labeling was significantly decreased at 7 (p<0.001) and 21 days (p<0.001) compared 
to 3 days post-injury, and an additional significant decrease in area stained was observed 
between 7 and 21 days post-injury (p<0.05).  The post hoc analysis for the interaction 
effect revealed that both groups of injured animals were different from the corresponding 
sham-injured group at 3 days post-injury (Fig. A2.2H; vehicle, p<0.01; minocycline, 
p<0.001), but no such intragroup differences were found at 7 or 21 days post-injury; there 
was no effect of treatment at any time point.  In the thalamus, ED1 labeling was only 
present in the laterodorsal nucleus 2.0 mm posterior to bregma at 3 days post-injury (data 
not shown).  There was also no discernible ED1 labeling in the hippocampus.   
 
A2.4.3 Minocycline does not affect traumatic axonal injury. 
 
 There was no observable APP labeling in sham-injured animals (Fig. A2.3A).  
Intra-axonal APP labeling in the white matter of brain-injured animals primarily appeared 
as terminal bulbs, suggesting that the axons had disconnected and/or retracted (Fig. 
A2.3B,C).   These APP-positive profiles were present in the cingulum and dorsal portions 
of the corpus callosum in rostral sections (0.5 mm to 2 mm posterior to bregma) and 
through both dorsal and ventral portions of the fiber bundle more caudally (2 mm to 5.5 
mm)  indicating that APP labeling was increased under the impact site.  Axonal APP 
labeling was present in the corpus callosum at 3 days post-injury and was not visible at 7 
days post-injury.  Quantitative grid analyses revealed no significant difference in the 
extent of APP labeling between brain-injured vehicle-treated and minocycline-treated 
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animals (Fig. A2.3D). No APP-positive profiles were observed in the thalamus at any 
time post-injury (data not shown).   
 
A2.4.4 Minocycline does not affect neurodegeneration. 
 
 In the corpus callosum, FJB(+) profiles were punctate and diffuse, suggestive of 
axonal degeneration (Fig. A2.4A,B).    Labeling in the corpus callosum was extensive at 
3 days post-injury (Fig. A2.4A,B) and much less at the 7 and 21 day time points (not 
shown).  Minocycline appeared to have no effect on the extent of labeling when 
compared to vehicle-treated injured animals (Fig. A2.4A,B).  FJB(+) profiles in the 
cortex exhibited neuronal morphology (Fig. A2.4D,E) and were present in the agranular 
retrosplenial cortex, the frontal cortex (rostral) and the occipital cortex (caudal).  Labeled 
profiles were visible at 3 days after injury (Fig. A2.4D,E), but not at 7 or 21 days post-
injury (data not shown).  However, the number of FJB(+) profiles in the cortex did not 
differ between vehicle- and minocycline-treated brain-treated injured animals (Fig. 
A2.4I).  FJB labeling in the injured thalamus exhibited a mix of diffuse, punctate labeling 
(axonal) and cellular labeling (Fig. A2.4G,H).  FJB(+) profiles were present in the 
laterodorsal thalamus (rostral) and the lateral geniculate nucleus (caudal) up to 21 days.  
Treatment with minocycline did not affect the number of FJB(+) profiles at 3 days post-
injury (Fig. A2.4I) or at later times (data not shown). Labeled profiles were not present in 
the hippocampus (data not shown).  No FJB(+) profiles were visible in any region of the 
sham-injured brain (Fig. A2.4C,F). 
 
A2.4.5 Minocycline does not affect tissue loss. 
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Repeated impacts to the skull of the 11-day-old rat did not result in any overt tears 
in the white or grey matter and there was no evidence of lesion or cavitation (Fig. A2.5).  
Area measurement of the subcortical white matter tract between the two cingula revealed 
an injury effect [F2,47=218.04, p<0.001] and post hoc analysis indicated that brain-injured 
animals had significantly decreased white matter areas compared to sham-injured animals 
(p<0.001).  There was also an interaction effect between injury and time [F4,47=8.88, 
p<0.01] and the post hoc analysis revealed that brain-injured animals within each time 
point had significantly decreased areas compared to their corresponding sham-injured 
animals (Fig. A2.5J; p<0.001).  There was no difference between the vehicle-treated and 
minocycline-treated brain-injured groups at any time point.  Cortical area analysis at 3, 7, 
and 21 days post-injury revealed a significant effect of injury [F2,47=6.20, p<0.01] and 
time [F2,47=8.22, p<0.001] (Fig. A2.5K).  Post hoc analysis of the injury effect revealed 
that brain-injured animals had significantly lower cortical areas than sham-injured 
animals (vehicle, p<0.01; minocycline, p<0.05), but there was no difference between 
vehicle- and minocycline-treated brain-injured animals.  Analysis of the time effect 
revealed that cortical area was significantly increased at 21 days compared to 3 (p<0.01) 
and 7 (p<0.05) days which may be a consequence of age.   
 
A 2.4.6 Minocycline exacerbates spatial retention deficits. 
 
Brain-injured animals had significantly longer latencies to find the hidden 
platform in the spatial learning task compared to sham-injured animals in the second 
week following injury (Fig. A2.6A).  Analysis of the latencies revealed an injury effect 
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[F2,66=20.13, p<0.001], a time effect (learning days) [F3,66=15.24, p<0.001], and an 
interaction effect [F6,66=2.86, p<0.05].  Post hoc analysis of the injury effect revealed that 
both vehicle- and minocycline-treated brain-injured animals displayed increased escape 
latencies when compared to the latencies of sham-injured animals (p<0.001).  Post hoc 
analysis of the interaction effect confirmed this injury effect and revealed that the 
latencies of vehicle-treated brain-injured animals did not differ from the latencies of 
minocycline-treated brain-injured animals.  In the probe trials, brain-injured animals 
spent significantly more time in the periphery of the maze [F2,22=9.83, p<0.001] and 
significantly less time in the zone corresponding to the platform location [F2,22=6.44, 
p<0.01] (Fig. A2.6B).  Post hoc analysis revealed that there was no difference in time 
spent in either zone between sham-injured animals and vehicle-treated brain-injured 
animals.  In contrast, brain-injured minocycline-treated animals spent significantly more 
time in the peripheral zone (p<0.001) and less time in the platform zone (p<0.01) than the 
sham-injured animals.  Additionally, brain-injured minocycline-treated animals spent 
more time in the peripheral zone than brain-injured vehicle-treated animals (p<0.05).  
During the visible platform trial, an injury effect was observed [F2,22=4.01, p<003] and 
post hoc analysis indicated that both vehicle-treated brain-injured animals (p=0.05) and 
minocycline-treated brain-injured animals (p=0.06) had difficulty locating the exposed 
platform compared to the sham-injured animals, suggestive of a visual deficit.  Despite 
this deficit, it must be noted that brain-injured animals were able to find the hidden 
platform (time effect vide supra) and demonstrated searching behavior through the 4 days 
of learning and during the probe trial.   
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A2.5 DISCUSSION 
 
The results of the present study demonstrate that minocycline, administered to 
neonate rats subjected to repetitive brain trauma, reduced the extent of ED1-labeled 
microglia/macrophages in the corpus callosum but had no effect on the extent of 
traumatic axonal injury or axonal degeneration. This effect was observed immediately 
after the cessation of minocycline treatment and did not extend to the 7 or 21 day time 
points. Furthermore, the extent of microglia/macrophage activation in the cortex and 
thalamus and the associated neurodegeneration was unaffected by minocycline treatment. 
Whereas injury-induced deficits in spatial learning were not reversed, minocycline 
treatment exacerbated the spatial retention deficits observed in brain-injured animals. 
Collectively, these data (Table 1) suggest that minocycline may not be an effective 
therapeutic intervention for neonate animals in the acute period following repetitive TBI. 
Whereas minocycline has never been used in a rodent model of neonatal TBI, 
systemic administration of minocycline has been effective in reducing injury-induced 
increases in microglial/macrophage activation in models of adult TBI and spinal cord 
injury (SCI), and neonatal hypoxic-ischemia (HI) (Cai et al., 2006, Fan et al., 2006, 
Festoff et al., 2006, Bye et al., 2007, Carty et al., 2008, Ng et al., 2012). Using a 
combination of immunohistochemistry with antibodies to proteins such as Iba1, F4/80 
and CD11b or lectin histochemistry and morphology (resting, intermediately-reactive and 
amoeboid), minocycline administration was observed to reduce the number of activated 
microglia/macrophages following HI in the neonate rat (Cai et al., 2006, Fan et al., 2006, 
Carty et al., 2008, Leonardo et al., 2008, Tang et al., 2010) or closed head injury in the 
adult mouse (Bye et al., 2007, Ng et al., 2012); interestingly, minocycline only decreased 
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the number of activated cells and did not affect the number of intermediately reactive 
cells following TBI (Bye et al., 2007). Because of the extensive and robust nature of 
microglial/macrophage activation observed in the brain-injured animals in the present 
study, cell counts could not be performed. Instead, an alternate approach based on a 
threshold of staining intensity was taken which encompasses changes in cell number, 
morphology (cells becoming larger) and alterations in the expression of the protein/cell 
surface marker (Donnelly et al., 2009). Whereas this approach has been successful in 
determining an effect of minocycline on injury-induced microglia/macrophage activation 
using Iba-1 immunohistochemisty (Ng et al., 2012), the lack of an overall effect using 
this approach in the present may be indicative of the relative insensitivity of the 
technique.      
Alternatively, the antibody to CD68 (ED1) selectively labels activated (amoeboid) 
cells by binding to a glycosylated protein that is present in the membranes of phagosomes 
and lysosomes which are indicative of a phagocytic phenotype (Damoiseaux et al., 1994). 
Minocycline has been reported to reduce ED1-labeled cells in the cortex and white matter 
tracts following HI in the neonatal rat (Cai et al., 2006, Lechpammer et al., 2008). 
Similarly, activated microglia/macrophages labeled with human alveolar macrophage-56 
(HAM-56) were reduced following minocycline treatment following SCI in the adult rat 
(Festoff et al., 2006).  In the present study, the decrease in the area of ED1 
immunoreactivity following minocycline treatment was limited to the corpus callosum 
and did not extend to the cortex.  Similar regional differences in acute minocycline 
treatment after neonatal HI were observed wherein the numbers of Iba1-labeled activated 
microglia/macrophages were decreased in the thalamus and the dorsal raphé, but not the 
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frontal cortex (Wixey et al., 2011).  Although the majority of preclinical studies indicate 
that acute treatment with minocycline does reduce microglia/macrophage activation, one 
study did demonstrate that minocycline was ineffective in reducing the number of ED1-
labeled activated microglia/macrophages in the cortex after stroke in the neonate rat (Fox 
et al., 2005).  
In the current study, minocycline treatment did not affect injury-induced 
neurodegeneration and/or tissue atrophy in the cortex or thalamus. In part, this may 
explain the visual deficit (which was not affected by minocycline treatment) observed in 
the repetitively brain-injured animals in the current study; FJB(+) neurons were observed 
in the lateral geniculate nucleus of the thalamus and the occipital cortex, areas that are 
directly involved in the visual pathway (Peters and Feldman, 1976). In addition, damage 
to the optic nerve which has been reported following repetitive TBI in adult mice 
(Tzekov et al., 2014), may underlie the visual deficit and warrants further investigation. 
In contrast, minocycline has demonstrated success in reducing lesion area in the cortex in 
models of adult TBI, juvenile asphyxia and neonatal stroke (Sanchez Mejia et al., 2001, 
Arvin et al., 2002, Bye et al., 2007, Homsi et al., 2009, Tang et al., 2010). The success of 
minocycline in reducing cellular degeneration is mixed with one study in a model of adult 
TBI reporting that the effect of minocycline was transient (Bye et al., 2007) and another 
wherein treatment with minocycline after neonatal HI in the mouse resulted in an 
increase in tissue loss (Tsuji et al., 2004). Minocycline has been reported to limit 
apoptotic cell death in animal models of several neurodegenerative diseases (Zhu et al., 
2002, Wang et al., 2003), SCI (Teng et al., 2004), cardiac arrest (Tang et al., 2010) and 
neonatal HI (Cai et al., 2006, Fan et al., 2006, Carty et al., 2008) in addition to decreasing 
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levels of activated caspase-3 (Arvin et al., 2002).  In contrast, minocycline was not 
effective in reducing the number of apoptotic cells following TBI in the adult mouse (Bye 
et al., 2007). Despite the attenuation of activated microglial/macrophage reactivity in the 
corpus callosum, minocycline had no effect on axonal injury and degeneration or white 
matter tissue loss in the brain-injured animals. By contrast, in neonatal rodent HI brain 
injury, minocycline attenuated both microglial/macrophage reactivity and the loss of 
myelin and white matter volume (Cai et al., 2006, Fan et al., 2006, Carty et al., 2008, 
Lechpammer et al., 2008).  Following TBI in adult mice, acute administration of 
minocycline was associated with a reduction in microglial activation which accompanied 
an attenuation of tissue loss in the corpus callosum, but had no effect on trauma-induced 
increase in axonal injury (Homsi et al., 2010, Siopi et al., 2011).  Although microglial 
activation shares a spatiotemporal relationship with axonal injury/degeneration, 
ultrastructural or functional analyses do not demonstrate a clear cause-and-effect 
mechanism in adult rodent TBI models (Kelley et al., 2007, Bennett and Brody, 2014).  
Given the absence of any overt neuroprotective effects, it is not surprising that 
post-injury minocycline treatment was ineffective in reducing spatial learning and 
retention deficits.  Brain-injured animals, irrespective of treatment, did not learn the task 
efficiently and therefore had difficulty in the consolidation phase as reflected in the 
deficit in the probe trial.  In a model of central fluid percussion injury in the adult rat, 
spatial learning and memory deficits were observed in the absence of overt pathology in 
the hippocampus (Lyeth et al., 1990).  These deficits, however, were associated with 
alterations in long term potentiation (LTP) in the hippocampus (Miyazaki et al., 1992).  
While there was no overt pathology present in the hippocampus, other brain regions that 
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are thought to be involved in spatial learning and memory were affected by the injury.  In 
the present study, brain-injured animals demonstrated neurodegeneration in the 
retrosplenial cortex (RSC) and the laterodorsal nucleus of the thalamus (LDN); lesions in 
these areas result in spatial learning deficits in the Morris water maze task (Harker and 
Whishaw, 2002, van Groen et al., 2002, Vann et al., 2003).  
Moreover, the exacerbation of the retention deficit observed in the minocycline-
treated animals suggest that minocycline may, by altering  microglial-derived soluble 
mediators such as interleukins-1β, -6, and -18 and tumor necrosis factor-α (TNFα) 
(Krady et al., 2005, Bye et al., 2007, Wasserman and Schlichter, 2007, Henry et al., 
2008), compound injury-induced deficits in synaptic plasticity. It has been demonstrated 
that these interleukins regulate maintenance of long-term potentiation (LTP) (McAfoose 
and Baune, 2009, del Rey et al., 2013) while TNFα can upregulate surface expression of 
α-amino-3-hydorxy-5-methyl-4-isozazoleproprionic (AMPA) receptors and strengthen 
LTP (Beattie et al., 2002). However, it is unclear if this theory holds true in the injured 
brain as cytokines levels are significantly increased following injury (Ziebell and 
Morganti-Kossmann, 2010).  For example, pathologic increases in IL-1β can inhibit both 
LTP and the acquisition and retention of a spatial memory task (Ross et al., 2003, 
Trofimov et al., 2012). Alternatively, the reduction in the number of phagocytic 
microglia/macrophages in the corpus callosum may have prevented the removal of 
cellular debris such as myelin fragments or apoptotic oligodendrocytes, thereby 
preventing white matter repair  (Takahashi et al., 2005, Neumann and Takahashi, 2007).  
In contrast to our observations in the neonate rat, minocycline treatment in adult brain-
injured mice has been observed to reduce impairments in the novel object recognition 
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task (Siopi et al., 2012). Minocycline treatment has also been effective in reducing injury-
induced deficits in non-cognitive behaviors such as locomotion, hyperactivity and 
anxiety-like behavior following either TBI in adult mice or HI in the neonate rat (Sanchez 
Mejia et al., 2001, Fan et al., 2006, Homsi et al., 2010).  
One potential caveat to the current study is that we only used one dose (45 
mg/kg/injection) and one dosing paradigm (every 12 hours for 3 days).  The dose and 
dosing paradigms were chosen based on their efficacy and use in several models of brain 
injury in both adult and neonatal animals (Sanchez Mejia et al., 2001, Bye et al., 2007, 
Buller et al., 2009, Plane et al., 2010, Tang et al., 2010). Future efforts will focus on 
continuing the dosing to the later time points, which has demonstrated success (Carty et 
al., 2008).  Nevertheless, the apparent lack of efficacy of minocycline in neonatal brain 
trauma raises the possibility that this compound may be acting on anti-inflammatory 
subsets of microglia/macrophages.  Very few studies have investigated the effect of 
minocycline on microglial/macrophage polarization into M1 (pro-inflammatory) and M2 
(anti-inflammatory) phenotypes.  Although minocycline was successful in decreasing M1 
pro-inflammatory markers while leaving M2 markers unaffected in a mouse model of 
amyotrophic lateral sclerosis (Kobayashi et al., 2013), it has been reported to increase 
pro-inflammatory markers in animals that exhibit depressive-like behavior (Burke et al., 
2014).  Based on the observation that depletion of microglia at the time of injury 
exacerbated tissue loss following stroke (Faustino et al., 2011), it is tempting to suggest 
that pro-inflammatory mediators released in acute post-traumatic period may be 
necessary for neuroprotection after neonatal TBI. Future efforts will be directed at 
determining the appropriate dosing paradigm and the cellular mechanisms, such as 
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cytokine synthesis and release and cellular activity, underlying the efficacy of 
minocycline as an effective intervention for repeated TBI in immature animals. 
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A2.6 FIGURE LEGENDS 
 
Figure A2.1. Minocycline does not reduce microglia/macrophage activation induced 
by repeated brain trauma 
Representative photomicrographs illustrate Iba1-labeled microglia/macrophages 
in the corpus callosum (A-C), cortex (D-F), and thalamus (G-I) of sham-injured (A, D, 
G), brain-injured vehicle-treated (B, E, H), and brain-injured minocycline-treated animals 
(C, F, I) at 3 days post-injury.  Note the increase in Iba1 immunoreactivity and the cell 
density in the injured brain sections. Quantification of the area labeled with Iba1 above 
threshold (as described in the Methods) in the corpus callosum (J), cortex (K), and 
thalamus (L) expressed as a percent of the total area of the corresponding region from 
Nissl-myelin stained sections. *, p<0.05 compared to the sham-injured values at the 
corresponding time point.  Scale bar in panel L = 50μm.  
 
Figure A2.2.  Minocycline reduces ED1-labeled microglia/macrophages in the 
corpus callosum of brain-injured animals. 
Representative photomicrographs illustrate ED1-labeled microglia/macrophages 
in the corpus callosum (A-C) and cortex (D-F) of sham-injured (A, D), brain-injured 
vehicle-treated (B, E), and brain-injured minocycline-treated animals (C, F) at 3 days 
post-injury.  Note the relative paucity of ED1 labeled cells in sham-injured brains and the 
robust increase in the cell size and intensity of ED1 immunoreactivity in the brain-injured 
animals. Quantification of area labeled with ED1 above threshold (as described in the 
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Methods) in the corpus callosum (G) and cortex (H) expressed as percent of the total area 
of the corresponding region from Nissl-myelin stained sections. *, p<0.05 compared to 
the sham-injured values at the corresponding time point;  #, p = 0.05 compared to the 
brain-injured vehicle-treated group at the corresponding time point.  Scale bar in panel F 
= 25 μm.  
 
Figure A2.3. Minocycline does not reduce the extent of traumatic axonal injury in 
the corpus callosum of brain-injured animals. 
Representative photomicrographs illustrate intra-axonal accumulation of amyloid 
precursor protein in the corpus callosum of brain-injured vehicle-treated (B), and brain-
injured minocycline-treated (C) animals at 3 days post injury; note the absence of 
immunoreactivity in sham-injured animals (A).  Panel D denotes the quantification of 
APP-labeled profiles using the grid analysis method.  Scale bar in panel C = 25μm. 
 
Figure A2.4. Minocycline does not reduce the extent of Fluoro-Jade B labeling in 
brain-injured animals. 
Representative photomicrographs illustrate Fluoro-Jade B labeling in the corpus 
callosum (A-C), cortex (D-F), and thalamus (G,H) of brain-injured vehicle-treated (A, D, 
G), brain-injured minocycline-treated (B, E, H) and sham-injured animals (C, F) at 3 days 
post-injury. Note the absence of Fluoro-Jade B reactivity in sham-injured animals (C, F). 
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Quantification of FJB(+) profiles in each high power field as described in the Methods 
(I). Scale bar in panel H = 50μm.  
 
Figure A2.5. Minocycline does not reverse injury-induced decrease in loss of corpus 
callosum area.  
Representative Nissl-myelin stained sections from sham-injured (A, D, G), brain-
injured vehicle-treated (B, E, H), and brain-injured minocycline-treated animals (C, F, I) 
at 3 days (A-C), 7 days (D-F), and 21 days post-injury (G-I).  Note the appearance of 
enlarged ventricles at 21 days post-injury in brain-injured animals (panels H and I). 
Quantification of the area of the corpus callosum (J) and cortex (K). *, p<0.001 compared 
to sham-injured values at the corresponding time point.  Scale bar in panel I = 1000μm.  
 
Figure A2.6.  Minocycline does not attenuate injury-induced spatial learning deficits 
but exacerbates retention deficits. 
(A) Latency to the platform in the spatial learning task using the Morris water 
maze illustrates the deficit in the time taken to reach the hidden platform in brain-injured 
animals. (B) Times spent in the periphery of the maze and the area surrounding the 
platform location during the probe trial. *, p<0.01 when compared to the sham-injured 
animals;  #, p<0.05 when compared to the brain injured vehicle-treated animals. 
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A2.7 FIGURES 
 
Figure A2.1. Effect of minocycline on microglia/macrophage activation induced by 
repeated brain trauma 
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Figure A2.2.  Effect of minocycline on microglial/macrophage activation in the 
corpus callosum of repetitively brain-injured animals. 
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Figure A2.3. Effect of minocycline on traumatic axonal injury in the corpus 
callosum following repetitive brain injury. 
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Figure A2.4. Effect of minocycline on Fluoro-Jade B labeling in repetitively brain-
injured animals. 
 
 
 
 
 
 
 
352 
 
Figure A2.5. Effect of minocycline on tissue atrophy following repetitive brain 
injury in the neonate rat.  
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Figure A2.6. Effect of minocycline on injury-induced spatial learning and memory 
deficits. 
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